Immunogenicity, Safety and Tolerability of a Neisseria Me... | NCT02534935 | Trialant
NCT02534935
Sponsor
Pfizer
Status
Completed
Last Update Posted
Sep 27, 2021Actual
Enrollment
396Actual
Phase
Phase 2
Conditions
Meningococcal B Disease
Interventions
rLP2086 vaccine
Pediatric HAV vaccine
Countries
Australia
Czechia
Finland
Poland
Protocol Section
Identification Module
NCT ID
NCT02534935
Obsolete or Duplicate NCT IDs
Not provided
Organization Study
B1971035
Secondary IDs
ID
Type
Description
Link
2011-004400-38
EudraCT Number
Brief Title
Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.
Official Title
A PHASE 2, RANDOMIZED, CONTROLLED, OBSERVER-BLINDED STUDY CONDUCTED TO DESCRIBE THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF A NEISSERIA MENINGITIDIS SEROGROUP B BIVALENT RECOMBINANT LIPOPROTEIN 2086 VACCINE (BIVALENT RLP2086) WHEN ADMINISTERED TO HEALTHY TODDLERS AGED 12 TO <18 MONTHS OR 18 TO <24 MONTHS, AND THE SAFETY AND IMMUNOGENICITY OF A BOOSTER DOSE OF BIVALENT RLP2086
Acronym
Not provided
Organization
PfizerINDUSTRY
Status Module
Record Verification Date
Aug 2021
Overall Recruitment Status or Expanded Access Status
Completed
Last Known Status
Not provided
Delayed Posting
Not provided
Why Stopped
Not provided
Expanded Access Info
No
Start Date
Aug 31, 2015Actual
Primary Completion Date
Aug 21, 2017Actual
Completion Date
Mar 17, 2020Actual
First Submitted Date
Feb 23, 2015
First Submission Date that Met QC Criteria
Aug 25, 2015
First Posted Date
Aug 28, 2015Estimated
Results Waived
Not provided
Results First Submitted Date
Feb 19, 2018
Results First Submitted that Met QC Criteria
Mar 16, 2018
Results First Posted Date
Apr 17, 2018Actual
Certification/Extension (aka Delayed Results) First Submitted Date
Not provided
Certification/Extension First Submitted that Passed QC Review
Not provided
Certification/Extension First Posted Date
Not provided
Last Update Submitted Date
Aug 30, 2021
Last Update Posted Date
Sep 27, 2021Actual
Sponsor/Collaborators Module
Responsible Party, by Official Title
Sponsor
Lead Sponsor
PfizerINDUSTRY
Collaborators
Not provided
Oversight Module
Has Data Monitoring Committee (DMC)
Yes
Is FDA Regulated Drug
Not provided
Is FDA Regulated Device
Not provided
Is Unapproved Device
Not provided
Pediatric Postmarket Surveillance of a Device Product
Not provided
Product Exported from US
Not provided
FDAAA801 Violation
Not provided
Description Module
Brief Summary
The purpose of this study is to investigate the immunogenicity, safety and tolerability of a new vaccine that might prevent meningococcal B disease. The study will be conducted in healthy toddlers aged between 12 and 24 months.
Detailed Description
Not provided
Conditions Module
Conditions
Meningococcal B Disease
Keywords
Phase 2 Immunogenicity
Safety
Tolerability Study
rLP2086 Vaccine
Healthy Toddlers
Neisseria meningitidis
Duration of Immunogenicity
Design Module
Study Type
Interventional
Number of References to an Expanded Access Study
Not provided
Expanded Access Types
Not provided
Patient Registry
Not provided
Target Follow-Up Duration
Not provided
Phases
Phase 2
Interventional Study Design
Allocation
Biospecimen
No data available
No data is available for this block.
Enrollment
396Actual
Arms/Interventions Module
Arm Groups
Label
Type
Description
Intervention Names
rLP2086 vaccine
Experimental
Arm stratified by age:
≥12 to <18 months and ≥18 to <24 months
Biological: rLP2086 vaccine
Control
Active Comparator
Arm stratified by age:
≥12 to <18 months and ≥18 to <24 months
Biological: Pediatric HAV vaccine
Interventions
Name
Type
Description
Arm Group Labels
Other Names
rLP2086 vaccine
Biological
60 mcg or 120mcg at 0, 2 and 6 months
rLP2086 vaccine
Outcomes Module
Primary Outcomes
Measure
Description
Time Frame
Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >= Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Neisseria Meningitidis Serogroup B (MnB) Test Strains 1 Month After Vaccination 3
Percentage of participants achieving hSBA titer >= LLOQ were computed along with corresponding 2-sided 95 percent (%) confidence interval (CIs). LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44).
1 month after Vaccination 3
Percentage of Participants Reporting Pre-specified Local Reactions Within 7 Days After Vaccination 1
Local reactions included tenderness at injection site, swelling and redness collected by using an electronic diary (e-diary). Tenderness was graded as: mild (hurted if gently touched), moderate (hurted if gently touched with crying) and severe (caused limitation of limb movement). Redness and swelling were graded as: mild (0.5-2.0 centimeter [cm]), moderate (2.5 to 7.0 cm) and severe (>7.0 cm).
within 7 Days after Vaccination 1
Percentage of Participants Reporting Pre-specified Local Reactions Within 7 Days After Vaccination 2
Local reactions included tenderness at injection site, swelling and redness collected by using an e-diary. Tenderness was graded as: mild (hurted if gently touched), moderate (hurted if gently touched with crying) and severe (caused limitation of limb movement). Redness and swelling were graded as: mild (0.5-2.0 cm), moderate (2.5 to 7.0 cm) and severe (>7.0 cm).
within 7 Days after Vaccination 2
Percentage of Participants Reporting Pre-specified Local Reactions Within 7 Days After Vaccination 3
Local reactions included tenderness at injection site, swelling and redness collected by using an e-diary. Tenderness was graded as: mild (hurted if gently touched), moderate (hurted if gently touched with crying) and severe (caused limitation of limb movement). Redness and swelling were graded as: mild (0.5-2.0 cm), moderate (2.5 to 7.0 cm) and severe (>7.0 cm).
Secondary Outcomes
Measure
Description
Time Frame
Percentage of Participants With hSBA Titer Between 12 Months to Less Than (<) 24 Months >= LLOQ for Each of the 4 Primary MnB Test Strains at 1, 6, 12, and 24 Months After Vaccination 3
Percentage of participants achieving hSBA titer >= LLOQ were computed along with corresponding 2-sided 95% CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24), and PMB2707 (B44).
1, 6, 12, 24 months after Vaccination 3
Other Outcomes
Not provided
Eligibility Module
Eligibility Criteria
Inclusion Criteria:
Male or female subject aged 12 to <15 months or 18 to <24 months during sentinel-cohort enrollment, Or,12 to <24 months during expanded-cohort enrollment.
Subjects must have received all vaccinations in the relevant National Immunization Program (NIP) for their age group.
Subject is determined to be in good health by medical history, physical examination, and judgment of the investigator.
Exclusion Criteria:
Previous vaccination with any meningococcal serogroup B vaccine.
Previous vaccination with HAV vaccine, or requirement to receive nonstudy HAV vaccine during Stage 1 of the study.
Contraindication to vaccination with any HAV vaccine or known latex allergy.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
A known or suspected disorder of the immune system that would prevent an immune response to the vaccine, such as subjects with congenital or acquired defects in B-cell function or those receiving systemic immunosuppressive therapy. Subjects with terminal complement deficiency may be included.
History of microbiologically proven disease caused by N meningitidis or Neisseria gonorrhoeae.
Significant neurologic disorder or history of seizure (excluding simple febrile seizure).
Receipt of any blood products, including immunoglobulin, within 6 months before the first study vaccination until the end of Stage 1.
Current chronic use of systemic antibiotics.
Received any investigational drugs, vaccines or devices within 28 days before administration of the first study vaccination and/or during study participation.
Any neuroinflammatory or autoimmune condition, including but not limited to transverse myelitis, uveitis, optic neuritis, and multiple sclerosis.
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.
In Stage 1, participants received 60 or 120 microgram (mcg) of bivalent rLP2086 vaccine or HAV/saline at Month 1, 2 and 6, and then followed up for 24 months. In Stage 2, participants who received bivalent rLP2086 during Stage 1 had a follow up visit at Month 24. Further participants who received 120 mcg bivalent rLP2086 during Stage 1 were eligible for receiving booster vaccination 6 months after Month 24 visit.
Recruitment Details
Not provided
Type of Units Analyzed
Not provided
Arm/Group Information
ID
Title
Description
FG000
Group 1: 60- mcg Bivalent rLP2086 (>=12 Months to <24 Months)
Participants from greater than or equal to (>=) 12 months to less than (<) 24 months of age, received intramuscular injection of 60 mcg of bivalent rLP2086 vaccine on months 0 vaccine on a 0, 2, 6 month schedule.
FG001
Group 2: 120-mcg Bivalent rLP2086 (>=12 Months to <24 Months)
Periods
Title
Milestones
Reasons Not Completed
Stage 1: 24 Months
Type
Comment
Milestone Data
STARTED
Baseline Characteristics Module
Baseline Analysis Population Description
Outcome Measures Module
Outcome Measures
Adverse Events Module
Frequency Threshold
1
More Info Module
Limitations and Caveats
Annotation Section
No data available
No data is available for this block.
Document Section
Large Document Module
Document Has No Statistical Analysis Plan (SAP)
Not provided
Uploaded Document Information
Type
Includes Protocol
Includes SAP
Includes ICF
Document Label
Document Date
Document Uploaded Date
Document File Name
Prot
Yes
No
No
Study Protocol
Apr 19, 2016
Feb 19, 2018
Derived Section
Miscellaneous Info Module
Version Holder
Jul 10, 2026
Removed Countries
Not provided
Submission Tracking
No data available
No data is available for this block.
Condition Browse Module
No data available
No data is available for this block.
Intervention Browse Module
No data available
No data is available for this block.
Randomized
Intervention Model
Parallel Assignment
Intervention Model Description
Not provided
Primary Purpose
Prevention
Observational Model
Not provided
Time Perspective
Not provided
Masking Info
Masking
Triple
Masking Description
Not provided
Who Masked
ParticipantCare ProviderInvestigator
Pediatric HAV vaccine
Biological
0.5-mL dose at months 0 and 6. Normal saline at month 2.
Control
within 7 Days after Vaccination 3
Percentage of Participants Reporting Systemic Events and Antipyretic Use Within 7 Days After Vaccination 1
Systemic reactions included fever, irritability, drowsiness, loss of or decreased appetite and were recorded by using an e-diary. Fever was graded as 38.0 to 38.4 degree Celsius (C), 38.5 to 38.9 degree C, 39.0 to 39.4 degree C, >39.5 to 40.0 degree C and >40.0 degree C. Irritability was graded as mild (easily consolable), moderate (requiring increased attention) and severe (inconsolable). Drowsiness was graded as mild (Increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity) and severe (disabling not interested in usual daily activity). Loss of or decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed).
within 7 Days after Vaccination 1
Percentage of Participants Reporting Systemic Events and Antipyretic Use Within 7 Days After Vaccination 2
Systemic reactions included fever, irritability, drowsiness, loss of or decreased appetite and were recorded by using an e-diary. Fever was graded as 38.0 to 38.4 degree C, 38.5 to 38.9 degree C, 39.0 to 39.4 degree C, >39.5 to 40.0 degree C and >40.0 degree C. Irritability was graded as mild (easily consolable), moderate (requiring increased attention) and severe (inconsolable). Drowsiness was graded as mild (Increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity) and severe (disabling not interested in usual daily activity). Loss of or decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed).
within 7 Days after Vaccination 2
Percentage of Participants Reporting Systemic Events and Antipyretic Use Within 7 Days After Vaccination 3
Systemic reactions included fever, irritability, drowsiness, loss of or decreased appetite and were recorded by using an e-diary. Fever was graded as 38.0 to 38.4 degree C, 38.5 to 38.9 degree C, 39.0 to 39.4 degree C, >39.5 to 40.0 degree C and >40.0 degree C. Irritability was graded as mild (easily consolable), moderate (requiring increased attention) and severe (inconsolable). Drowsiness was graded as mild (Increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity) and severe (disabling not interested in usual daily activity). Loss of or decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed).
within 7 Days after Vaccination 3
Percentage of Participants With at Least 1 Adverse Event (AE), Serious Adverse Event (SAE), Medically Attended Adverse Event (MAE), Newly Diagnosed Chronic Medical Condition (NDCMC) and Immediate Adverse Event (IAE) Within 30 Days After Vaccination 1
An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication; important medical event. A MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects. Immediate AE was defined as AEs occurring within the first 30 minutes after investigational product administration.
within 30 Days after Vaccination 1
Percentage of Participants With at Least 1 Adverse Event (AE), Serious Adverse Event (SAE), Medically Attended Adverse Event (MAE), Newly Diagnosed Chronic Medical Condition (NDCMC) and Immediate Adverse Event (IAE) Within 30 Days After Vaccination 2
An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication; important medical event. A MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects. Immediate AE was defined as AEs occurring within the first 30 minutes after investigational product administration.
within 30 Days after Vaccination 2
Percentage of Participants With at Least 1 Adverse Event (AE), Serious Adverse Event (SAE), Medically Attended Adverse Event (MAE), Newly Diagnosed Chronic Medical Condition (NDCMC) and Immediate Adverse Event (IAE) Within 30 Days After Vaccination 3
An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication; important medical event. A MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects. Immediate AE was defined as AEs occurring within the first 30 minutes after investigational product administration.
within 30 Days after Vaccination 3
Percentage of Participants With at Least 1 Adverse Event (AE), Serious Adverse Event (SAE), Medically Attended Adverse Event (MAE) and Newly Diagnosed Chronic Medical Condition (NDCMC) Within 30 Days After Any Vaccination
An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication; important medical event. A MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.
within 30 Days after any Vaccination
Percentage of Participants With at Least 1 Adverse Event (AE), Serious Adverse Event (SAE), Medically Attended Adverse Event (MAE) and Newly Diagnosed Chronic Medical Condition (NDCMC) During the Vaccination Phase
An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication; important medical event. A MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.
From the Vaccination 1 up to 1 month after Vaccination 3
Percentage of Participants With at Least 1 Serious Adverse Event (SAE), Medically Attended Adverse Event (MAE) and Newly Diagnosed Chronic Medical Condition (NDCMC) During the Follow up Phase
An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication; important medical event. A MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.
From 1 month after Vaccination 3 up to 6 months after Vaccination 3
Percentage of Participants With at Least 1 Serious Adverse Event (SAE), Medically Attended Adverse Event (MAE) and Newly Diagnosed Chronic Medical Condition (NDCMC) From Vaccination 1 up to 6 Months After Vaccination 3
An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication; important medical event. A MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.
From Vaccination 1 up to 6 months after Vaccination 3
Percentage of Participants With hSBA Titer >= LLOQ for Each of the 4 Primary MnB Test Strains 1 Month After Vaccination 2
Percentage of participants achieving hSBA titer >= LLOQ were computed along with corresponding 2-sided 95% CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24), and PMB2707 (B44).
1 month (Mon) after Vaccination (Vac) 2
Percentage of Participants With Serum Bactericidal Assay Using hSBA Titers >=1:4, >=1:8, >=1:16, >=1:32, >=1:64 and >=1:128 for Each of the 4 Primary Test Strains
Before Vaccination 1 (T1), 1 month after Vaccination 2 (T2), 1 month after Vaccination 3 (T3), 6 months after Vaccination 3 (T4), 12 months after Vaccination 3 (T5) and 24 months after Vaccination 3 (T6)
Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs) for Each of the 4 Primary Test Strains
Before Vaccination 1 (T1), 1 month after Vaccination 2 (T2), 1 month after Vaccination 3 (T3), 6 months after Vaccination 3 (T4), 12 months after Vaccination 3 (T5) and 24 months after Vaccination 3 (T6)
Percentage of Participants Reporting Pre-specified Local Reactions Within 7 Days After Booster Vaccination
Local reactions included pain at injection site, swelling and redness collected by using an e-diary. Pain at injection site was graded as: mild (does not interfere with activity), moderate (interferes with activity) and severe (prevents daily activity). A caliper was used to measure the redness or swelling area. Caliper units were converted to centimeters (cm) according to 1 caliper unit = 0.5 cm. Redness and swelling were graded as: none (0 cm) mild (0.5-2.0 cm), moderate (>=2.0 to 7.0 cm) and severe (>7.0 cm).
Within 7 days after booster vaccination
Percentage of Participants Reporting Systemic Events and Antipyretic Use Within 7 Days After Booster Vaccination
Systemic reactions included fever, vomiting, diarrhea, headache, fatigue, muscle pain and joint pain were recorded by using an e-diary. Fever was defined as a temperature of greater than or equal to (>=) 38.0 degree Celsius and was graded as 38.0 degree Celsius (C) to 38.4 degree C, 38.5 degree C to 38.9 degree C, 39.0 degree C to 39.4 degree C, 39.5 degree C to 40.0 degree C, >40.0 degree C. Vomiting was graded as mild (1 to 2 times in 24 hours), moderate (>2 times in 24 hours) and severe (requires IV hydration). Diarrhea was graded as mild (2 to 3 loose stools in 24 hours), moderate (4 to 5 loose stools in 24 hours), and severe (6 or more loose stools in 24 hours). Fatigue, headache, muscle pain and joint pain were graded as: mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily routine activity). The use and type of antipyretic medication was also recorded in the e-diary daily.
Within 7 days after booster vaccination
Percentage of Participants With SAE, MAE, NDCMC From Booster Vaccination to 1 Month After Booster Vaccination, 1 Month After Booster Vaccination to 6 Months After Booster Vaccination and Booster Vaccination Through 6 Months After Booster Vaccination
SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication; important medical event. A MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.
Booster vaccination to 1 month after booster vaccination (T1), 1 month after booster vaccination to 6 months after booster vaccination (T2) and booster vaccination through 6 months after booster vaccination (T3)
Percentage of Participants With at Least 1 Adverse Event (AE) From Booster Vaccination to 1 Month After Booster Vaccination
An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship.
Booster vaccination up to 1 month after booster vaccination
Percentage of Participants With Immediate Adverse Event (IAE) After Booster Vaccination
Immediate AE was defined as AEs occurring within the first 30 minutes after investigational product administration.
Within 30 minutes after booster vaccination
Percentage of Participants With hSBA Titer >=LLOQ >=1:4, >=1:8, >=1:16, >=1:32, >=1:64 and >=1:128 for Each of the 4 Primary Test Strains Before Booster Vaccination, and 1 Month After Booster Vaccination
Percentage of participants achieving hSBA titer >= LLOQ were computed along with corresponding 2-sided 95 % CIs. The LLOQ was 1:16 for A22 and 1:8 for A56, B24, and B44.
Before booster vaccination and 1 month after booster vaccination
Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs) for Each of the 4 MnB Primary Test Strains at Before Booster Vaccination and 1 Month After Booster Vaccination
The LLOQ was 1:16 for A22, 1:8 for A56, B24, and B44. Titers below the LLOQ were set to 0.5*LLOQ for analysis. Titers were expressed in terms of 1/dilution.
Before booster vaccination and 1 month after booster vaccination
Maroubra
New South Wales
2035
Australia
Maroubra Medical Centre
Maroubra
New South Wales
2035
Australia
Women's And Children's Hospital
North Adelaide
South Australia
5006
Australia
Murdoch Children's Research Institute
Parkville
Victoria
3052
Australia
Vaccine Trials Group, Telethon Kids Institute, Perth Children's Hospital
Nedlands
Western Australia
6009
Australia
Ordinace praktickeho lekare pro deti a dorost
Jindřichův Hradec
377 01
Czechia
Samostatna ordinace praktickeho lekare pro deti a dorost
Jindřichův Hradec
377 01
Czechia
Medicentrum 6 s.r.o
Praha 6 - Vokovice
160 00
Czechia
Prakticky Lekar Pro Deti A Mladez
Týnec nad Sázavou
257 41
Czechia
Espoo Vaccine Research Clinic
Espoo
02230
Finland
Helsinki South Vaccine Research Clinic
Helsinki
00100
Finland
Helsinki East Vaccine Research Clinic
Helsinki
00930
Finland
Jarvenpaa Vaccine Research Center
Jarvenpaa
04400
Finland
Pori Vaccine Research Clinic
Pori
28100
Finland
Tampere Vaccine Research Clinic
Tampere
33100
Finland
Turku Vaccine Research Clinic
Turku
20520
Finland
NZOZ Vitamed
Bydgoszcz
85-079
Poland
Prywatny Gabinet Lekarski dr n. med. Jerzy Brzostek
Dębica
39-200
Poland
Indywidualna Specjalistyczna Praktyka Lekarska Hanna Czajka
Krakow
31-302
Poland
Specjalistyczna Praktyka Lekarska GRAVITA
Lodz
91-347
Poland
NZOZ Praktyka Lekarza Rodzinnego Eskulap sp. z o.o
Lublin
20-044
Poland
Niepubliczny Zaklad Lecznictwa Ambulatoryjnego Michalkowice Jarosz i Partnerzy Spolka Lekarska
Siemianowice ÅšlÄ…skie
41-103
Poland
Szpital im. Sw. Jadwigi Slaskiej w Trzebnicy Oddzial Pediatryczny
Trzebnica
55-100
Poland
Uniwersytecki Szpital Kliniczny im. J. Mikulicza-Radeckiego we Wroclawiu Klinika Pediatrii i Chorob
Wroclaw
50-368
Poland
Participants from >=12 months to <24 months of age, received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine on a 0, 2, 6 month schedule. All participants who received 3 doses of 120 mcg bivalent rLP2086 in Stage 1 and gave consent for booster vaccination, received intramuscular injection of single booster dose of 120 mcg of bivalent rLP2086 after 23 to 24 months of Vaccination 3, in Stage 2. Participants were followed up approximately 6 months after the booster vaccination.
FG002
Group 3: HAV/Saline (>=12 Months to <24 Months): Stage 1
Participants from >=12 months to <24 months of age, received intramuscular injection of saline on 2 month and HAV vaccine on a 0, 6 month schedule.
FG00044 subjects
FG001220 subjects
FG002132 subjects
COMPLETED
FG00044 subjects
FG001210 subjects
FG002127 subjects
NOT COMPLETED
FG0000 subjects
FG00110 subjects
FG0025 subjects
Type
Comment
Reasons
Withdrawal by Subject
FG0000 subjects
FG0013 subjects
FG0023 subjects
No longer willing to participate in study
FG0000 subjects
FG0011 subjects
FG0021 subjects
No longer meets eligibility criteria
FG0000 subjects
FG0013 subjects
FG0020 subjects
Lost to Follow-up
FG0000 subjects
FG0011 subjects
FG0021 subjects
Adverse Event
FG0000 subjects
FG0012 subjects
FG0020 subjects
Stage 2: 8 Months
Type
Comment
Milestone Data
STARTED
FG00040 subjectsParticipants entered into Stage 2.
FG001174 subjectsParticipants who received all 3 doses and entered Stage 2.
FG0020 subjectsParticipants of HAV/Saline were not eligible for Stage 2.
COMPLETED
FG00040 subjects
FG001170 subjects
FG0020 subjects
NOT COMPLETED
FG0000 subjects
FG0014 subjects
FG0020 subjects
Type
Comment
Reasons
Moved away/parents resigned from study
FG0000 subjects
FG0014 subjects
FG0020 subjects
Stage 2: Booster Phase (6 Months)
Type
Comment
Milestone Data
STARTED
FG0000 subjectsParticipants were not eligible for Booster vaccination in Stage 2.
FG001148 subjectsParticipants who received 3 doses of bivalent rLP2086 in Stage 1 and gave consent for booster vaccination.
FG0020 subjectsParticipants of HAV/Saline were not eligible for Stage 2.
COMPLETED
FG0000 subjects
FG001147 subjects
FG0020 subjects
NOT COMPLETED
FG0000 subjects
FG0011 subjects
FG0020 subjects
Type
Comment
Reasons
Not received booster vaccination
FG0000 subjects
FG0011 subjects
FG0020 subjects
Safety population included all participants who received at least 1 dose of the investigational product (rLP2086, HAV vaccine or saline) and had safety data available.
Type of Units Analyzed
Not provided
Arm/Group Information
ID
Title
Description
BG000
Group 1: 60- mcg Bivalent rLP2086 (>=12 Months to <24 Months)
Participants from greater than or equal to (>=) 12 months to less than (<) 24 months of age, received intramuscular injection of 60 mcg of bivalent rLP2086 vaccine on months 0 vaccine on a 0, 2, 6 month schedule.
BG001
Group 2: 120-mcg Bivalent rLP2086 (>=12 Months to <24 Months)
Participants from >=12 months to <24 months of age, received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine on a 0, 2, 6 month schedule. All participants who received 3 doses of 120 mcg bivalent rLP2086 in Stage 1 and gave consent for booster vaccination, received intramuscular injection of single booster dose of 120 mcg of bivalent rLP2086 after 23 to 24 months of Vaccination 3, in Stage 2. Participants were followed up approximately 6 months after the booster vaccination.
BG002
Group 3: HAV/Saline (>=12 Months to <24 Months): Stage 1
Participants from >=12 months to <24 months of age, received intramuscular injection of saline on 2 month and HAV vaccine on a 0, 6 month schedule.
BG003
Total
Total of all reporting groups
Denominators
Units
Counts
Participants
BG00044
BG001220
BG002132
BG003396
Baseline Measures
Title
Description
Population Description
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Denominator Units Selected
Denominators
Classes
Age, Continuous
Mean
Standard Deviation
months
Title
Denominators
Categories
Title
Measurements
BG00016.9± 4.08
BG00117.4± 3.54
BG00217.3± 3.58
BG003
Sex: Female, Male
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
Female
BG00021
BG001114
BG002
Race/Ethnicity, Customized
Count of Participants
Participants
Title
Denominators
Categories
Race: White
Title
Measurements
BG00037
BG001210
BG002
Race/Ethnicity, Customized
Count of Participants
Participants
Title
Denominators
Categories
Ethnicity: Hispanic
Title
Measurements
BG0000
BG0012
BG002
Type
Title
Description
Population Description
Reporting Status
Anticipated Posting Date
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Time Frame
Units Analyzed
Denominator Units Selected
Arm/Group Information
Denominators
Classes
Analyses
Primary
Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >= Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Neisseria Meningitidis Serogroup B (MnB) Test Strains 1 Month After Vaccination 3
Percentage of participants achieving hSBA titer >= LLOQ were computed along with corresponding 2-sided 95 percent (%) confidence interval (CIs). LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44).
All eligible participants randomized to study received,scheduled investigational products, had pre and post vaccination blood drawn with valid and determinate assay results and had no important protocol deviation. Here,overall number of participants analyzed (N) signifies number of participants evaluable for this outcome measure.
Posted
Number
95% Confidence Interval
percentage of participants
1 month after Vaccination 3
ID
Title
Description
OG000
Group 1: 60-µg Bivalent rLP2086 (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG001
Group 1: 60-µg Bivalent rLP2086 (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG002
Group 2: 120-µg Bivalent rLP2086 (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG003
Group 2: 120-µg Bivalent rLP2086 (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG004
Group 3: HAV/Saline (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.
OG005
Group 3: HAV/Saline (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.
Units
Counts
Participants
OG0009
OG00111
OG00247
OG003
Title
Denominators
Categories
PMB80 [A22]
ParticipantsOG0009
ParticipantsOG00111
ParticipantsOG00245
ParticipantsOG003
Primary
Percentage of Participants Reporting Pre-specified Local Reactions Within 7 Days After Vaccination 1
Local reactions included tenderness at injection site, swelling and redness collected by using an electronic diary (e-diary). Tenderness was graded as: mild (hurted if gently touched), moderate (hurted if gently touched with crying) and severe (caused limitation of limb movement). Redness and swelling were graded as: mild (0.5-2.0 centimeter [cm]), moderate (2.5 to 7.0 cm) and severe (>7.0 cm).
Safety population: all participants who received at least 1 dose of an investigational product (rLP2086 or HAV vaccine) and had safety data available.
Posted
Number
95% Confidence Interval
percentage of participants
within 7 Days after Vaccination 1
ID
Title
Description
OG000
Group 1: 60-µg Bivalent rLP2086 (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG001
Group 1: 60-µg Bivalent rLP2086 (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG002
Group 1: 60- mcg Bivalent rLP2086 (>=12 Months to <24 Months)
Primary
Percentage of Participants Reporting Pre-specified Local Reactions Within 7 Days After Vaccination 2
Local reactions included tenderness at injection site, swelling and redness collected by using an e-diary. Tenderness was graded as: mild (hurted if gently touched), moderate (hurted if gently touched with crying) and severe (caused limitation of limb movement). Redness and swelling were graded as: mild (0.5-2.0 cm), moderate (2.5 to 7.0 cm) and severe (>7.0 cm).
Safety population: all participants who received at least 1 dose of an investigational product (rLP2086 or HAV vaccine) and had safety data available. Here, N signifies number of participants evaluable for this outcome measure.
Posted
Number
95% Confidence Interval
percentage of Participants
within 7 Days after Vaccination 2
ID
Title
Description
OG000
Group 1: 60-µg Bivalent rLP2086 (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG001
Group 1: 60-µg Bivalent rLP2086 (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG002
Group 1: 60- mcg Bivalent rLP2086 (>=12 Months to <24 Months)
Primary
Percentage of Participants Reporting Pre-specified Local Reactions Within 7 Days After Vaccination 3
Local reactions included tenderness at injection site, swelling and redness collected by using an e-diary. Tenderness was graded as: mild (hurted if gently touched), moderate (hurted if gently touched with crying) and severe (caused limitation of limb movement). Redness and swelling were graded as: mild (0.5-2.0 cm), moderate (2.5 to 7.0 cm) and severe (>7.0 cm).
Safety population: all participants who received at least 1 dose of an investigational product (rLP2086 or HAV vaccine) and had safety data available. Here, N signifies number of participants evaluable for this outcome measure.
Posted
Number
95% Confidence Interval
percentage of Participants
within 7 Days after Vaccination 3
ID
Title
Description
OG000
Group 1: 60-µg Bivalent rLP2086 (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG001
Group 1: 60-µg Bivalent rLP2086 (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG002
Group 1: 60- mcg Bivalent rLP2086 (>=12 Months to <24 Months)
Primary
Percentage of Participants Reporting Systemic Events and Antipyretic Use Within 7 Days After Vaccination 1
Systemic reactions included fever, irritability, drowsiness, loss of or decreased appetite and were recorded by using an e-diary. Fever was graded as 38.0 to 38.4 degree Celsius (C), 38.5 to 38.9 degree C, 39.0 to 39.4 degree C, >39.5 to 40.0 degree C and >40.0 degree C. Irritability was graded as mild (easily consolable), moderate (requiring increased attention) and severe (inconsolable). Drowsiness was graded as mild (Increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity) and severe (disabling not interested in usual daily activity). Loss of or decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed).
Safety population: all participants who received at least 1 dose of an investigational product (rLP2086 or HAV vaccine) and had safety data available.
Posted
Number
95% Confidence Interval
percentage of Participants
within 7 Days after Vaccination 1
ID
Title
Description
OG000
Group 1: 60-µg Bivalent rLP2086 (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG001
Group 1: 60-µg Bivalent rLP2086 (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
Primary
Percentage of Participants Reporting Systemic Events and Antipyretic Use Within 7 Days After Vaccination 2
Systemic reactions included fever, irritability, drowsiness, loss of or decreased appetite and were recorded by using an e-diary. Fever was graded as 38.0 to 38.4 degree C, 38.5 to 38.9 degree C, 39.0 to 39.4 degree C, >39.5 to 40.0 degree C and >40.0 degree C. Irritability was graded as mild (easily consolable), moderate (requiring increased attention) and severe (inconsolable). Drowsiness was graded as mild (Increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity) and severe (disabling not interested in usual daily activity). Loss of or decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed).
Safety population: all participants who received at least 1 dose of an investigational product (rLP2086 or HAV vaccine) and had safety data available. Here, N signifies number of participants evaluable for this outcome measure.
Posted
Number
95% Confidence Interval
percentage of Participants
within 7 Days after Vaccination 2
ID
Title
Description
OG000
Group 1: 60-µg Bivalent rLP2086 (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG001
Group 1: 60-µg Bivalent rLP2086 (>=18 Months to <24 Months)
Primary
Percentage of Participants Reporting Systemic Events and Antipyretic Use Within 7 Days After Vaccination 3
Systemic reactions included fever, irritability, drowsiness, loss of or decreased appetite and were recorded by using an e-diary. Fever was graded as 38.0 to 38.4 degree C, 38.5 to 38.9 degree C, 39.0 to 39.4 degree C, >39.5 to 40.0 degree C and >40.0 degree C. Irritability was graded as mild (easily consolable), moderate (requiring increased attention) and severe (inconsolable). Drowsiness was graded as mild (Increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity) and severe (disabling not interested in usual daily activity). Loss of or decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed).
Safety population: all participants who received at least 1 dose of an investigational product (rLP2086 or HAV vaccine) and had safety data available. Here, N signifies number of participants evaluable for this outcome measure.
Posted
Number
95% Confidence Interval
percentage of Participants
within 7 Days after Vaccination 3
ID
Title
Description
OG000
Group 1: 60-µg Bivalent rLP2086 (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG001
Group 1: 60-µg Bivalent rLP2086 (>=18 Months to <24 Months)
Primary
Percentage of Participants With at Least 1 Adverse Event (AE), Serious Adverse Event (SAE), Medically Attended Adverse Event (MAE), Newly Diagnosed Chronic Medical Condition (NDCMC) and Immediate Adverse Event (IAE) Within 30 Days After Vaccination 1
An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication; important medical event. A MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects. Immediate AE was defined as AEs occurring within the first 30 minutes after investigational product administration.
Safety population: all participants who received at least 1 dose of an investigational product (rLP2086 or HAV vaccine) and had safety data available.
Posted
Number
95% Confidence Interval
percentage of Participants
within 30 Days after Vaccination 1
ID
Title
Description
OG000
Group 1: 60-µg Bivalent rLP2086 (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
Primary
Percentage of Participants With at Least 1 Adverse Event (AE), Serious Adverse Event (SAE), Medically Attended Adverse Event (MAE), Newly Diagnosed Chronic Medical Condition (NDCMC) and Immediate Adverse Event (IAE) Within 30 Days After Vaccination 2
An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication; important medical event. A MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects. Immediate AE was defined as AEs occurring within the first 30 minutes after investigational product administration.
Safety population: all participants who received at least 1 dose of an investigational product (rLP2086 or HAV vaccine) and had safety data available. Here, N signifies number of participants evaluable for this outcome measure.
Posted
Number
95% Confidence Interval
percentage of Participants
within 30 Days after Vaccination 2
ID
Title
Description
OG000
Group 1: 60-µg Bivalent rLP2086 (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
Primary
Percentage of Participants With at Least 1 Adverse Event (AE), Serious Adverse Event (SAE), Medically Attended Adverse Event (MAE), Newly Diagnosed Chronic Medical Condition (NDCMC) and Immediate Adverse Event (IAE) Within 30 Days After Vaccination 3
An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication; important medical event. A MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects. Immediate AE was defined as AEs occurring within the first 30 minutes after investigational product administration.
Safety population: all participants who received at least 1 dose of an investigational product (rLP2086 or HAV vaccine) and had safety data available. Here, N signifies number of participants evaluable for this outcome measure.
Posted
Number
95% Confidence Interval
percentage of Participants
within 30 Days after Vaccination 3
ID
Title
Description
OG000
Group 1: 60-µg Bivalent rLP2086 (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
Primary
Percentage of Participants With at Least 1 Adverse Event (AE), Serious Adverse Event (SAE), Medically Attended Adverse Event (MAE) and Newly Diagnosed Chronic Medical Condition (NDCMC) Within 30 Days After Any Vaccination
An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication; important medical event. A MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.
Safety population: all participants who received at least 1 dose of the investigational product (rLP2086 or HAV/saline) and had safety data available.
Posted
Number
95% Confidence Interval
percentage of Participants
within 30 Days after any Vaccination
ID
Title
Description
OG000
Group 1: 60-µg Bivalent rLP2086 (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG001
Group 1: 60-µg Bivalent rLP2086 (>=18 Months to <24 Months)
Primary
Percentage of Participants With at Least 1 Adverse Event (AE), Serious Adverse Event (SAE), Medically Attended Adverse Event (MAE) and Newly Diagnosed Chronic Medical Condition (NDCMC) During the Vaccination Phase
An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication; important medical event. A MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.
Safety population: all participants who received at least 1 dose of the investigational product (rLP2086 or HAV/saline) and had safety data available.
Posted
Number
95% Confidence Interval
percentage of Participants
From the Vaccination 1 up to 1 month after Vaccination 3
ID
Title
Description
OG000
Group 1: 60-µg Bivalent rLP2086 (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG001
Group 1: 60-µg Bivalent rLP2086 (>=18 Months to <24 Months)
Primary
Percentage of Participants With at Least 1 Serious Adverse Event (SAE), Medically Attended Adverse Event (MAE) and Newly Diagnosed Chronic Medical Condition (NDCMC) During the Follow up Phase
An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication; important medical event. A MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.
Safety population: all participants who received at least 1 dose of the investigational product (rLP2086 or HAV/saline) and had safety data available. Here "N" signifies number of participants evaluable for this outcome measure.
Posted
Number
95% Confidence Interval
percentage of Participants
From 1 month after Vaccination 3 up to 6 months after Vaccination 3
ID
Title
Description
OG000
Group 1: 60-µg Bivalent rLP2086 (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG001
Primary
Percentage of Participants With at Least 1 Serious Adverse Event (SAE), Medically Attended Adverse Event (MAE) and Newly Diagnosed Chronic Medical Condition (NDCMC) From Vaccination 1 up to 6 Months After Vaccination 3
An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication; important medical event. A MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.
Safety population: all participants who received at least 1 dose of the investigational product (rLP2086 or HAV/saline) and had safety data available.
Posted
Number
95% Confidence Interval
percentage of Participants
From Vaccination 1 up to 6 months after Vaccination 3
ID
Title
Description
OG000
Group 1: 60-µg Bivalent rLP2086 (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG001
Group 1: 60-µg Bivalent rLP2086 (>=18 Months to <24 Months)
Secondary
Percentage of Participants With hSBA Titer Between 12 Months to Less Than (<) 24 Months >= LLOQ for Each of the 4 Primary MnB Test Strains at 1, 6, 12, and 24 Months After Vaccination 3
Percentage of participants achieving hSBA titer >= LLOQ were computed along with corresponding 2-sided 95% CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24), and PMB2707 (B44).
Evaluable immunogenicity population: all eligible participants randomized to study, received scheduled investigational products, had pre and post vaccination blood drawn with valid and determinate assay results and had no important protocol deviation. Here N signifies number of participants evaluable for this outcome measure and "number analyzed" (n) signifies participants evaluable at specific rows.
Posted
Number
95% Confidence Interval
percentage of Participants
1, 6, 12, 24 months after Vaccination 3
ID
Title
Description
OG000
Group 1: 60- mcg Bivalent rLP2086 (>=12 Months to <24 Months)
Participants from greater than or equal to (>=) 12 months to less than (<) 24 months of age, received intramuscular injection of 60 mcg of bivalent rLP2086 vaccine on months 0 vaccine on a 0, 2, 6 month schedule.
OG001
Group 2: 120-mcg Bivalent rLP2086 (>=12 Months to <24 Months)
Participants from >=12 months to <24 months of age, received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine on a 0, 2, 6 month schedule. All participants who received 3 doses of 120 mcg bivalent rLP2086 in Stage 1 and gave consent for booster vaccination, received intramuscular injection of single booster dose of 120 mcg of bivalent rLP2086 after 23 to 24 months of Vaccination 3, in Stage 2. Participants were followed up approximately 6 months after the booster vaccination.
Secondary
Percentage of Participants With hSBA Titer >= LLOQ for Each of the 4 Primary MnB Test Strains 1 Month After Vaccination 2
Percentage of participants achieving hSBA titer >= LLOQ were computed along with corresponding 2-sided 95% CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24), and PMB2707 (B44).
Evaluable immunogenicity population: all eligible participants randomized to study, received scheduled investigational products, had pre and post vaccination blood drawn with valid and determinate assay results and had no important protocol deviation. Here "N" signifies number of participants evaluable for this outcome measure.
Posted
Number
95% Confidence Interval
percentage of Participants
1 month (Mon) after Vaccination (Vac) 2
ID
Title
Description
OG000
Group 1: 60-µg Bivalent rLP2086 (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG001
Group 1: 60-µg Bivalent rLP2086 (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG002
Group 1: 60- mcg Bivalent rLP2086 (>=12 Months to <24 Months)
Secondary
Percentage of Participants With Serum Bactericidal Assay Using hSBA Titers >=1:4, >=1:8, >=1:16, >=1:32, >=1:64 and >=1:128 for Each of the 4 Primary Test Strains
Evaluable immunogenicity population: all eligible participants randomized to study, received scheduled investigational products, had pre and post vaccination blood drawn with valid and determinate assay results and had no important protocol deviation. Here N signifies number of participants evaluable for this outcome measure and n signifies participants evaluable at specific rows.
Posted
Number
95% Confidence Interval
percentage of Participants
Before Vaccination 1 (T1), 1 month after Vaccination 2 (T2), 1 month after Vaccination 3 (T3), 6 months after Vaccination 3 (T4), 12 months after Vaccination 3 (T5) and 24 months after Vaccination 3 (T6)
ID
Title
Description
OG000
Group 1: 60-µg Bivalent rLP2086 (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG001
Group 1: 60-µg Bivalent rLP2086 (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG002
Group 1: 60- mcg Bivalent rLP2086 (>=12 Months to <24 Months)
Secondary
Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs) for Each of the 4 Primary Test Strains
Evaluable immunogenicity population: all eligible participants randomized to study, received scheduled investigational products, had pre and post vaccination blood drawn with valid and determinate assay results and had no important protocol deviation. Here N signifies number of participants evaluable for this outcome measure and n signifies participants evaluable at specific rows.
Posted
Geometric Mean
95% Confidence Interval
titer
Before Vaccination 1 (T1), 1 month after Vaccination 2 (T2), 1 month after Vaccination 3 (T3), 6 months after Vaccination 3 (T4), 12 months after Vaccination 3 (T5) and 24 months after Vaccination 3 (T6)
ID
Title
Description
OG000
Group 1: 60-µg Bivalent rLP2086 (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG001
Group 1: 60-µg Bivalent rLP2086 (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG002
Group 1: 60- mcg Bivalent rLP2086 (>=12 Months to <24 Months)
Secondary
Percentage of Participants Reporting Pre-specified Local Reactions Within 7 Days After Booster Vaccination
Local reactions included pain at injection site, swelling and redness collected by using an e-diary. Pain at injection site was graded as: mild (does not interfere with activity), moderate (interferes with activity) and severe (prevents daily activity). A caliper was used to measure the redness or swelling area. Caliper units were converted to centimeters (cm) according to 1 caliper unit = 0.5 cm. Redness and swelling were graded as: none (0 cm) mild (0.5-2.0 cm), moderate (>=2.0 to 7.0 cm) and severe (>7.0 cm).
Booster safety population included all participants who received the booster dose at 23 months after vaccination 3 (Visit 12), and for whom safety information was available.
Posted
Number
95% Confidence Interval
percentage of participants
Within 7 days after booster vaccination
ID
Title
Description
OG000
120-mcg Bivalent rLP2086: Stage 2 Booster Phase
Participants who were randomly assigned to bivalent rLP2086 (irrespective of dose level) were eligible for booster vaccination. Participants received intramuscular injection of 120-mcg of bivalent rLP2086 vaccine after 23 months of visit 3.
Units
Counts
Participants
Secondary
Percentage of Participants Reporting Systemic Events and Antipyretic Use Within 7 Days After Booster Vaccination
Systemic reactions included fever, vomiting, diarrhea, headache, fatigue, muscle pain and joint pain were recorded by using an e-diary. Fever was defined as a temperature of greater than or equal to (>=) 38.0 degree Celsius and was graded as 38.0 degree Celsius (C) to 38.4 degree C, 38.5 degree C to 38.9 degree C, 39.0 degree C to 39.4 degree C, 39.5 degree C to 40.0 degree C, >40.0 degree C. Vomiting was graded as mild (1 to 2 times in 24 hours), moderate (>2 times in 24 hours) and severe (requires IV hydration). Diarrhea was graded as mild (2 to 3 loose stools in 24 hours), moderate (4 to 5 loose stools in 24 hours), and severe (6 or more loose stools in 24 hours). Fatigue, headache, muscle pain and joint pain were graded as: mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily routine activity). The use and type of antipyretic medication was also recorded in the e-diary daily.
Booster safety population included all participants who received the booster dose at 23 months after Vaccination 3 (Visit 12), and for whom safety information was available.
Posted
Number
95% Confidence Interval
percentage of participants
Within 7 days after booster vaccination
ID
Title
Description
OG000
120-mcg Bivalent rLP2086: Stage 2 Booster Phase
Participants who were randomly assigned to bivalent rLP2086 (irrespective of dose level) were eligible for booster vaccination. Participants received intramuscular injection of 120-mcg of bivalent rLP2086 vaccine after 23 months of visit 3.
Secondary
Percentage of Participants With SAE, MAE, NDCMC From Booster Vaccination to 1 Month After Booster Vaccination, 1 Month After Booster Vaccination to 6 Months After Booster Vaccination and Booster Vaccination Through 6 Months After Booster Vaccination
SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication; important medical event. A MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.
Booster safety population included all participants who received the booster dose at 23 months after Vaccination 3 (Visit 12), and for whom safety information was available.
Posted
Number
95% Confidence Interval
percentage of participants
Booster vaccination to 1 month after booster vaccination (T1), 1 month after booster vaccination to 6 months after booster vaccination (T2) and booster vaccination through 6 months after booster vaccination (T3)
ID
Title
Description
OG000
120-mcg Bivalent rLP2086: Stage 2 Booster Phase
Participants who were randomly assigned to bivalent rLP2086 (irrespective of dose level) were eligible for booster vaccination. Participants received intramuscular injection of 120-mcg of bivalent rLP2086 vaccine after 23 months of visit 3.
Secondary
Percentage of Participants With at Least 1 Adverse Event (AE) From Booster Vaccination to 1 Month After Booster Vaccination
An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship.
Booster safety population included all participants who received the booster dose at 23 months after Vaccination 3 (Visit 12), and for whom safety information was available.
Posted
Number
95% Confidence Interval
percentage of participants
Booster vaccination up to 1 month after booster vaccination
ID
Title
Description
OG000
120-mcg Bivalent rLP2086: Stage 2 Booster Phase
Participants who were randomly assigned to bivalent rLP2086 (irrespective of dose level) were eligible for booster vaccination. Participants received intramuscular injection of 120-mcg of bivalent rLP2086 vaccine after 23 months of visit 3.
Units
Counts
Participants
OG000
Secondary
Percentage of Participants With Immediate Adverse Event (IAE) After Booster Vaccination
Immediate AE was defined as AEs occurring within the first 30 minutes after investigational product administration.
Booster safety population included all participants who received the booster dose at 23 months after vaccination 3 (Visit 12), and for whom safety information was available.
Posted
Number
95% Confidence Interval
percentage of participants
Within 30 minutes after booster vaccination
ID
Title
Description
OG000
120-mcg Bivalent rLP2086: Stage 2 Booster Phase
Participants who were randomly assigned to bivalent rLP2086 (irrespective of dose level) were eligible for booster vaccination. Participants received intramuscular injection of 120-mcg of bivalent rLP2086 vaccine after 23 months of visit 3.
Units
Counts
Participants
OG000
Secondary
Percentage of Participants With hSBA Titer >=LLOQ >=1:4, >=1:8, >=1:16, >=1:32, >=1:64 and >=1:128 for Each of the 4 Primary Test Strains Before Booster Vaccination, and 1 Month After Booster Vaccination
Percentage of participants achieving hSBA titer >= LLOQ were computed along with corresponding 2-sided 95 % CIs. The LLOQ was 1:16 for A22 and 1:8 for A56, B24, and B44.
Booster evaluable immunogenicity population: participants eligible for study, randomized to 120 mcg bivalent rLP2086 during stage 1, received scheduled investigational products, had blood drawn prior to booster vaccination dose and post-booster vaccination blood drawn (Visit 13) within 28-42 days from booster vaccination (Visit 12) and had no important protocol deviation. N=number of participants evaluable for this outcome measure and number analyzed=participants evaluable at specific rows.
Posted
Number
95% Confidence Interval
percentage of participants
Before booster vaccination and 1 month after booster vaccination
ID
Title
Description
OG000
120-mcg Bivalent rLP2086: Stage 2 Booster Phase
Participants who were randomly assigned to bivalent rLP2086 (irrespective of dose level) were eligible for booster vaccination. Participants received intramuscular injection of 120-mcg of bivalent rLP2086 vaccine after 23 months of visit 3.
Units
Counts
Participants
Secondary
Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs) for Each of the 4 MnB Primary Test Strains at Before Booster Vaccination and 1 Month After Booster Vaccination
The LLOQ was 1:16 for A22, 1:8 for A56, B24, and B44. Titers below the LLOQ were set to 0.5*LLOQ for analysis. Titers were expressed in terms of 1/dilution.
Booster evaluable immunogenicity population: participants eligible for study, randomized to 120 mcg bivalent rLP2086 during stage 1, received scheduled investigational products, had blood drawn prior to booster vaccination dose and post-booster vaccination blood drawn (Visit 13) within 28-42 days from booster vaccination (Visit 12) and had no important protocol deviation. N=number of participants evaluable for this outcome measure and number analyzed=participants evaluable at specific rows.
Posted
Geometric Mean
95% Confidence Interval
titer
Before booster vaccination and 1 month after booster vaccination
ID
Title
Description
OG000
120-mcg Bivalent rLP2086: Stage 2 Booster Phase
Participants who were randomly assigned to bivalent rLP2086 (irrespective of dose level) were eligible for booster vaccination. Participants received intramuscular injection of 120-mcg of bivalent rLP2086 vaccine after 23 months of visit 3.
Units
Counts
Participants
Time Frame
Stage 1: SAEs:Recorded from Vaccination(Vacc) 1 through 6 months after Vacc. 3 (Month 12). Local reactions and systemic events in e-diary: 7 days after Vacc 1, 2 and 3. NSAEs: Vaccination 1 through 1 month after Vacc 3 (Month 7). Stage 2 Follow up phase: Month 24 visit (up to 30 days). Stage 2 Booster phase: SAEs: From booster vacc up to 6 months after booster vacc NSAEs: From booster vacc up to 1 month after booster vacc. Local reactions and systemic events in e-diary: 7 days after booster vacc
Description
SAEs and AEs were grouped by system organ class and preferred term. AEs included AEs collected in the e-diary (local and systemic reactions; systematic assessment) and AEs collected on the case report form at each visit (nonsystematic assessment).
All-Cause Mortality Comment
Not provided
Arm/Groups
ID
Title
Description
Deaths (Affected)
Deaths (At Risk)
Serious Events (Affected)
Serious Events (At Risk)
Other Events (Affected)
Other Events (At Risk)
EG000
Group 1: 60- Microgram (mcg) Bivalent rLP2086 (>=12 Months to <24 Months): Stage 1
Participants from greater than or equal to (>=) 12 months to less than (<) 24 months of age, received intramuscular injection of 60 mcg of bivalent rLP2086 vaccine on months 0 (visit 1, vaccination1), 2 (visit 4, vaccination 2), and 6 (visit 6, vaccination 3).
0
44
4
44
43
44
EG001
Group 2: 120-mcg Bivalent rLP2086 (>=12 Months to <24 Months):Stage 1
Participants from >=12 months to <24 months of age, received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine on months 0 (visit 1, vaccination1), 2 (visit 4, vaccination 2), and 6 (visit 6, vaccination 3). All eligible participants (who received 3 doses of bivalent rLP2086 in stage 1 at the 120 mcg dose level) received intramuscular injection of single booster dose of 120 mcg of bivalent rLP2086 after 23 months of vaccination 3 (visit 12) in stage 2. Participants were followed up approximately 6 months after the booster vaccination.
0
220
19
220
209
220
EG002
Group 3: HAV/Saline (>=12 Months to <24 Months): Stage 1
Participants from >=12 months to <24 months of age, received intramuscular injection of saline on 2 month and HAV vaccine on a 0, 6 month schedule.
0
132
8
132
113
132
EG003
120-mcg Bivalent rLP2086: Stage 2 Booster Phase
Participants who were randomly assigned to bivalent rLP2086 (irrespective of dose level) were eligible for booster vaccination. Participants received intramuscular injection of 120-mcg of bivalent rLP2086 vaccine after 23 months of visit 3.
0
147
2
147
121
147
EG004
Group 1: 60-mcg Bivalent rLP2086 (>=12 Months to <24 Months): Follow up
Participants from >=12 months to <24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on months 0 (visit 1, vaccination1), 2 (visit 4, vaccination 2), and 6 (visit 6, vaccination 3).
0
44
0
44
0
44
EG005
Group 2: 120-mcg Bivalent rLP2086 (>=12 Months to <24 Months): Follow up
Participants from >=12 months to <24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on months 0 (visit 1, vaccination1), 2 (visit 4, vaccination 2), and 6 (visit 6, vaccination 3).
0
220
3
220
0
220
EG006
Group 3: HAV/Saline (>=12 Months to <24 Months): Follow up
Participants from >=12 months to <24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on months 0 (visit 1, vaccination1), 2 (visit 4, vaccination 2), and 6 (visit 6, vaccination 3).
0
132
0
132
0
132
Serious Adverse Events
Term
Organ System
Source Vocabulary
Assessment Type
Notes
Statistical Information
Eyelid ptosis
Eye disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0011 affected220 at risk
EG0020 affected132 at risk
EG0030 affected147 at risk
EG004
Enteritis
Gastrointestinal disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0001 affected44 at risk
EG0010 affected220 at risk
EG0020 affected132 at risk
EG003
Gastrooesophageal reflux disease
Gastrointestinal disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0010 affected220 at risk
EG0021 affected132 at risk
EG003
Inguinal hernia
Gastrointestinal disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0010 affected220 at risk
EG0021 affected132 at risk
EG003
Nausea
Gastrointestinal disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0011 affected220 at risk
EG0020 affected132 at risk
EG003
Crying
General disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0011 affected220 at risk
EG0020 affected132 at risk
EG003
Pyrexia
General disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0011 affected220 at risk
EG0020 affected132 at risk
EG003
Bronchiolitis
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0012 affected220 at risk
EG0020 affected132 at risk
EG003
Bronchitis
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0011 affected220 at risk
EG0022 affected132 at risk
EG003
Croup infectious
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0010 affected220 at risk
EG0021 affected132 at risk
EG003
Enterovirus infection
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0010 affected220 at risk
EG0021 affected132 at risk
EG003
Gastroenteritis
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0013 affected220 at risk
EG0021 affected132 at risk
EG003
Otitis media
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0012 affected220 at risk
EG0020 affected132 at risk
EG003
Otitis media chronic
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0001 affected44 at risk
EG0010 affected220 at risk
EG0020 affected132 at risk
EG003
Pneumonia
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0013 affected220 at risk
EG0020 affected132 at risk
EG003
Pneumonia respiratory syncytial viral
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0011 affected220 at risk
EG0020 affected132 at risk
EG003
Respiratory tract infection viral
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0011 affected220 at risk
EG0020 affected132 at risk
EG003
Tonsillitis
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0001 affected44 at risk
EG0012 affected220 at risk
EG0020 affected132 at risk
EG003
Urinary tract infection
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0011 affected220 at risk
EG0020 affected132 at risk
EG003
Viral tonsillitis
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0012 affected220 at risk
EG0020 affected132 at risk
EG003
Viral upper respiratory tract infection
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0010 affected220 at risk
EG0021 affected132 at risk
EG003
Accidental exposure to product
Injury, poisoning and procedural complications
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0010 affected220 at risk
EG0021 affected132 at risk
EG003
Head injury
Injury, poisoning and procedural complications
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0011 affected220 at risk
EG0020 affected132 at risk
EG003
Balance disorder
Nervous system disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0011 affected220 at risk
EG0020 affected132 at risk
EG003
Cerebellar ataxia
Nervous system disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0001 affected44 at risk
EG0010 affected220 at risk
EG0020 affected132 at risk
EG003
Irritability
Psychiatric disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0011 affected220 at risk
EG0020 affected132 at risk
EG003
Polydipsia psychogenic
Psychiatric disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0011 affected220 at risk
EG0020 affected132 at risk
EG003
Adenoidal hypertrophy
Respiratory, thoracic and mediastinal disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0001 affected44 at risk
EG0010 affected220 at risk
EG0020 affected132 at risk
EG003
Constipation
Gastrointestinal disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0010 affected220 at risk
EG0020 affected132 at risk
EG003
Rhinovirus infection
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0010 affected220 at risk
EG0020 affected132 at risk
EG003
Cellulitis
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0010 affected220 at risk
EG0020 affected132 at risk
EG003
Sleep apnoea syndrome
Respiratory, thoracic and mediastinal disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0010 affected220 at risk
EG0020 affected132 at risk
EG003
Influenza
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0010 affected220 at risk
EG0020 affected132 at risk
EG003
Other Adverse Events
Term
Organ System
Source Vocabulary
Assessment Type
Notes
Statistical Information
Eustachian tube disorder
Ear and labyrinth disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0001 affected44 at risk
EG0011 affected220 at risk
EG0021 affected132 at risk
EG0030 affected147 at risk
EG004
Middle ear effusion
Ear and labyrinth disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0018 affected220 at risk
EG0023 affected132 at risk
EG003
Anisometropia
Eye disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0001 affected44 at risk
EG0010 affected220 at risk
EG0020 affected132 at risk
EG003
Astigmatism
Eye disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0001 affected44 at risk
EG0010 affected220 at risk
EG0020 affected132 at risk
EG003
Conjunctivitis allergic
Eye disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0001 affected44 at risk
EG0010 affected220 at risk
EG0020 affected132 at risk
EG003
Hypermetropia
Eye disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0001 affected44 at risk
EG0011 affected220 at risk
EG0020 affected132 at risk
EG003
Aphthous ulcer
Gastrointestinal disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0003 affected44 at risk
EG0011 affected220 at risk
EG0020 affected132 at risk
EG003
Diarrhoea
Gastrointestinal disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0001 affected44 at risk
EG00111 affected220 at risk
EG0025 affected132 at risk
EG003
Enteritis
Gastrointestinal disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0001 affected44 at risk
EG0010 affected220 at risk
EG0020 affected132 at risk
EG003
Flatulence
Gastrointestinal disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0001 affected44 at risk
EG0010 affected220 at risk
EG0020 affected132 at risk
EG003
Teething
Gastrointestinal disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0018 affected220 at risk
EG0024 affected132 at risk
EG003
Vomiting
Gastrointestinal disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0001 affected44 at risk
EG0018 affected220 at risk
EG0025 affected132 at risk
EG003
Chills
General disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0013 affected220 at risk
EG0020 affected132 at risk
EG003
Injection site erythema (redness)
General disorders
Systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG00030 affected44 at risk
EG001137 affected220 at risk
EG00228 affected132 at risk
EG003
Injection site erythema
General disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0001 affected44 at risk
EG0010 affected220 at risk
EG0020 affected132 at risk
EG003
Injection site pain (tenderness at injection site)
General disorders
Systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG00035 affected44 at risk
EG001160 affected220 at risk
EG00241 affected132 at risk
EG003
Injection site pain
General disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0001 affected44 at risk
EG0014 affected220 at risk
EG0020 affected132 at risk
EG003
Injection site swelling (swelling)
General disorders
Systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG00017 affected44 at risk
EG001103 affected220 at risk
EG00220 affected132 at risk
EG003
Pyrexia (fever)
General disorders
Systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG00016 affected44 at risk
EG00182 affected220 at risk
EG00220 affected132 at risk
EG003
Pyrexia
General disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0001 affected44 at risk
EG00118 affected220 at risk
EG0026 affected132 at risk
EG003
Vaccination site pain
General disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0001 affected44 at risk
EG0012 affected220 at risk
EG0021 affected132 at risk
EG003
Vessel puncture site bruise
General disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0001 affected44 at risk
EG0010 affected220 at risk
EG0020 affected132 at risk
EG003
Food allergy
Immune system disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0001 affected44 at risk
EG0010 affected220 at risk
EG0020 affected132 at risk
EG003
Bronchiolitis
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0013 affected220 at risk
EG0022 affected132 at risk
EG003
Bronchitis
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0005 affected44 at risk
EG00122 affected220 at risk
EG00211 affected132 at risk
EG003
Cellulitis
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0001 affected44 at risk
EG0012 affected220 at risk
EG0020 affected132 at risk
EG003
Conjunctivitis
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0001 affected44 at risk
EG00122 affected220 at risk
EG00213 affected132 at risk
EG003
Croup infectious
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0019 affected220 at risk
EG0022 affected132 at risk
EG003
Enterobiasis
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0012 affected220 at risk
EG0022 affected132 at risk
EG003
Exanthema subitum
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0013 affected220 at risk
EG0020 affected132 at risk
EG003
Gastroenteritis viral
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0001 affected44 at risk
EG00110 affected220 at risk
EG0023 affected132 at risk
EG003
Gastroenteritis
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0004 affected44 at risk
EG00129 affected220 at risk
EG00211 affected132 at risk
EG003
Hand-foot-and-mouth disease
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0002 affected44 at risk
EG00110 affected220 at risk
EG0026 affected132 at risk
EG003
Impetigo
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0001 affected44 at risk
EG0013 affected220 at risk
EG0023 affected132 at risk
EG003
Infected bite
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0001 affected44 at risk
EG0012 affected220 at risk
EG0020 affected132 at risk
EG003
Laryngitis
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0002 affected44 at risk
EG0013 affected220 at risk
EG0025 affected132 at risk
EG003
Lower respiratory tract infection
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0014 affected220 at risk
EG0022 affected132 at risk
EG003
Molluscum contagiosum
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0001 affected44 at risk
EG0010 affected220 at risk
EG0020 affected132 at risk
EG003
Nasopharyngitis
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0007 affected44 at risk
EG0013 affected220 at risk
EG0027 affected132 at risk
EG003
Otitis externa
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0010 affected220 at risk
EG0022 affected132 at risk
EG003
Otitis media acute
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0001 affected44 at risk
EG0012 affected220 at risk
EG0022 affected132 at risk
EG003
Otitis media
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0003 affected44 at risk
EG00127 affected220 at risk
EG00220 affected132 at risk
EG003
Pharyngitis streptococcal
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0011 affected220 at risk
EG0022 affected132 at risk
EG003
Pharyngitis
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0006 affected44 at risk
EG00118 affected220 at risk
EG00215 affected132 at risk
EG003
Pharyngotonsillitis
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0001 affected44 at risk
EG0010 affected220 at risk
EG0020 affected132 at risk
EG003
Pneumonia
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0017 affected220 at risk
EG0022 affected132 at risk
EG003
Respiratory tract infection viral
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0002 affected44 at risk
EG0013 affected220 at risk
EG0021 affected132 at risk
EG003
Respiratory tract infection
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0014 affected220 at risk
EG0021 affected132 at risk
EG003
Rhinitis
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0003 affected44 at risk
EG0018 affected220 at risk
EG0023 affected132 at risk
EG003
Skin candida
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0001 affected44 at risk
EG0010 affected220 at risk
EG0020 affected132 at risk
EG003
Tonsillitis
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0004 affected44 at risk
EG0016 affected220 at risk
EG0029 affected132 at risk
EG003
Tracheitis
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0001 affected44 at risk
EG0011 affected220 at risk
EG0025 affected132 at risk
EG003
Upper respiratory tract infection
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0006 affected44 at risk
EG00158 affected220 at risk
EG00234 affected132 at risk
EG003
Urinary tract infection
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0017 affected220 at risk
EG0023 affected132 at risk
EG003
Varicella
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0002 affected44 at risk
EG0015 affected220 at risk
EG0023 affected132 at risk
EG003
Viral infection
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0001 affected44 at risk
EG0013 affected220 at risk
EG0022 affected132 at risk
EG003
Viral pharyngitis
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0002 affected44 at risk
EG0010 affected220 at risk
EG0021 affected132 at risk
EG003
Viral tonsillitis
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0001 affected44 at risk
EG0012 affected220 at risk
EG0020 affected132 at risk
EG003
Viral upper respiratory tract infection
Infections and infestations
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0005 affected44 at risk
EG00145 affected220 at risk
EG00223 affected132 at risk
EG003
Arthropod bite
Injury, poisoning and procedural complications
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0013 affected220 at risk
EG0021 affected132 at risk
EG003
Arthropod sting
Injury, poisoning and procedural complications
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0001 affected44 at risk
EG0010 affected220 at risk
EG0020 affected132 at risk
EG003
Concussion
Injury, poisoning and procedural complications
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0010 affected220 at risk
EG0023 affected132 at risk
EG003
Contusion
Injury, poisoning and procedural complications
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0015 affected220 at risk
EG0022 affected132 at risk
EG003
Craniocerebral injury
Injury, poisoning and procedural complications
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0010 affected220 at risk
EG0022 affected132 at risk
EG003
Excoriation
Injury, poisoning and procedural complications
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0001 affected44 at risk
EG0010 affected220 at risk
EG0021 affected132 at risk
EG003
Face injury
Injury, poisoning and procedural complications
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0010 affected220 at risk
EG0022 affected132 at risk
EG003
Fall
Injury, poisoning and procedural complications
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0002 affected44 at risk
EG0015 affected220 at risk
EG0027 affected132 at risk
EG003
Hand fracture
Injury, poisoning and procedural complications
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0001 affected44 at risk
EG0010 affected220 at risk
EG0020 affected132 at risk
EG003
Laceration
Injury, poisoning and procedural complications
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0001 affected44 at risk
EG0014 affected220 at risk
EG0020 affected132 at risk
EG003
Lip injury
Injury, poisoning and procedural complications
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0013 affected220 at risk
EG0020 affected132 at risk
EG003
Decreased appetite (loss of appetite)
Metabolism and nutrition disorders
Systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG00022 affected44 at risk
EG001142 affected220 at risk
EG00250 affected132 at risk
EG003
Decreased appetite
Metabolism and nutrition disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0001 affected44 at risk
EG0011 affected220 at risk
EG0022 affected132 at risk
EG003
Synovitis
Musculoskeletal and connective tissue disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0010 affected220 at risk
EG0022 affected132 at risk
EG003
Headache
Nervous system disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0001 affected44 at risk
EG0010 affected220 at risk
EG0020 affected132 at risk
EG003
Somnolence (drowsiness)
Nervous system disorders
Systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG00023 affected44 at risk
EG001127 affected220 at risk
EG00240 affected132 at risk
EG003
Somnolence
Nervous system disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0013 affected220 at risk
EG0022 affected132 at risk
EG003
Irritability
Psychiatric disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0005 affected44 at risk
EG00121 affected220 at risk
EG0025 affected132 at risk
EG003
Cough
Respiratory, thoracic and mediastinal disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0001 affected44 at risk
EG0018 affected220 at risk
EG0023 affected132 at risk
EG003
Rhinitis allergic
Respiratory, thoracic and mediastinal disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0001 affected44 at risk
EG0012 affected220 at risk
EG0020 affected132 at risk
EG003
Rhinorrhoea
Respiratory, thoracic and mediastinal disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0002 affected44 at risk
EG00111 affected220 at risk
EG0022 affected132 at risk
EG003
Dermatitis allergic
Skin and subcutaneous tissue disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0001 affected44 at risk
EG0014 affected220 at risk
EG0022 affected132 at risk
EG003
Dermatitis contact
Skin and subcutaneous tissue disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0014 affected220 at risk
EG0021 affected132 at risk
EG003
Dermatitis diaper
Skin and subcutaneous tissue disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0013 affected220 at risk
EG0020 affected132 at risk
EG003
Eczema
Skin and subcutaneous tissue disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0014 affected220 at risk
EG0024 affected132 at risk
EG003
Miliaria
Skin and subcutaneous tissue disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0001 affected44 at risk
EG0011 affected220 at risk
EG0021 affected132 at risk
EG003
Rash generalised
Skin and subcutaneous tissue disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0001 affected44 at risk
EG0010 affected220 at risk
EG0020 affected132 at risk
EG003
Rash
Skin and subcutaneous tissue disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0013 affected220 at risk
EG0021 affected132 at risk
EG003
Urticaria
Skin and subcutaneous tissue disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0014 affected220 at risk
EG0022 affected132 at risk
EG003
Irritability
Psychiatric disorders
Systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG00031 affected44 at risk
EG001176 affected220 at risk
EG00269 affected132 at risk
EG003
Dermatitis
Skin and subcutaneous tissue disorders
Non-systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0013 affected220 at risk
EG0023 affected132 at risk
EG003
Vomiting
Gastrointestinal disorders
Systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0010 affected220 at risk
EG0020 affected132 at risk
EG003
Fatigue
General disorders
Systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0010 affected220 at risk
EG0020 affected132 at risk
EG003
Injection site pain
General disorders
Systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0010 affected220 at risk
EG0020 affected132 at risk
EG003
Arthralgia
Musculoskeletal and connective tissue disorders
Systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0010 affected220 at risk
EG0020 affected132 at risk
EG003
Myalgia
Musculoskeletal and connective tissue disorders
Systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0010 affected220 at risk
EG0020 affected132 at risk
EG003
Headache
Nervous system disorders
Systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups.
EG0000 affected44 at risk
EG0010 affected220 at risk
EG0020 affected132 at risk
EG003
Diarrhoea
Gastrointestinal disorders
Systematic Assessment
MedDRA v20.0 for Group 1: 60mcg bivalent rLP2086 (>=12 months to <24 months), Group 2: 120mcg bivalent rLP2086 (>=12 months to <24 months), Group 3: HAV/Saline (>=12 months to <24 months); MedDRA v23.0 for booster stage and safety follow up groups
EG0000 affected44 at risk
EG0010 affected220 at risk
EG0020 affected132 at risk
EG003
The immunogenicity data at 36 and 48 months after vaccination 3 was not collected due to change in planned analysis as per latest protocol amendment, according to which blood draw of participants at 36 and 48 months after Vaccination 3 was removed.
Certain Agreements
Are all PI(s) employees of the sponsor?
No
Restriction Type
OTHER
Results Disclosure Restriction on PI(s)?
Yes
Other Details
Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
Participants from greater than or equal to (>=) 12 months to less than (<) 24 months of age, received intramuscular injection of 60 mcg of bivalent rLP2086 vaccine on months 0 vaccine on a 0, 2, 6 month schedule.
OG003
Group 2: 120-µg Bivalent rLP2086 (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG004
Group 2: 120-µg Bivalent rLP2086 (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG005
Group 2: 120-mcg Bivalent rLP2086 (>=12 Months to <24 Months)
Participants from >=12 months to <24 months of age, received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine on a 0, 2, 6 month schedule. All participants who received 3 doses of 120 mcg bivalent rLP2086 in Stage 1 and gave consent for booster vaccination, received intramuscular injection of single booster dose of 120 mcg of bivalent rLP2086 after 23 to 24 months of Vaccination 3, in Stage 2. Participants were followed up approximately 6 months after the booster vaccination.
OG006
Group 3: HAV/Saline (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.
OG007
Group 3: HAV/Saline (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.
OG008
Group 3: HAV/Saline (>=12 Months to <24 Months): Stage 1
Participants from >=12 months to <24 months of age, received intramuscular injection of saline on 2 month and HAV vaccine on a 0, 6 month schedule.
Units
Counts
Participants
OG00022
OG00122
OG00244
OG003110
OG004110
OG005220
OG00666
OG00766
OG008132
Title
Denominators
Categories
Tenderness at injection site: Any
Title
Measurements
OG00068.2(45.1 to 86.1)
OG00150.0(28.2 to 71.8)
OG00259.1(43.2 to 73.7)
OG00350.9(41.2 to 60.6)
OG00464.5(54.9 to 73.4)
OG00557.7(50.9 to 64.3)
OG00615.2(7.5 to 26.1)
OG00719.7(10.9 to 31.3)
OG00817.4(11.4 to 25.0)
Tenderness at injection site: Mild
Title
Measurements
OG00045.5(24.4 to 67.8)
OG00127.3(10.7 to 50.2)
OG00236.4(22.4 to 52.2)
OG003
Tenderness at injection site: Moderate
Title
Measurements
OG00022.7(7.8 to 45.4)
OG00118.2(5.2 to 40.3)
OG00220.5(9.8 to 35.3)
OG003
Tenderness at injection site: Severe
Title
Measurements
OG0000.0(0.0 to 15.4)
OG0014.5(0.1 to 22.8)
OG0022.3(0.1 to 12.0)
OG003
Redness: Any
Title
Measurements
OG00068.2(45.1 to 86.1)
OG00140.9(20.7 to 63.6)
OG00254.5(38.8 to 69.6)
OG003
Redness: Mild
Title
Measurements
OG00040.9(20.7 to 63.6)
OG00127.3(10.7 to 50.2)
OG00234.1(20.5 to 49.9)
OG003
Redness: Moderate
Title
Measurements
OG00027.3(10.7 to 50.2)
OG00113.6(2.9 to 34.9)
OG00220.5(9.8 to 35.3)
OG003
Redness: Severe
Title
Measurements
OG0000.0(0.0 to 15.4)
OG0010.0(0.0 to 15.4)
OG0020.0(0.0 to 8.0)
OG003
Swelling: Any
Title
Measurements
OG00036.4(17.2 to 59.3)
OG00122.7(7.8 to 45.4)
OG00229.5(16.8 to 45.2)
OG003
Swelling: Mild
Title
Measurements
OG00022.7(7.8 to 45.4)
OG00113.6(2.9 to 34.9)
OG00218.2(8.2 to 32.7)
OG003
Swelling: Moderate
Title
Measurements
OG00013.6(2.9 to 34.9)
OG0019.1(1.1 to 29.2)
OG00211.4(3.8 to 24.6)
OG003
Swelling: Severe
Title
Measurements
OG0000.0(0.0 to 15.4)
OG0010.0(0.0 to 15.4)
OG0020.0(0.0 to 8.0)
OG003
Participants from greater than or equal to (>=) 12 months to less than (<) 24 months of age, received intramuscular injection of 60 mcg of bivalent rLP2086 vaccine on months 0 vaccine on a 0, 2, 6 month schedule.
OG003
Group 2: 120-µg Bivalent rLP2086 (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG004
Group 2: 120-µg Bivalent rLP2086 (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG005
Group 2: 120-mcg Bivalent rLP2086 (>=12 Months to <24 Months)
Participants from >=12 months to <24 months of age, received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine on a 0, 2, 6 month schedule. All participants who received 3 doses of 120 mcg bivalent rLP2086 in Stage 1 and gave consent for booster vaccination, received intramuscular injection of single booster dose of 120 mcg of bivalent rLP2086 after 23 to 24 months of Vaccination 3, in Stage 2. Participants were followed up approximately 6 months after the booster vaccination.
OG006
Group 3: HAV/Saline (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.
OG007
Group 3: HAV/Saline (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.
OG008
Group 3: HAV/Saline (>=12 Months to <24 Months): Stage 1
Participants from >=12 months to <24 months of age, received intramuscular injection of saline on 2 month and HAV vaccine on a 0, 6 month schedule.
Units
Counts
Participants
OG00022
OG00122
OG00244
OG003105
OG004107
OG005212
OG00663
OG00765
OG008128
Title
Denominators
Categories
Tenderness at injection site: Any
Title
Measurements
OG00045.5(24.4 to 67.8)
OG00150.0(28.2 to 71.8)
OG00247.7(32.5 to 63.3)
OG00345.7(36.0 to 55.7)
OG00460.7(50.8 to 70.0)
OG00553.3(46.3 to 60.2)
OG00614.3(6.7 to 25.4)
OG00715.4(7.6 to 26.5)
OG00814.8(9.2 to 22.2)
Tenderness at injection site: Mild
Title
Measurements
OG00031.8(13.9 to 54.9)
OG00140.9(20.7 to 63.6)
OG00236.4(22.4 to 52.2)
OG003
Tenderness at injection site: Moderate
Title
Measurements
OG00013.6(2.9 to 34.9)
OG0019.1(1.1 to 29.2)
OG00211.4(3.8 to 24.6)
OG003
Tenderness at injection site: Severe
Title
Measurements
OG0000.0(0.0 to 15.4)
OG0010.0(0.0 to 15.4)
OG0020.0(0.0 to 8.0)
OG003
Redness: Any
Title
Measurements
OG00050.0(28.2 to 71.8)
OG00131.8(13.9 to 54.9)
OG00240.9(26.3 to 56.8)
OG003
Redness: Mild
Title
Measurements
OG00040.9(20.7 to 63.6)
OG00127.3(10.7 to 50.2)
OG00234.1(20.5 to 49.9)
OG003
Redness: Moderate
Title
Measurements
OG0009.1(1.1 to 29.2)
OG0014.5(0.1 to 22.8)
OG0026.8(1.4 to 18.7)
OG003
Redness: Severe
Title
Measurements
OG0000.0(0.0 to 15.4)
OG0010.0(0.0 to 15.4)
OG0020.0(0.0 to 8.0)
OG003
Swelling: Any
Title
Measurements
OG00018.2(5.2 to 40.3)
OG00127.3(10.7 to 50.2)
OG00222.7(11.5 to 37.8)
OG003
Swelling: Mild
Title
Measurements
OG00018.2(5.2 to 40.3)
OG00113.6(2.9 to 34.9)
OG00215.9(6.6 to 30.1)
OG003
Swelling: Moderate
Title
Measurements
OG0000.0(0.0 to 15.4)
OG00113.6(2.9 to 34.9)
OG0026.8(1.4 to 18.7)
OG003
Swelling: Severe
Title
Measurements
OG0000.0(0.0 to 15.4)
OG0010.0(0.0 to 15.4)
OG0020.0(0.0 to 8.0)
OG003
Participants from greater than or equal to (>=) 12 months to less than (<) 24 months of age, received intramuscular injection of 60 mcg of bivalent rLP2086 vaccine on months 0 vaccine on a 0, 2, 6 month schedule.
OG003
Group 2: 120-µg Bivalent rLP2086 (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG004
Group 2: 120-µg Bivalent rLP2086 (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG005
Group 2: 120-mcg Bivalent rLP2086 (>=12 Months to <24 Months)
Participants from >=12 months to <24 months of age, received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine on a 0, 2, 6 month schedule. All participants who received 3 doses of 120 mcg bivalent rLP2086 in Stage 1 and gave consent for booster vaccination, received intramuscular injection of single booster dose of 120 mcg of bivalent rLP2086 after 23 to 24 months of Vaccination 3, in Stage 2. Participants were followed up approximately 6 months after the booster vaccination.
OG006
Group 3: HAV/Saline (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.
OG007
Group 3: HAV/Saline (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.
OG008
Group 3: HAV/Saline (>=12 Months to <24 Months): Stage 1
Participants from >=12 months to <24 months of age, received intramuscular injection of saline on 2 month and HAV vaccine on a 0, 6 month schedule.
Units
Counts
Participants
OG00022
OG00122
OG00244
OG003104
OG004108
OG005212
OG00665
OG00763
OG008128
Title
Denominators
Categories
Tenderness at injection site: Any
Title
Measurements
OG00054.5(32.2 to 75.6)
OG00159.1(36.4 to 79.3)
OG00256.8(41.0 to 71.7)
OG00351.9(41.9 to 61.8)
OG00462.0(52.2 to 71.2)
OG00557.1(50.1 to 63.8)
OG00616.9(8.8 to 28.3)
OG00714.3(6.7 to 25.4)
OG00815.6(9.8 to 23.1)
Tenderness at injection site: Mild
Title
Measurements
OG00022.7(7.8 to 45.4)
OG00140.9(20.7 to 63.6)
OG00231.8(18.6 to 47.6)
OG003
Tenderness at injection site: Moderate
Title
Measurements
OG00031.8(13.9 to 54.9)
OG00118.2(5.2 to 40.3)
OG00225.0(13.2 to 40.3)
OG003
Tenderness at injection site: Severe
Title
Measurements
OG0000.0(0.0 to 15.4)
OG0010.0(0.0 to 15.4)
OG0020.0(0.0 to 8.0)
OG003
Redness: Any
Title
Measurements
OG00040.9(20.7 to 63.6)
OG00136.4(17.2 to 59.3)
OG00238.6(24.4 to 54.5)
OG003
Redness: Mild
Title
Measurements
OG00031.8(13.9 to 54.9)
OG00127.3(10.7 to 50.2)
OG00229.5(16.8 to 45.2)
OG003
Redness: Moderate
Title
Measurements
OG0009.1(1.1 to 29.2)
OG0019.1(1.1 to 29.2)
OG0029.1(2.5 to 21.7)
OG003
Redness: Severe
Title
Measurements
OG0000.0(0.0 to 15.4)
OG0010.0(0.0 to 15.4)
OG0020.0(0.0 to 8.0)
OG003
Swelling: Any
Title
Measurements
OG00018.2(5.2 to 40.3)
OG00127.3(10.7 to 50.2)
OG00222.7(11.5 to 37.8)
OG003
Swelling: Mild
Title
Measurements
OG0009.1(1.1 to 29.2)
OG00113.6(2.9 to 34.9)
OG00211.4(3.8 to 24.6)
OG003
Swelling: Moderate
Title
Measurements
OG0009.1(1.1 to 29.2)
OG00113.6(2.9 to 34.9)
OG00211.4(3.8 to 24.6)
OG003
Swelling: Severe
Title
Measurements
OG0000.0(0.0 to 15.4)
OG0010.0(0.0 to 15.4)
OG0020.0(0.0 to 8.0)
OG003
OG002
Group 1: 60- mcg Bivalent rLP2086 (>=12 Months to <24 Months)
Participants from greater than or equal to (>=) 12 months to less than (<) 24 months of age, received intramuscular injection of 60 mcg of bivalent rLP2086 vaccine on months 0 vaccine on a 0, 2, 6 month schedule.
OG003
Group 2: 120-µg Bivalent rLP2086 (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG004
Group 2: 120-µg Bivalent rLP2086 (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG005
Group 2: 120-mcg Bivalent rLP2086 (>=12 Months to <24 Months)
Participants from >=12 months to <24 months of age, received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine on a 0, 2, 6 month schedule. All participants who received 3 doses of 120 mcg bivalent rLP2086 in Stage 1 and gave consent for booster vaccination, received intramuscular injection of single booster dose of 120 mcg of bivalent rLP2086 after 23 to 24 months of Vaccination 3, in Stage 2. Participants were followed up approximately 6 months after the booster vaccination.
OG006
Group 3: HAV/Saline (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.
OG007
Group 3: HAV/Saline (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.
OG008
Group 3: HAV/Saline (>=12 Months to <24 Months): Stage 1
Participants from >=12 months to <24 months of age, received intramuscular injection of saline on 2 month and HAV vaccine on a 0, 6 month schedule.
Units
Counts
Participants
OG00022
OG00122
OG00244
OG003110
OG004110
OG005220
OG00666
OG00766
OG008132
Title
Denominators
Categories
Fever >=38 degrees C
Title
Measurements
OG00040.9(20.7 to 63.6)
OG00131.8(13.9 to 54.9)
OG00236.4(22.4 to 52.2)
OG00328.2(20.0 to 37.6)
OG00427.3(19.2 to 36.6)
OG00527.7(21.9 to 34.1)
OG00610.6(4.4 to 20.6)
OG0071.5(0.0 to 8.2)
OG0086.1(2.7 to 11.6)
Fever 38 to <38.5 degrees C
Title
Measurements
OG00022.7(7.8 to 45.4)
OG00118.2(5.2 to 40.3)
OG00220.5(9.8 to 35.3)
OG003
Fever 38.5 to <39 degrees C
Title
Measurements
OG00013.6(2.9 to 34.9)
OG0019.1(1.1 to 29.2)
OG00211.4(3.8 to 24.6)
OG003
Fever 39 to <39.5 degrees C
Title
Measurements
OG0000.0(0.0 to 15.4)
OG0010.0(0.0 to 15.4)
OG0020.0(0.0 to 8.0)
OG003
Fever 39.5 to <=40 degrees C
Title
Measurements
OG0004.5(0.1 to 22.8)
OG0014.5(0.1 to 22.8)
OG0024.5(0.6 to 15.5)
OG003
Fever >40 degrees C
Title
Measurements
OG0000.0(0.0 to 15.4)
OG0010.0(0.0 to 15.4)
OG0020.0(0.0 to 8.0)
OG003
Irritability: Any
Title
Measurements
OG00063.6(40.7 to 82.8)
OG00150.0(28.2 to 71.8)
OG00256.8(41.0 to 71.7)
OG003
Irritability: Mild
Title
Measurements
OG00027.3(10.7 to 50.2)
OG0019.1(1.1 to 29.2)
OG00218.2(8.2 to 32.7)
OG003
Irritability: Moderate
Title
Measurements
OG00031.8(13.9 to 54.9)
OG00140.9(20.7 to 63.6)
OG00236.4(22.4 to 52.2)
OG003
Irritability: Severe
Title
Measurements
OG0004.5(0.1 to 22.8)
OG0010.0(0.0 to 15.4)
OG0022.3(0.1 to 12.0)
OG003
Drowsiness: Any
Title
Measurements
OG00045.5(24.4 to 67.8)
OG00140.9(20.7 to 63.6)
OG00243.2(28.3 to 59.0)
OG003
Drowsiness: Mild
Title
Measurements
OG00036.4(17.2 to 59.3)
OG00131.8(13.9 to 54.9)
OG00234.1(20.5 to 49.9)
OG003
Drowsiness: Moderate
Title
Measurements
OG0009.1(1.1 to 29.2)
OG0019.1(1.1 to 29.2)
OG0029.1(2.5 to 21.7)
OG003
Drowsiness: Severe
Title
Measurements
OG0000.0(0.0 to 15.4)
OG0010.0(0.0 to 15.4)
OG0020.0(0.0 to 8.0)
OG003
Loss of or decrease appetite: Any
Title
Measurements
OG00036.4(17.2 to 59.3)
OG00136.4(17.2 to 59.3)
OG00236.4(22.4 to 52.2)
OG003
Loss of or decrease appetite: Mild
Title
Measurements
OG00022.7(7.8 to 45.4)
OG00118.2(5.2 to 40.3)
OG00220.5(9.8 to 35.3)
OG003
Loss of or decrease appetite: Moderate
Title
Measurements
OG00013.6(2.9 to 34.9)
OG0019.1(1.1 to 29.2)
OG00211.4(3.8 to 24.6)
OG003
Loss of or decrease appetite: Severe
Title
Measurements
OG0000.0(0.0 to 15.4)
OG0019.1(1.1 to 29.2)
OG0024.5(0.6 to 15.5)
OG003
Antipyretic medication use
Title
Measurements
OG00045.5(24.4 to 67.8)
OG00159.1(36.4 to 79.3)
OG00252.3(36.7 to 67.5)
OG003
Participants from >=18 months to <24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG002
Group 1: 60- mcg Bivalent rLP2086 (>=12 Months to <24 Months)
Participants from greater than or equal to (>=) 12 months to less than (<) 24 months of age, received intramuscular injection of 60 mcg of bivalent rLP2086 vaccine on months 0 vaccine on a 0, 2, 6 month schedule.
OG003
Group 2: 120-µg Bivalent rLP2086 (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG004
Group 2: 120-µg Bivalent rLP2086 (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG005
Group 2: 120-mcg Bivalent rLP2086 (>=12 Months to <24 Months)
Participants from >=12 months to <24 months of age, received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine on a 0, 2, 6 month schedule. All participants who received 3 doses of 120 mcg bivalent rLP2086 in Stage 1 and gave consent for booster vaccination, received intramuscular injection of single booster dose of 120 mcg of bivalent rLP2086 after 23 to 24 months of Vaccination 3, in Stage 2. Participants were followed up approximately 6 months after the booster vaccination.
OG006
Group 3: HAV/Saline (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.
OG007
Group 3: HAV/Saline (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.
OG008
Group 3: HAV/Saline (>=12 Months to <24 Months): Stage 1
Participants from >=12 months to <24 months of age, received intramuscular injection of saline on 2 month and HAV vaccine on a 0, 6 month schedule.
Units
Counts
Participants
OG00022
OG00122
OG00244
OG003105
OG004107
OG005212
OG00663
OG00765
OG008128
Title
Denominators
Categories
Fever >=38 degrees C
Title
Measurements
OG00013.6(2.9 to 34.9)
OG0019.1(1.1 to 29.2)
OG00211.4(3.8 to 24.6)
OG00314.3(8.2 to 22.5)
OG00414.0(8.1 to 22.1)
OG00514.2(9.8 to 19.6)
OG0066.3(1.8 to 15.5)
OG0073.1(0.4 to 10.7)
OG0084.7(1.7 to 9.9)
Fever 38 to <38.5 degrees C
Title
Measurements
OG00013.6(2.9 to 34.9)
OG0010.0(0.0 to 15.4)
OG0026.8(1.4 to 18.7)
OG003
Fever 38.5 to <39 degrees C
Title
Measurements
OG0000.0(0.0 to 15.4)
OG0014.5(0.1 to 22.8)
OG0022.3(0.1 to 12.0)
OG003
Fever 39 to <39.5 degrees C
Title
Measurements
OG0000.0(0.0 to 15.4)
OG0010.0(0.0 to 15.4)
OG0020.0(0.0 to 8.0)
OG003
Fever 39.5 to <=40 degrees C
Title
Measurements
OG0000.0(0.0 to 15.4)
OG0014.5(0.1 to 22.8)
OG0022.3(0.1 to 12.0)
OG003
Fever >40 degrees C
Title
Measurements
OG0000.0(0.0 to 15.4)
OG0010.0(0.0 to 15.4)
OG0020.0(0.0 to 8.0)
OG003
Irritability: Any
Title
Measurements
OG00050.0(28.2 to 71.8)
OG00140.9(20.7 to 63.6)
OG00245.5(30.4 to 61.2)
OG003
Irritability: Mild
Title
Measurements
OG00040.9(20.7 to 63.6)
OG00118.2(5.2 to 40.3)
OG00229.5(16.8 to 45.2)
OG003
Irritability: Moderate
Title
Measurements
OG0004.5(0.1 to 22.8)
OG00122.7(7.8 to 45.4)
OG00213.6(5.2 to 27.4)
OG003
Irritability: Severe
Title
Measurements
OG0004.5(0.1 to 22.8)
OG0010.0(0.0 to 15.4)
OG0022.3(0.1 to 12.0)
OG003
Drowsiness: Any
Title
Measurements
OG00013.6(2.9 to 34.9)
OG00118.2(5.2 to 40.3)
OG00215.9(6.6 to 30.1)
OG003
Drowsiness: Mild
Title
Measurements
OG0009.1(1.1 to 29.2)
OG00118.2(5.2 to 40.3)
OG00213.6(5.2 to 27.4)
OG003
Drowsiness: Moderate
Title
Measurements
OG0004.5(0.1 to 22.8)
OG0010.0(0.0 to 15.4)
OG0022.3(0.1 to 12.0)
OG003
Drowsiness: Severe
Title
Measurements
OG0000.0(0.0 to 15.4)
OG0010.0(0.0 to 15.4)
OG0020.0(0.0 to 8.0)
OG003
Loss of or decreased appetite: Any
Title
Measurements
OG00031.8(13.9 to 54.9)
OG00118.2(5.2 to 40.3)
OG00225.0(13.2 to 40.3)
OG003
Loss of or decreased appetite: Mild
Title
Measurements
OG00027.3(10.7 to 50.2)
OG00118.2(5.2 to 40.3)
OG00222.7(11.5 to 37.8)
OG003
Loss of or decreased appetite: Moderate
Title
Measurements
OG0004.5(0.1 to 22.8)
OG0010.0(0.0 to 15.4)
OG0022.3(0.1 to 12.0)
OG003
Loss of or decreased appetite: Severe
Title
Measurements
OG0000.0(0.0 to 15.4)
OG0010.0(0.0 to 15.4)
OG0020.0(0.0 to 8.0)
OG003
Antipyretic medication use
Title
Measurements
OG00045.5(24.4 to 67.8)
OG00127.3(10.7 to 50.2)
OG00236.4(22.4 to 52.2)
OG003
Participants from >=18 months to <24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG002
Group 1: 60- mcg Bivalent rLP2086 (>=12 Months to <24 Months)
Participants from greater than or equal to (>=) 12 months to less than (<) 24 months of age, received intramuscular injection of 60 mcg of bivalent rLP2086 vaccine on months 0 vaccine on a 0, 2, 6 month schedule.
OG003
Group 2: 120-µg Bivalent rLP2086 (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG004
Group 2: 120-µg Bivalent rLP2086 (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG005
Group 2: 120-mcg Bivalent rLP2086 (>=12 Months to <24 Months)
Participants from >=12 months to <24 months of age, received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine on a 0, 2, 6 month schedule. All participants who received 3 doses of 120 mcg bivalent rLP2086 in Stage 1 and gave consent for booster vaccination, received intramuscular injection of single booster dose of 120 mcg of bivalent rLP2086 after 23 to 24 months of Vaccination 3, in Stage 2. Participants were followed up approximately 6 months after the booster vaccination.
OG006
Group 3: HAV/Saline (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.
OG007
Group 3: HAV/Saline (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.
OG008
Group 3: HAV/Saline (>=12 Months to <24 Months): Stage 1
Participants from >=12 months to <24 months of age, received intramuscular injection of saline on 2 month and HAV vaccine on a 0, 6 month schedule.
Units
Counts
Participants
OG00022
OG00122
OG00244
OG003104
OG004108
OG005212
OG00665
OG00763
OG008128
Title
Denominators
Categories
Fever >=38 degrees C
Title
Measurements
OG0004.5(0.1 to 22.8)
OG0014.5(0.1 to 22.8)
OG0024.5(0.6 to 15.5)
OG00310.6(5.4 to 18.1)
OG00414.8(8.7 to 22.9)
OG00512.7(8.6 to 18.0)
OG0064.6(1.0 to 12.9)
OG0077.9(2.6 to 17.6)
OG0086.3(2.7 to 11.9)
Fever 38 to <38.5 degrees C
Title
Measurements
OG0004.5(0.1 to 22.8)
OG0014.5(0.1 to 22.8)
OG0024.5(0.6 to 15.5)
OG003
Fever 38.5 to <39 degrees C
Title
Measurements
OG0000.0(0.0 to 15.4)
OG0010.0(0.0 to 15.4)
OG0020.0(0.0 to 8.0)
OG003
Fever 39 to <39.5 degrees C
Title
Measurements
OG0000.0(0.0 to 15.4)
OG0010.0(0.0 to 15.4)
OG0020.0(0.0 to 8.0)
OG003
Fever 39.5 to <=40 degrees C
Title
Measurements
OG0000.0(0.0 to 15.4)
OG0010.0(0.0 to 15.4)
OG0020.0(0.0 to 8.0)
OG003
Fever >40 degrees C
Title
Measurements
OG0000.0(0.0 to 15.4)
OG0010.0(0.0 to 15.4)
OG0020.0(0.0 to 8.0)
OG003
Irritability: Any
Title
Measurements
OG00036.4(17.2 to 59.3)
OG00136.4(17.2 to 59.3)
OG00236.4(22.4 to 52.2)
OG003
Irritability: Mild
Title
Measurements
OG00022.7(7.8 to 45.4)
OG00118.2(5.2 to 40.3)
OG00220.5(9.8 to 35.3)
OG003
Irritability: Moderate
Title
Measurements
OG00013.6(2.9 to 34.9)
OG00118.2(5.2 to 40.3)
OG00215.9(6.6 to 30.1)
OG003
Irritability: Severe
Title
Measurements
OG0000.0(0.0 to 15.4)
OG0010.0(0.0 to 15.4)
OG0020.0(0.0 to 8.0)
OG003
Drowsiness: Any
Title
Measurements
OG0004.5(0.1 to 22.8)
OG00122.7(7.8 to 45.4)
OG00213.6(5.2 to 27.4)
OG003
Drowsiness: Mild
Title
Measurements
OG0004.5(0.1 to 22.8)
OG00122.7(7.8 to 45.4)
OG00213.6(5.2 to 27.4)
OG003
Drowsiness: Moderate
Title
Measurements
OG0000.0(0.0 to 15.4)
OG0010.0(0.0 to 15.4)
OG0020.0(0.0 to 8.0)
OG003
Drowsiness: Severe
Title
Measurements
OG0000.0(0.0 to 15.4)
OG0010.0(0.0 to 15.4)
OG0020.0(0.0 to 8.0)
OG003
Loss of or decreased appetite: Any
Title
Measurements
OG00013.6(2.9 to 34.9)
OG00122.7(7.8 to 45.4)
OG00218.2(8.2 to 32.7)
OG003
Loss of or decreased appetite: Mild
Title
Measurements
OG00013.6(2.9 to 34.9)
OG00122.7(7.8 to 45.4)
OG00215.9(6.6 to 30.1)
OG003
Loss of or decreased appetite: Moderate
Title
Measurements
OG0000.0(0.0 to 15.4)
OG0010.0(0.0 to 15.4)
OG0020.0(0.0 to 8.0)
OG003
Loss of or decreased appetite: Severe
Title
Measurements
OG0000.0(0.0 to 15.4)
OG0010.0(0.0 to 15.4)
OG0022.3(0.1 to 12.0)
OG003
Antipyretic medication use
Title
Measurements
OG00018.2(5.2 to 40.3)
OG00118.2(5.2 to 40.3)
OG00218.2(8.2 to 32.7)
OG003
OG001
Group 1: 60-µg Bivalent rLP2086 (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG002
Group 1: 60- mcg Bivalent rLP2086 (>=12 Months to <24 Months)
Participants from greater than or equal to (>=) 12 months to less than (<) 24 months of age, received intramuscular injection of 60 mcg of bivalent rLP2086 vaccine on months 0 vaccine on a 0, 2, 6 month schedule.
OG003
Group 2: 120-µg Bivalent rLP2086 (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG004
Group 2: 120-µg Bivalent rLP2086 (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG005
Group 2: 120-mcg Bivalent rLP2086 (>=12 Months to <24 Months)
Participants from >=12 months to <24 months of age, received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine on a 0, 2, 6 month schedule. All participants who received 3 doses of 120 mcg bivalent rLP2086 in Stage 1 and gave consent for booster vaccination, received intramuscular injection of single booster dose of 120 mcg of bivalent rLP2086 after 23 to 24 months of Vaccination 3, in Stage 2. Participants were followed up approximately 6 months after the booster vaccination.
OG006
Group 3: HAV/Saline (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.
OG007
Group 3: HAV/Saline (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.
OG008
Group 3: HAV/Saline (>=12 Months to <24 Months): Stage 1
Participants from >=12 months to <24 months of age, received intramuscular injection of saline on 2 month and HAV vaccine on a 0, 6 month schedule.
Units
Counts
Participants
OG00022
OG00122
OG00244
OG003110
OG004110
OG005220
OG00666
OG00766
OG008132
Title
Denominators
Categories
AE
Title
Measurements
OG00018.2(5.2 to 40.3)
OG00145.5(24.4 to 67.8)
OG00231.8(18.6 to 47.6)
OG00338.2(29.1 to 47.9)
OG00441.8(32.5 to 51.6)
OG00540.0(33.5 to 46.8)
OG00633.3(22.2 to 46.0)
OG00727.3(17.0 to 39.6)
OG00830.3(22.6 to 38.9)
SAE
Title
Measurements
OG0000.0(0.0 to 15.4)
OG0014.5(0.1 to 22.8)
OG0022.3(0.1 to 12.0)
OG003
MAE
Title
Measurements
OG0009.1(1.1 to 29.2)
OG00113.6(2.9 to 34.9)
OG00211.4(3.8 to 24.6)
OG003
NDCMC
Title
Measurements
OG0000.0(0.0 to 15.4)
OG0010.0(0.0 to 15.4)
OG0020.0(0.0 to 8.0)
OG003
IAE
Title
Measurements
OG0000.0(0.0 to 15.4)
OG0014.5(0.1 to 22.8)
OG0022.3(0.1 to 12.0)
OG003
OG001
Group 1: 60-µg Bivalent rLP2086 (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG002
Group 1: 60- mcg Bivalent rLP2086 (>=12 Months to <24 Months)
Participants from greater than or equal to (>=) 12 months to less than (<) 24 months of age, received intramuscular injection of 60 mcg of bivalent rLP2086 vaccine on months 0 vaccine on a 0, 2, 6 month schedule.
OG003
Group 2: 120-µg Bivalent rLP2086 (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG004
Group 2: 120-µg Bivalent rLP2086 (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG005
Group 2: 120-mcg Bivalent rLP2086 (>=12 Months to <24 Months)
Participants from >=12 months to <24 months of age, received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine on a 0, 2, 6 month schedule. All participants who received 3 doses of 120 mcg bivalent rLP2086 in Stage 1 and gave consent for booster vaccination, received intramuscular injection of single booster dose of 120 mcg of bivalent rLP2086 after 23 to 24 months of Vaccination 3, in Stage 2. Participants were followed up approximately 6 months after the booster vaccination.
OG006
Group 3: HAV/Saline (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.
OG007
Group 3: HAV/Saline (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.
OG008
Group 3: HAV/Saline (>=12 Months to <24 Months): Stage 1
Participants from >=12 months to <24 months of age, received intramuscular injection of saline on 2 month and HAV vaccine on a 0, 6 month schedule.
Units
Counts
Participants
OG00022
OG00122
OG00244
OG003105
OG004108
OG005213
OG00666
OG00765
OG008131
Title
Denominators
Categories
AE
Title
Measurements
OG00018.2(5.2 to 40.3)
OG00127.3(10.7 to 50.2)
OG00222.7(11.5 to 37.8)
OG00334.3(25.3 to 44.2)
OG00434.3(25.4 to 44.0)
OG00534.3(27.9 to 41.1)
OG00624.2(14.5 to 36.4)
OG00732.3(21.2 to 45.1)
OG00828.2(20.7 to 36.8)
SAE
Title
Measurements
OG0000.0(0.0 to 15.4)
OG0010.0(0.0 to 15.4)
OG0020.0(0.0 to 8.0)
OG003
MAE
Title
Measurements
OG00013.6(2.9 to 34.9)
OG0019.1(1.1 to 29.2)
OG00211.4(3.8 to 24.6)
OG003
NDCMC
Title
Measurements
OG0000.0(0.0 to 15.4)
OG0010.0(0.0 to 15.4)
OG0020.0(0.0 to 8.0)
OG003
IAE
Title
Measurements
OG0000.0(0.0 to 15.4)
OG0010.0(0.0 to 15.4)
OG0020.0(0.0 to 8.0)
OG003
OG001
Group 1: 60-µg Bivalent rLP2086 (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG002
Group 1: 60- mcg Bivalent rLP2086 (>=12 Months to <24 Months)
Participants from greater than or equal to (>=) 12 months to less than (<) 24 months of age, received intramuscular injection of 60 mcg of bivalent rLP2086 vaccine on months 0 vaccine on a 0, 2, 6 month schedule.
OG003
Group 2: 120-µg Bivalent rLP2086 (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG004
Group 2: 120-µg Bivalent rLP2086 (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG005
Group 2: 120-mcg Bivalent rLP2086 (>=12 Months to <24 Months)
Participants from >=12 months to <24 months of age, received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine on a 0, 2, 6 month schedule. All participants who received 3 doses of 120 mcg bivalent rLP2086 in Stage 1 and gave consent for booster vaccination, received intramuscular injection of single booster dose of 120 mcg of bivalent rLP2086 after 23 to 24 months of Vaccination 3, in Stage 2. Participants were followed up approximately 6 months after the booster vaccination.
OG006
Group 3: HAV/Saline (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.
OG007
Group 3: HAV/Saline (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.
OG008
Group 3: HAV/Saline (>=12 Months to <24 Months): Stage 1
Participants from >=12 months to <24 months of age, received intramuscular injection of saline on 2 month and HAV vaccine on a 0, 6 month schedule.
Units
Counts
Participants
OG00022
OG00122
OG00244
OG003104
OG004108
OG005212
OG00665
OG00764
OG008129
Title
Denominators
Categories
AE
Title
Measurements
OG00018.2(5.2 to 40.3)
OG00140.9(20.7 to 63.6)
OG00229.5(16.8 to 45.2)
OG00325.0(17.0 to 34.4)
OG00430.6(22.1 to 40.2)
OG00527.8(21.9 to 34.4)
OG00624.6(14.8 to 36.9)
OG00728.1(17.6 to 40.8)
OG00826.4(19.0 to 34.8)
SAE
Title
Measurements
OG0000.0(0.0 to 15.4)
OG0010.0(0.0 to 15.4)
OG0020.0(0.0 to 8.0)
OG003
MAE
Title
Measurements
OG0009.1(1.1 to 29.2)
OG00127.3(10.7 to 50.2)
OG00218.2(8.2 to 32.7)
OG003
NDCMC
Title
Measurements
OG0000.0(0.0 to 15.4)
OG0010.0(0.0 to 15.4)
OG0020.0(0.0 to 8.0)
OG003
IAE
Title
Measurements
OG0000.0(0.0 to 15.4)
OG0010.0(0.0 to 15.4)
OG0020.0(0.0 to 8.0)
OG003
Participants from >=18 months to <24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG002
Group 1: 60- mcg Bivalent rLP2086 (>=12 Months to <24 Months)
Participants from greater than or equal to (>=) 12 months to less than (<) 24 months of age, received intramuscular injection of 60 mcg of bivalent rLP2086 vaccine on months 0 vaccine on a 0, 2, 6 month schedule.
OG003
Group 2: 120-µg Bivalent rLP2086 (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG004
Group 2: 120-µg Bivalent rLP2086 (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG005
Group 2: 120-mcg Bivalent rLP2086 (>=12 Months to <24 Months)
Participants from >=12 months to <24 months of age, received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine on a 0, 2, 6 month schedule. All participants who received 3 doses of 120 mcg bivalent rLP2086 in Stage 1 and gave consent for booster vaccination, received intramuscular injection of single booster dose of 120 mcg of bivalent rLP2086 after 23 to 24 months of Vaccination 3, in Stage 2. Participants were followed up approximately 6 months after the booster vaccination.
OG006
Group 3: HAV/Saline (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.
OG007
Group 3: HAV/Saline (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.
OG008
Group 3: HAV/Saline (>=12 Months to <24 Months): Stage 1
Participants from >=12 months to <24 months of age, received intramuscular injection of saline on 2 month and HAV vaccine on a 0, 6 month schedule.
Units
Counts
Participants
OG00022
OG00122
OG00244
OG003110
OG004110
OG005220
OG00666
OG00766
OG008132
Title
Denominators
Categories
AE
Title
Measurements
OG00036.4(17.2 to 59.3)
OG00163.6(40.7 to 82.8)
OG00250.0(34.6 to 65.4)
OG00354.5(44.8 to 64.1)
OG00461.8(52.1 to 70.9)
OG00558.2(51.4 to 64.8)
OG00653.0(40.3 to 65.4)
OG00754.5(41.8 to 66.9)
OG00853.8(44.9 to 62.5)
SAE
Title
Measurements
OG0000.0(0.0 to 15.4)
OG0014.5(0.1 to 22.8)
OG0022.3(0.1 to 12.0)
OG003
MAE
Title
Measurements
OG00022.7(7.8 to 45.4)
OG00140.9(20.7 to 63.6)
OG00231.8(18.6 to 47.6)
OG003
NDCMC
Title
Measurements
OG0000.0(0.0 to 15.4)
OG0010.0(0.0 to 15.4)
OG0020.0(0.0 to 8.0)
OG003
Participants from >=18 months to <24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG002
Group 1: 60- mcg Bivalent rLP2086 (>=12 Months to <24 Months)
Participants from greater than or equal to (>=) 12 months to less than (<) 24 months of age, received intramuscular injection of 60 mcg of bivalent rLP2086 vaccine on months 0 vaccine on a 0, 2, 6 month schedule.
OG003
Group 2: 120-µg Bivalent rLP2086 (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG004
Group 2: 120-µg Bivalent rLP2086 (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG005
Group 2: 120-mcg Bivalent rLP2086 (>=12 Months to <24 Months)
Participants from >=12 months to <24 months of age, received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine on a 0, 2, 6 month schedule. All participants who received 3 doses of 120 mcg bivalent rLP2086 in Stage 1 and gave consent for booster vaccination, received intramuscular injection of single booster dose of 120 mcg of bivalent rLP2086 after 23 to 24 months of Vaccination 3, in Stage 2. Participants were followed up approximately 6 months after the booster vaccination.
OG006
Group 3: HAV/Saline (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.
OG007
Group 3: HAV/Saline (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.
OG008
Group 3: HAV/Saline (>=12 Months to <24 Months): Stage 1
Participants from >=12 months to <24 months of age, received intramuscular injection of saline on 2 month and HAV vaccine on a 0, 6 month schedule.
Units
Counts
Participants
OG00022
OG00122
OG00244
OG003110
OG004110
OG005220
OG00666
OG00766
OG008132
Title
Denominators
Categories
AE
Title
Measurements
OG00054.5(32.2 to 75.6)
OG00177.3(54.6 to 92.2)
OG00265.9(50.1 to 79.5)
OG00368.2(58.6 to 76.7)
OG00471.8(62.4 to 80.0)
OG00570.0(63.5 to 76.0)
OG00665.2(52.4 to 76.5)
OG00763.6(50.9 to 75.1)
OG00864.4(55.6 to 72.5)
SAE
Title
Measurements
OG0000.0(0.0 to 15.4)
OG0019.1(1.1 to 29.2)
OG0024.5(0.6 to 15.5)
OG003
MAE
Title
Measurements
OG00036.4(17.2 to 59.3)
OG00145.5(24.4 to 67.8)
OG00240.9(26.3 to 56.8)
OG003
NDCMC
Title
Measurements
OG0000.0(0.0 to 15.4)
OG0010.0(0.0 to 15.4)
OG0020.0(0.0 to 8.0)
OG003
Group 1: 60-µg Bivalent rLP2086 (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG002
Group 1: 60- mcg Bivalent rLP2086 (>=12 Months to <24 Months)
Participants from greater than or equal to (>=) 12 months to less than (<) 24 months of age, received intramuscular injection of 60 mcg of bivalent rLP2086 vaccine on months 0 vaccine on a 0, 2, 6 month schedule.
OG003
Group 2: 120-µg Bivalent rLP2086 (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG004
Group 2: 120-µg Bivalent rLP2086 (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG005
Group 2: 120-mcg Bivalent rLP2086 (>=12 Months to <24 Months)
Participants from >=12 months to <24 months of age, received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine on a 0, 2, 6 month schedule. All participants who received 3 doses of 120 mcg bivalent rLP2086 in Stage 1 and gave consent for booster vaccination, received intramuscular injection of single booster dose of 120 mcg of bivalent rLP2086 after 23 to 24 months of Vaccination 3, in Stage 2. Participants were followed up approximately 6 months after the booster vaccination.
OG006
Group 3: HAV/Saline (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.
OG007
Group 3: HAV/Saline (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.
OG008
Group 3: HAV/Saline (>=12 Months to <24 Months): Stage 1
Participants from >=12 months to <24 months of age, received intramuscular injection of saline on 2 month and HAV vaccine on a 0, 6 month schedule.
Units
Counts
Participants
OG00022
OG00122
OG00244
OG003108
OG004107
OG005215
OG00665
OG00763
OG008128
Title
Denominators
Categories
SAE
Title
Measurements
OG0004.5(0.1 to 22.8)
OG0019.1(1.1 to 29.2)
OG0026.8(1.4 to 18.7)
OG0030.9(0.0 to 5.1)
OG0043.7(1.0 to 9.3)
OG0052.3(0.8 to 5.3)
OG0061.5(0.0 to 8.3)
OG0071.6(0.0 to 8.5)
OG0081.6(0.2 to 5.5)
MAE
Title
Measurements
OG00022.7(7.8 to 45.4)
OG00140.9(20.7 to 63.6)
OG00231.8(18.6 to 47.6)
OG003
NDCMC
Title
Measurements
OG0004.5(0.1 to 22.8)
OG0010.0(0.0 to 15.4)
OG0022.3(0.1 to 12.0)
OG003
Participants from >=18 months to <24 months of age, received intramuscular injection of 60 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG002
Group 1: 60- mcg Bivalent rLP2086 (>=12 Months to <24 Months)
Participants from greater than or equal to (>=) 12 months to less than (<) 24 months of age, received intramuscular injection of 60 mcg of bivalent rLP2086 vaccine on months 0 vaccine on a 0, 2, 6 month schedule.
OG003
Group 2: 120-µg Bivalent rLP2086 (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG004
Group 2: 120-µg Bivalent rLP2086 (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG005
Group 2: 120-mcg Bivalent rLP2086 (>=12 Months to <24 Months)
Participants from >=12 months to <24 months of age, received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine on a 0, 2, 6 month schedule. All participants who received 3 doses of 120 mcg bivalent rLP2086 in Stage 1 and gave consent for booster vaccination, received intramuscular injection of single booster dose of 120 mcg of bivalent rLP2086 after 23 to 24 months of Vaccination 3, in Stage 2. Participants were followed up approximately 6 months after the booster vaccination.
OG006
Group 3: HAV/Saline (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.
OG007
Group 3: HAV/Saline (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.
OG008
Group 3: HAV/Saline (>=12 Months to <24 Months): Stage 1
Participants from >=12 months to <24 months of age, received intramuscular injection of saline on 2 month and HAV vaccine on a 0, 6 month schedule.
Units
Counts
Participants
OG00022
OG00122
OG00244
OG003110
OG004110
OG005220
OG00666
OG00766
OG008132
Title
Denominators
Categories
SAE
Title
Measurements
OG0004.5(0.1 to 22.8)
OG00113.6(2.9 to 34.9)
OG0029.1(2.5 to 21.7)
OG00310.9(5.8 to 18.3)
OG0046.4(2.6 to 12.7)
OG0058.6(5.3 to 13.2)
OG0066.1(1.7 to 14.8)
OG0076.1(1.7 to 14.8)
OG0086.1(2.7 to 11.6)
MAE
Title
Measurements
OG00054.5(32.2 to 75.6)
OG00168.2(45.1 to 86.1)
OG00261.4(45.5 to 75.6)
OG003
NDCMC
Title
Measurements
OG0004.5(0.1 to 22.8)
OG0010.0(0.0 to 15.4)
OG0022.3(0.1 to 12.0)
OG003
OG002
Group 3: HAV/Saline (>=12 Months to <24 Months): Stage 1
Participants from >=12 months to <24 months of age, received intramuscular injection of saline on 2 month and HAV vaccine on a 0, 6 month schedule.
Units
Counts
Participants
OG00021
OG00197
OG00260
Title
Denominators
Categories
PMB80 (A22) 1 Month after Vaccination 3
ParticipantsOG00020
ParticipantsOG00196
ParticipantsOG00260
Title
Measurements
OG00090.0(68.3 to 98.8)
OG00189.6(81.7 to 94.9)
OG0025.0(1.0 to 13.9)
PMB80 (A22): 6 Months after Vaccination 3
ParticipantsOG00020
ParticipantsOG00197
ParticipantsOG00258
Title
Measurements
OG000
PMB80 (A22): 12 Months after Vaccination 3
ParticipantsOG00021
ParticipantsOG00195
ParticipantsOG00255
Title
Measurements
OG000
PMB80 (A22): 24 Months after Vaccination 3
ParticipantsOG00019
ParticipantsOG00181
ParticipantsOG0020
Title
Measurements
OG000
PMB2001 (A56): 1 Month after Vaccination 3
ParticipantsOG00019
ParticipantsOG00195
ParticipantsOG00254
Title
Measurements
OG000
PMB2001 (A56): 6 months after Vaccination 3
ParticipantsOG00018
ParticipantsOG00188
ParticipantsOG00252
Title
Measurements
OG000
PMB2001 (A56): 12 months after Vaccination 3
ParticipantsOG00016
ParticipantsOG00193
ParticipantsOG00253
Title
Measurements
OG000
PMB2001 (A56): 24 months after Vaccination 3
ParticipantsOG00017
ParticipantsOG00179
ParticipantsOG0020
Title
Measurements
OG000
PMB2948 (B24): 1 Month after Vaccination 3
ParticipantsOG00020
ParticipantsOG00195
ParticipantsOG00260
Title
Measurements
OG000
PMB2948 (B24): 6 month after Vaccination 3
ParticipantsOG00020
ParticipantsOG00197
ParticipantsOG00258
Title
Measurements
OG000
PMB2948 (B24): 12 month after Vaccination 3
ParticipantsOG00021
ParticipantsOG00193
ParticipantsOG00255
Title
Measurements
OG000
PMB2948 (B24): 24 month after Vaccination 3
ParticipantsOG00019
ParticipantsOG00182
ParticipantsOG0020
Title
Measurements
OG000
PMB2707 (B44): 1 Month after Vaccination 3
ParticipantsOG00019
ParticipantsOG00194
ParticipantsOG00254
Title
Measurements
OG000
PMB2707 (B44): 6 month after Vaccination 3
ParticipantsOG00016
ParticipantsOG00189
ParticipantsOG00253
Title
Measurements
OG000
PMB2707 (B44): 12 month after Vaccination 3
ParticipantsOG00016
ParticipantsOG00190
ParticipantsOG00251
Title
Measurements
OG000
PMB2707 (B44): 24 month after Vaccination 3
ParticipantsOG00017
ParticipantsOG00180
ParticipantsOG0020
Title
Measurements
OG000
Participants from greater than or equal to (>=) 12 months to less than (<) 24 months of age, received intramuscular injection of 60 mcg of bivalent rLP2086 vaccine on months 0 vaccine on a 0, 2, 6 month schedule.
OG003
Group 2: 120-µg Bivalent rLP2086 (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG004
Group 2: 120-µg Bivalent rLP2086 (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG005
Group 2: 120-mcg Bivalent rLP2086 (>=12 Months to <24 Months)
Participants from >=12 months to <24 months of age, received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine on a 0, 2, 6 month schedule. All participants who received 3 doses of 120 mcg bivalent rLP2086 in Stage 1 and gave consent for booster vaccination, received intramuscular injection of single booster dose of 120 mcg of bivalent rLP2086 after 23 to 24 months of Vaccination 3, in Stage 2. Participants were followed up approximately 6 months after the booster vaccination.
OG006
Group 3: HAV/Saline (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.
OG007
Group 3: HAV/Saline (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.
OG008
Group 3: HAV/Saline (>=12 Months to <24 Months): Stage 1
Participants from >=12 months to <24 months of age, received intramuscular injection of saline on 2 month and HAV vaccine on a 0, 6 month schedule.
Units
Counts
Participants
OG00010
OG00110
OG00219
OG00347
OG00450
OG00595
OG00630
OG00729
OG00859
Title
Denominators
Categories
1 Mon after Vac2: PMB80[A22]
ParticipantsOG00010
ParticipantsOG0019
ParticipantsOG00219
ParticipantsOG00345
ParticipantsOG00450
ParticipantsOG00595
ParticipantsOG00630
ParticipantsOG00729
ParticipantsOG00859
Title
Measurements
OG00090.0(55.5 to 99.7)
OG00166.7(29.9 to 92.5)
OG00278.9(54.4 to 93.9)
OG003
1Mon after Vac2:PMB2001[A56]
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00219
ParticipantsOG00347
1Mon after Vac2:PMB2948[B24]
ParticipantsOG00010
ParticipantsOG0019
ParticipantsOG00219
ParticipantsOG00342
1Mon after Vac2:PMB2707[B44]
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00219
ParticipantsOG00347
Participants from greater than or equal to (>=) 12 months to less than (<) 24 months of age, received intramuscular injection of 60 mcg of bivalent rLP2086 vaccine on months 0 vaccine on a 0, 2, 6 month schedule.
OG003
Group 2: 120-µg Bivalent rLP2086 (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG004
Group 2: 120-µg Bivalent rLP2086 (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG005
Group 2: 120-mcg Bivalent rLP2086 (>=12 Months to <24 Months)
Participants from >=12 months to <24 months of age, received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine on a 0, 2, 6 month schedule. All participants who received 3 doses of 120 mcg bivalent rLP2086 in Stage 1 and gave consent for booster vaccination, received intramuscular injection of single booster dose of 120 mcg of bivalent rLP2086 after 23 to 24 months of Vaccination 3, in Stage 2. Participants were followed up approximately 6 months after the booster vaccination.
OG006
Group 3: HAV/Saline (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.
OG007
Group 3: HAV/Saline (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.
OG008
Group 3: HAV/Saline (>=12 Months to <24 Months): Stage 1
Participants from >=12 months to <24 months of age, received intramuscular injection of saline on 2 month and HAV vaccine on a 0, 6 month schedule.
Units
Counts
Participants
OG00010
OG00111
OG00221
OG00347
OG00451
OG00597
OG00631
OG00730
OG00861
Title
Denominators
Categories
T1: PMB80 [A22] - 1:4
ParticipantsOG0009
ParticipantsOG00111
ParticipantsOG00220
ParticipantsOG00346
ParticipantsOG00451
ParticipantsOG00597
ParticipantsOG00631
ParticipantsOG00730
ParticipantsOG00861
Title
Measurements
OG0000.0(0.0 to 33.6)
OG0010.0(0.0 to 28.5)
OG0020.0(0.0 to 16.8)
OG003
T1: PMB80 [A22] - 1:8
ParticipantsOG0009
ParticipantsOG00111
ParticipantsOG00220
ParticipantsOG00346
T1: PMB80 [A22] - 1:16
ParticipantsOG0009
ParticipantsOG00111
ParticipantsOG00220
ParticipantsOG00346
T1: PMB80 [A22] - 1:32
ParticipantsOG0009
ParticipantsOG00111
ParticipantsOG00220
ParticipantsOG00346
T1: PMB80 [A22] - 1:64
ParticipantsOG0009
ParticipantsOG00111
ParticipantsOG00220
ParticipantsOG00346
T1: PMB80 [A22] - 1:128
ParticipantsOG0009
ParticipantsOG00111
ParticipantsOG00220
ParticipantsOG00346
T1: PMB2001 (A56)-1:4
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00219
ParticipantsOG00346
T1: PMB2001 (A56)-1:8
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00219
ParticipantsOG00346
T1: PMB2001 (A56)-1:16
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00219
ParticipantsOG00346
T1: PMB2001 (A56)-1:32
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00219
ParticipantsOG00346
T1: PMB2001 (A56)-1:64
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00219
ParticipantsOG00346
T1: PMB2001 (A56)-1:128
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00219
ParticipantsOG00346
T1: PMB2948 (B24)-1:4
ParticipantsOG00010
ParticipantsOG00111
ParticipantsOG00221
ParticipantsOG00346
T1: PMB2948 (B24)-1:8
ParticipantsOG00010
ParticipantsOG00111
ParticipantsOG00221
ParticipantsOG00346
T1: PMB2948 (B24)-1:16
ParticipantsOG00010
ParticipantsOG00111
ParticipantsOG00221
ParticipantsOG00346
T1: PMB2948 (B24)-1:32
ParticipantsOG00010
ParticipantsOG00111
ParticipantsOG00221
ParticipantsOG00346
T1: PMB2948 (B24)-1:64
ParticipantsOG00010
ParticipantsOG00111
ParticipantsOG00221
ParticipantsOG00346
T1: PMB2948 (B24)-1:128
ParticipantsOG00010
ParticipantsOG00111
ParticipantsOG00221
ParticipantsOG00346
T1: PMB2707 (B44)-1:4
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00219
ParticipantsOG00346
T1: PMB2707 (B44)-1:8
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00219
ParticipantsOG00346
T1: PMB2707 (B44)-1:16
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00219
ParticipantsOG00346
T1: PMB2707 (B44)-1:32
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00219
ParticipantsOG00346
T1: PMB2707 (B44)-1:64
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00219
ParticipantsOG00346
T1: PMB2707 (B44)-1:128
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00219
ParticipantsOG00346
T2: PMB80 [A22] - 1:4
ParticipantsOG00010
ParticipantsOG0019
ParticipantsOG00219
ParticipantsOG00345
T2: PMB80 [A22] - 1:8
ParticipantsOG00010
ParticipantsOG0019
ParticipantsOG00219
ParticipantsOG00345
T2: PMB80 [A22] - 1:32
ParticipantsOG00010
ParticipantsOG0019
ParticipantsOG00219
ParticipantsOG00345
T2: PMB80 [A22] - 1:64
ParticipantsOG00010
ParticipantsOG0019
ParticipantsOG00219
ParticipantsOG00345
T2: PMB80 [A22] - 1:128
ParticipantsOG00010
ParticipantsOG0019
ParticipantsOG00219
ParticipantsOG00345
T2: PMB2001 [A56]- 1:4
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00219
ParticipantsOG00347
T2: PMB2001 [A56]- 1:16
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00219
ParticipantsOG00347
T2: PMB2001 [A56]- 1:32
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00219
ParticipantsOG00347
T2:PMB2001 [A56]- 1:64
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00219
ParticipantsOG00347
T2:PMB2001 [A56]-1:128
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00219
ParticipantsOG00347
T2: PMB2948 (B24)-1:4
ParticipantsOG00010
ParticipantsOG0019
ParticipantsOG00219
ParticipantsOG00342
T2: PMB2948 (B24)-1:16
ParticipantsOG00010
ParticipantsOG0019
ParticipantsOG00219
ParticipantsOG00342
T2: PMB2948 (B24)-1:32
ParticipantsOG00010
ParticipantsOG0019
ParticipantsOG00219
ParticipantsOG00342
T2: PMB2948 (B24)-1:64
ParticipantsOG00010
ParticipantsOG0019
ParticipantsOG00219
ParticipantsOG00342
T2: PMB2948 (B24)-1:128
ParticipantsOG00010
ParticipantsOG0019
ParticipantsOG00219
ParticipantsOG00342
T2: PMB2707 (B44)-1:4
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00219
ParticipantsOG00347
T2: PMB2707 (B44)-1:16
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00219
ParticipantsOG00347
T2: PMB2707 (B44)-1:32
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00219
ParticipantsOG00347
T2: PMB2707 (B44)-1:64
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00219
ParticipantsOG00347
T2: PMB2707 (B44)-1:128
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00219
ParticipantsOG00347
T3: PMB80 (A22)-1:4
ParticipantsOG0009
ParticipantsOG00111
ParticipantsOG00220
ParticipantsOG00345
T3: PMB80 (A22)-1:8
ParticipantsOG0009
ParticipantsOG00111
ParticipantsOG00220
ParticipantsOG00345
T3: PMB80 (A22)-1:32
ParticipantsOG0009
ParticipantsOG00111
ParticipantsOG00220
ParticipantsOG00345
T3: PMB80 (A22)-1:64
ParticipantsOG0009
ParticipantsOG00111
ParticipantsOG00220
ParticipantsOG00345
T3: PMB80 (A22)-1:128
ParticipantsOG0009
ParticipantsOG00111
ParticipantsOG00220
ParticipantsOG00345
T3: PMB2001 (A56)-1:4
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00219
ParticipantsOG00347
T3: PMB2001 (A56)-1:16
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00219
ParticipantsOG00347
T3: PMB2001 (A56)-1:32
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00219
ParticipantsOG00347
T3: PMB2001 (A56)-1:64
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00219
ParticipantsOG00347
T3: PMB2001 (A56)-1:128
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00219
ParticipantsOG00347
T3:PMB2948 (B24)-1:4
ParticipantsOG0009
ParticipantsOG00111
ParticipantsOG00220
ParticipantsOG00345
T3:PMB2948 (B24)-1:16
ParticipantsOG0009
ParticipantsOG00111
ParticipantsOG00220
ParticipantsOG00345
T3:PMB2948 (B24)-1:32
ParticipantsOG0009
ParticipantsOG00111
ParticipantsOG00220
ParticipantsOG00345
T3:PMB2948 (B24)-1:64
ParticipantsOG0009
ParticipantsOG00111
ParticipantsOG00220
ParticipantsOG00345
T3:PMB2948 (B24)-1:128
ParticipantsOG0009
ParticipantsOG00111
ParticipantsOG00220
ParticipantsOG00345
T3:PMB2707 (B44)-1:4
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00219
ParticipantsOG00347
T3:PMB2707 (B44)-1:16
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00219
ParticipantsOG00347
T3:PMB2707 (B44)-1:32
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00219
ParticipantsOG00347
T3:PMB2707 (B44)-1:64
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00219
ParticipantsOG00347
T3:PMB2707 (B44)-1:128
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00219
ParticipantsOG00347
T4: PMB80 (A22): 1: 4
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG00220
ParticipantsOG00346
T4: PMB80 (A22): 1: 8
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG00220
ParticipantsOG00346
T4: PMB80 (A22): 1: 16
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG00220
ParticipantsOG00346
T4: PMB80 (A22): 1: 32
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG00220
ParticipantsOG00346
T4: PMB80 (A22): 1: 64
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG00220
ParticipantsOG00346
T4: PMB80 (A22): 1: 128
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG00220
ParticipantsOG00346
T4: PMB2001 (A56): 1:4
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00218
ParticipantsOG00341
T4: PMB2001 (A56): 1:8
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00218
ParticipantsOG00341
T4: PMB2001 (A56): 1:16
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00218
ParticipantsOG00341
T4: PMB2001 (A56): 1:32
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00218
ParticipantsOG00341
T4: PMB2001 (A56): 1:64
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00218
ParticipantsOG00341
T4: PMB2001 (A56): 1:128
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00218
ParticipantsOG00341
T4: PMB2948 (B24): 1: 4
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG00220
ParticipantsOG00346
T4: PMB2948 (B24): 1: 8
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG00220
ParticipantsOG00346
T4: PMB2948 (B24): 1: 16
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG00220
ParticipantsOG00346
T4: PMB2948 (B24): 1: 32
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG00220
ParticipantsOG00346
T4: PMB2948 (B24): 1: 64
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG00220
ParticipantsOG00346
T4: PMB2948 (B24): 1: 128
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG00220
ParticipantsOG00346
T4: PMB2707 (B44): 1: 4
ParticipantsOG0008
ParticipantsOG0018
ParticipantsOG00216
ParticipantsOG00343
T4: PMB2707 (B44): 1: 8
ParticipantsOG0008
ParticipantsOG0018
ParticipantsOG00216
ParticipantsOG00343
T4: PMB2707 (B44): 1: 16
ParticipantsOG0008
ParticipantsOG0018
ParticipantsOG00216
ParticipantsOG00343
T4: PMB2707 (B44): 1: 32
ParticipantsOG0008
ParticipantsOG0018
ParticipantsOG00216
ParticipantsOG00343
T4: PMB2707 (B44): 1: 64
ParticipantsOG0008
ParticipantsOG0018
ParticipantsOG00216
ParticipantsOG00343
T4: PMB2707 (B44): 1: 128
ParticipantsOG0008
ParticipantsOG0018
ParticipantsOG00216
ParticipantsOG00343
T5: PMB80 (A22): 1:4
ParticipantsOG00010
ParticipantsOG00111
ParticipantsOG00221
ParticipantsOG00345
T5: PMB80 (A22): 1: 8
ParticipantsOG00010
ParticipantsOG00111
ParticipantsOG00221
ParticipantsOG00345
T5: PMB80 (A22): 1: 16
ParticipantsOG00010
ParticipantsOG00111
ParticipantsOG00221
ParticipantsOG00345
T5: PMB80 (A22): 1: 32
ParticipantsOG00010
ParticipantsOG00111
ParticipantsOG00221
ParticipantsOG00345
T5: PMB80 (A22): 1: 64
ParticipantsOG00010
ParticipantsOG00111
ParticipantsOG00221
ParticipantsOG00345
T5: PMB80 (A22): 1: 128
ParticipantsOG00010
ParticipantsOG00111
ParticipantsOG00221
ParticipantsOG00345
T5: PMB2001 (A56): 1: 4
ParticipantsOG0009
ParticipantsOG0017
ParticipantsOG00216
ParticipantsOG00345
T5: PMB2001 (A56): 1: 8
ParticipantsOG0009
ParticipantsOG0017
ParticipantsOG00216
ParticipantsOG00345
T5: PMB2001 (A56): 1: 16
ParticipantsOG0009
ParticipantsOG0017
ParticipantsOG00216
ParticipantsOG00345
T5: PMB2001 (A56): 1: 32
ParticipantsOG0009
ParticipantsOG0017
ParticipantsOG00216
ParticipantsOG00345
T5: PMB2001 (A56): 1: 64
ParticipantsOG0009
ParticipantsOG0017
ParticipantsOG00216
ParticipantsOG00345
T5: PMB2001 (A56): 1: 128
ParticipantsOG0009
ParticipantsOG0017
ParticipantsOG00216
ParticipantsOG00345
T5: PMB2948 (B24): 1: 4
ParticipantsOG00010
ParticipantsOG00111
ParticipantsOG00221
ParticipantsOG00344
T5: PMB2948 (B24): 1: 8
ParticipantsOG00010
ParticipantsOG00111
ParticipantsOG00221
ParticipantsOG00344
T5: PMB2948 (B24): 1: 16
ParticipantsOG00010
ParticipantsOG00111
ParticipantsOG00221
ParticipantsOG00344
T5: PMB2948 (B24): 1: 32
ParticipantsOG00010
ParticipantsOG00111
ParticipantsOG00221
ParticipantsOG00344
T5: PMB2948 (B24): 1: 64
ParticipantsOG00010
ParticipantsOG00111
ParticipantsOG00221
ParticipantsOG00344
T5: PMB2948 (B24): 1: 128
ParticipantsOG00010
ParticipantsOG00111
ParticipantsOG00221
ParticipantsOG00344
T5: PMB2707 (B44): 1:4
ParticipantsOG0009
ParticipantsOG0017
ParticipantsOG00216
ParticipantsOG00343
T5: PMB2707 (B44): 1:8
ParticipantsOG0009
ParticipantsOG0017
ParticipantsOG00216
ParticipantsOG00343
T5: PMB2707 (B44): 1:16
ParticipantsOG0009
ParticipantsOG0017
ParticipantsOG00216
ParticipantsOG00343
T5: PMB2707 (B44): 1:32
ParticipantsOG0009
ParticipantsOG0017
ParticipantsOG00216
ParticipantsOG00343
T5: PMB2707 (B44): 1:64
ParticipantsOG0009
ParticipantsOG0017
ParticipantsOG00216
ParticipantsOG00343
T5: PMB2707 (B44): 1:128
ParticipantsOG0009
ParticipantsOG0017
ParticipantsOG00216
ParticipantsOG00343
T6: PMB80 (A22): 1:4
ParticipantsOG00010
ParticipantsOG0019
ParticipantsOG00219
ParticipantsOG00334
T6: PMB80 (A22): 1:8
ParticipantsOG00010
ParticipantsOG0019
ParticipantsOG00219
ParticipantsOG00334
T6: PMB80 (A22): 1:16
ParticipantsOG00010
ParticipantsOG0019
ParticipantsOG00219
ParticipantsOG00334
T6: PMB80 (A22): 1:32
ParticipantsOG00010
ParticipantsOG0019
ParticipantsOG00219
ParticipantsOG00334
T6: PMB80 (A22): 1:64
ParticipantsOG00010
ParticipantsOG0019
ParticipantsOG00219
ParticipantsOG00334
T6: PMB80 (A22): 1:128
ParticipantsOG00010
ParticipantsOG0019
ParticipantsOG00219
ParticipantsOG00334
T6: PMB2001 (A56): 1:4
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG00217
ParticipantsOG00339
T6: PMB2001 (A56): 1:8
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG00217
ParticipantsOG00339
T6: PMB2001 (A56): 1:16
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG00217
ParticipantsOG00339
T6: PMB2001 (A56): 1:32
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG00217
ParticipantsOG00339
T6: PMB2001 (A56): 1:64
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG00217
ParticipantsOG00339
T6: PMB2001 (A56): 1:128
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG00217
ParticipantsOG00339
T6: PMB2948 (B24): 1: 4
ParticipantsOG00010
ParticipantsOG0019
ParticipantsOG00219
ParticipantsOG00334
T6: PMB2948 (B24): 1: 8
ParticipantsOG00010
ParticipantsOG0019
ParticipantsOG00219
ParticipantsOG00334
T6: PMB2948 (B24): 1: 16
ParticipantsOG00010
ParticipantsOG0019
ParticipantsOG00219
ParticipantsOG00334
T6: PMB2948 (B24): 1: 32
ParticipantsOG00010
ParticipantsOG0019
ParticipantsOG00219
ParticipantsOG00334
T6: PMB2948 (B24): 1: 64
ParticipantsOG00010
ParticipantsOG0019
ParticipantsOG00219
ParticipantsOG00334
T6: PMB2948 (B24): 1: 128
ParticipantsOG00010
ParticipantsOG0019
ParticipantsOG00219
ParticipantsOG00334
T6: PMB2707 (B44): 1: 4
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG00217
ParticipantsOG00339
T6: PMB2707 (B44): 1: 8
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG00217
ParticipantsOG00339
T6: PMB2707 (B44): 1: 16
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG00217
ParticipantsOG00339
T6: PMB2707 (B44): 1: 32
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG00217
ParticipantsOG00339
T6: PMB2707 (B44): 1: 64
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG00217
ParticipantsOG00339
T6: PMB2707 (B44): 1: 128
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG00217
ParticipantsOG00339
Participants from greater than or equal to (>=) 12 months to less than (<) 24 months of age, received intramuscular injection of 60 mcg of bivalent rLP2086 vaccine on months 0 vaccine on a 0, 2, 6 month schedule.
OG003
Group 2: 120-µg Bivalent rLP2086 (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG004
Group 2: 120-µg Bivalent rLP2086 (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of 120 µg of bivalent rLP2086 vaccine on a 0-, 2-, 6- month schedule.
OG005
Group 2: 120-mcg Bivalent rLP2086 (>=12 Months to <24 Months)
Participants from >=12 months to <24 months of age, received intramuscular injection of 120 mcg of bivalent rLP2086 vaccine on a 0, 2, 6 month schedule. All participants who received 3 doses of 120 mcg bivalent rLP2086 in Stage 1 and gave consent for booster vaccination, received intramuscular injection of single booster dose of 120 mcg of bivalent rLP2086 after 23 to 24 months of Vaccination 3, in Stage 2. Participants were followed up approximately 6 months after the booster vaccination.
OG006
Group 3: HAV/Saline (>=12 Months to <18 Months)
Participants from >=12 months to <18 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.
OG007
Group 3: HAV/Saline (>=18 Months to <24 Months)
Participants from >=18 months to <24 months of age, received intramuscular injection of saline on 2- month and HAV vaccine on a 0-, 6- month schedule.
OG008
Group 3: HAV/Saline (>=12 Months to <24 Months): Stage 1
Participants from >=12 months to <24 months of age, received intramuscular injection of saline on 2 month and HAV vaccine on a 0, 6 month schedule.
Units
Counts
Participants
OG00010
OG00111
OG00221
OG00347
OG00451
OG00597
OG00631
OG00730
OG00861
Title
Denominators
Categories
T1:PMB80 (A22)
ParticipantsOG0009
ParticipantsOG00111
ParticipantsOG00220
ParticipantsOG00346
ParticipantsOG00451
ParticipantsOG00597
ParticipantsOG00631
ParticipantsOG00730
ParticipantsOG00861
Title
Measurements
OG0008.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
OG0018.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
OG0028.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
OG003
T1: PMB2001 (A56)
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00219
ParticipantsOG00346
T1: PMB2948 (B24)
ParticipantsOG00010
ParticipantsOG00111
ParticipantsOG00221
ParticipantsOG00346
T1: PMB2707 (B44)
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00219
ParticipantsOG00346
T2: PMB80 (A22)
ParticipantsOG00010
ParticipantsOG0019
ParticipantsOG00219
ParticipantsOG00345
T2: PMB2001 (A56)
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00219
ParticipantsOG00347
T2: PMB2948 (B24)
ParticipantsOG00010
ParticipantsOG0019
ParticipantsOG00219
ParticipantsOG00342
T2: PMB2707 (B44)
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00219
ParticipantsOG00347
T3: PMB80 (A22)
ParticipantsOG0009
ParticipantsOG00111
ParticipantsOG00220
ParticipantsOG00345
T3: PMB2001 (A56)
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00219
ParticipantsOG00347
T3: PMB2948 (B24)
ParticipantsOG0009
ParticipantsOG00111
ParticipantsOG00220
ParticipantsOG00345
T3: PMB2707 (B44)
ParticipantsOG0009
ParticipantsOG00110
ParticipantsOG00219
ParticipantsOG00347
T4: PMB80 (A22)
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG00220
ParticipantsOG00346
T4: PMB2001 (A56)
ParticipantsOG0008
ParticipantsOG00110
ParticipantsOG00218
ParticipantsOG00341
T4: PMB2948 (B24)
ParticipantsOG00010
ParticipantsOG00110
ParticipantsOG00220
ParticipantsOG00346
T4: PMB2707 (B44)
ParticipantsOG0008
ParticipantsOG0018
ParticipantsOG00216
ParticipantsOG00343
T5: PMB80 (A22)
ParticipantsOG00010
ParticipantsOG00111
ParticipantsOG00221
ParticipantsOG00345
T5: PMB2001 (A56)
ParticipantsOG0009
ParticipantsOG0017
ParticipantsOG00216
ParticipantsOG00345
T5: PMB2948 (B24)
ParticipantsOG00010
ParticipantsOG00111
ParticipantsOG00221
ParticipantsOG00344
T5: PMB2707 (B44)
ParticipantsOG0009
ParticipantsOG0017
ParticipantsOG00216
ParticipantsOG00343
T6: PMB80 (A22)
ParticipantsOG00010
ParticipantsOG0019
ParticipantsOG00219
ParticipantsOG00334
T6: PMB2001 (A56)
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG00217
ParticipantsOG00339
T6: PMB2948 (B24)
ParticipantsOG00010
ParticipantsOG0019
ParticipantsOG00219
ParticipantsOG00334
T6: PMB2707 (B44)
ParticipantsOG0009
ParticipantsOG0018
ParticipantsOG00217
ParticipantsOG00339
OG000147
Title
Denominators
Categories
Pain at injection site: mild
Title
Measurements
OG00030.6(23.3 to 38.7)
Pain at injection site: moderate
Title
Measurements
OG00029.3(22.0 to 37.3)
Pain at injection site: severe
Title
Measurements
OG00010.2(5.8 to 16.3)
Redness: mild
Title
Measurements
OG00022.4(16.0 to 30.1)
Redness: moderate
Title
Measurements
OG00021.1(14.8 to 28.6)
Redness: severe
Title
Measurements
OG0004.8(1.9 to 9.6)
Swelling: mild
Title
Measurements
OG00018.4(12.5 to 25.6)
Swelling: moderate
Title
Measurements
OG00015.0(9.6 to 21.8)
Swelling: severe
Title
Measurements
OG0000.0(0.0 to 2.5)
Units
Counts
Participants
OG000147
Title
Denominators
Categories
Fever >=38 degree C
Title
Measurements
OG00010.2(5.8 to 16.3)
Fever 38 to <38.5 degree C
Title
Measurements
OG0006.1(2.8 to 11.3)
Fever 38.5 to <39 degree C
Title
Measurements
OG0003.4(1.1 to 7.8)
Fever 39 to <39.5 degree C
Title
Measurements
OG0000.7(0.0 to 3.7)
Fever 39.5 to <=40 degree C
Title
Measurements
OG0000.0(0.0 to 2.5)
Fever >40 degree C
Title
Measurements
OG0000.0(0.0 to 2.5)
Vomiting: mild
Title
Measurements
OG0004.8(1.9 to 9.6)
Vomiting: moderate
Title
Measurements
OG0001.4(0.2 to 4.8)
Vomiting: severe
Title
Measurements
OG0000.0(0.0 to 2.5)
Diarrhea: mild
Title
Measurements
OG0004.8(1.9 to 9.6)
Diarrhea: moderate
Title
Measurements
OG0000.7(0.0 to 3.7)
Diarrhea: severe
Title
Measurements
OG0000.0(0.0 to 2.5)
Headache: mild
Title
Measurements
OG0007.5(3.8 to 13.0)
Headache: moderate
Title
Measurements
OG00010.2(5.8 to 16.3)
Headache: severe
Title
Measurements
OG0001.4(0.2 to 4.8)
Fatigue: mild
Title
Measurements
OG00017.0(11.3 to 24.1)
Fatigue: moderate
Title
Measurements
OG00022.4(16.0 to 30.1)
Fatigue: severe
Title
Measurements
OG0006.8(3.3 to 12.2)
Muscle pain : mild
Title
Measurements
OG0006.1(2.8 to 11.3)
Muscle pain : moderate
Title
Measurements
OG0008.2(4.3 to 13.8)
Muscle pain : severe
Title
Measurements
OG0002.0(0.4 to 5.4)
Joint pain: mild
Title
Measurements
OG0004.1(1.5 to 8.7)
Joint pain: moderate
Title
Measurements
OG0006.1(2.8 to 11.3)
Joint pain: severe
Title
Measurements
OG0000.0(0.0 to 2.5)
Antipyretic medication use
Title
Measurements
OG00034.7(27.0 to 43.0)
Units
Counts
Participants
OG000147
Title
Denominators
Categories
SAE: T1
Title
Measurements
OG0000.7(0.0 to 3.7)
SAE: T2
Title
Measurements
OG0000.7(0.0 to 3.7)
SAE: T3
Title
Measurements
OG0001.4(0.2 to 4.8)
MAE: T1
Title
Measurements
OG0004.8(1.9 to 9.6)
MAE: T2
Title
Measurements
OG0002.7(0.7 to 6.8)
MAE: T3
Title
Measurements
OG0007.5(3.8 to 13.0)
NDCMC: T1
Title
Measurements
OG0000.0(0.0 to 2.5)
NDCMC: T2
Title
Measurements
OG0000.0(0.0 to 2.5)
NDCMC: T3
Title
Measurements
OG0000.0(0.0 to 2.5)
147
Title
Denominators
Categories
Title
Measurements
OG00013.6(8.5 to 20.2)
147
Title
Denominators
Categories
Title
Measurements
OG0000.0(0.0 to 2.5)
OG00069
Title
Denominators
Categories
PMB80 (A22): before booster vaccination
ParticipantsOG00069
Title
Measurements
OG0002.9(0.4 to 10.1)
PMB80 (A22):1 month after booster vaccination
ParticipantsOG00068
Title
Measurements
OG00092.6(83.7 to 97.6)
PMB2001 (A56):before booster vaccination
ParticipantsOG00066
Title
Measurements
OG00015.2(7.5 to 26.1)
PMB2001 (A56):1 month after booster vaccination
ParticipantsOG00068
Title
Measurements
OG000100.0(94.7 to 100.0)
PMB2948 (B24): before booster vaccination
ParticipantsOG00069
Title
Measurements
OG0007.2(2.4 to 16.1)
PMB2948 (B24):1 month after booster vaccination
ParticipantsOG00069
Title
Measurements
OG00092.8(83.9 to 97.6)
PMB2707 (B44): before booster vaccination
ParticipantsOG00067
Title
Measurements
OG0009.0(3.4 to 18.5)
PMB2707 (B44): 1 month after booster vaccination
ParticipantsOG00069
Title
Measurements
OG00095.7(87.8 to 99.1)
OG00069
Title
Denominators
Categories
PMB80 (A22): before booster vaccination
ParticipantsOG00069
Title
Measurements
OG0008.4(7.8 to 9.0)
PMB80 (A22):1 month after booster vaccination
ParticipantsOG00068
Title
Measurements
OG000112.1(87.2 to 144.2)
PMB2001 (A56):before booster vaccination
ParticipantsOG00066
Title
Measurements
OG0005.2(4.4 to 6.2)
PMB2001 (A56):1 month after booster vaccination
ParticipantsOG00068
Title
Measurements
OG000248.3(192.7 to 319.9)
PMB2948 (B24): before booster vaccination
ParticipantsOG00069
Title
Measurements
OG0004.5(4.0 to 5.1)
PMB2948 (B24):1 month after booster vaccination
ParticipantsOG00069
Title
Measurements
OG00048.3(37.6 to 62.0)
PMB2707 (B44): before booster vaccination
ParticipantsOG00067
Title
Measurements
OG0004.4(4.1 to 4.9)
PMB2707 (B44): 1 month after booster vaccination
ParticipantsOG00069
Title
Measurements
OG00098.6(71.4 to 136.2)
0 affected
44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
1 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
1 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0051 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0051 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0051 affected220 at risk
EG0060 affected132 at risk
0 affected
44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
71 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
49 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
15 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
2 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
2 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
3 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
5 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
2 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
2 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
0 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
9 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
68 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
103 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
15 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
24 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
28 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
8 affected
147 at risk
EG0040 affected44 at risk
EG0050 affected220 at risk
EG0060 affected132 at risk
100.0
(92.6 to 100.0)
OG0040.0(0.0 to 14.2)
OG0053.3(0.1 to 17.2)
72.0
(57.5 to 83.8)
OG0043.2(0.1 to 16.7)
OG0056.9(0.8 to 22.8)
85.1
(71.7 to 93.8)
OG0040.0(0.0 to 14.2)
OG0050.0(0.0 to 11.6)
27.3
(19.2 to 36.6)
OG00434.5(25.7 to 44.2)
OG00530.9(24.9 to 37.5)
OG00612.1(5.4 to 22.5)
OG00719.7(10.9 to 31.3)
OG00815.9(10.1 to 23.3)
20.9
(13.7 to 29.7)
OG00424.5(16.8 to 33.7)
OG00522.7(17.4 to 28.8)
OG0063.0(0.4 to 10.5)
OG0070.0(0.0 to 5.4)
OG0081.5(0.2 to 5.4)
2.7
(0.6 to 7.8)
OG0045.5(2.0 to 11.5)
OG0054.1(1.9 to 7.6)
OG0060.0(0.0 to 5.4)
OG0070.0(0.0 to 5.4)
OG0080.0(0.0 to 2.8)
50.9
(41.2 to 60.6)
OG00442.7(33.3 to 52.5)
OG00546.8(40.1 to 53.6)
OG00613.6(6.4 to 24.3)
OG00716.7(8.6 to 27.9)
OG00815.2(9.5 to 22.4)
35.5
(26.6 to 45.1)
OG00421.8(14.5 to 30.7)
OG00528.6(22.8 to 35.1)
OG00613.6(6.4 to 24.3)
OG00716.7(8.6 to 27.9)
OG00815.2(9.5 to 22.4)
14.5
(8.5 to 22.5)
OG00419.1(12.2 to 27.7)
OG00516.8(12.1 to 22.4)
OG0060.0(0.0 to 5.4)
OG0070.0(0.0 to 5.4)
OG0080.0(0.0 to 2.8)
0.9
(0.0 to 5.0)
OG0041.8(0.2 to 6.4)
OG0051.4(0.3 to 3.9)
OG0060.0(0.0 to 5.4)
OG0070.0(0.0 to 5.4)
OG0080.0(0.0 to 2.8)
30.0
(21.6 to 39.5)
OG00427.3(19.2 to 36.6)
OG00528.6(22.8 to 35.1)
OG0067.6(2.5 to 16.8)
OG00712.1(5.4 to 22.5)
OG0089.8(5.3 to 16.3)
15.5
(9.3 to 23.6)
OG00419.1(12.2 to 27.7)
OG00517.3(12.5 to 22.9)
OG0067.6(2.5 to 16.8)
OG00712.1(5.4 to 22.5)
OG0089.8(5.3 to 16.3)
13.6
(7.8 to 21.5)
OG0048.2(3.8 to 15.0)
OG00510.9(7.1 to 15.8)
OG0060.0(0.0 to 5.4)
OG0070.0(0.0 to 5.4)
OG0080.0(0.0 to 2.8)
0.9
(0.0 to 5.0)
OG0040.0(0.0 to 3.3)
OG0050.5(0.0 to 2.5)
OG0060.0(0.0 to 5.4)
OG0070.0(0.0 to 5.4)
OG0080.0(0.0 to 2.8)
31.4
(22.7 to 41.2)
OG00432.7(24.0 to 42.5)
OG00532.1(25.8 to 38.8)
OG00612.7(5.6 to 23.5)
OG00715.4(7.6 to 26.5)
OG00814.1(8.6 to 21.3)
12.4
(6.8 to 20.2)
OG00424.3(16.5 to 33.5)
OG00518.4(13.4 to 24.3)
OG0061.6(0.0 to 8.5)
OG0070.0(0.0 to 5.5)
OG0080.8(0.0 to 4.3)
1.9
(0.2 to 6.7)
OG0043.7(1.0 to 9.3)
OG0052.8(1.0 to 6.1)
OG0060.0(0.0 to 5.7)
OG0070.0(0.0 to 5.5)
OG0080.0(0.0 to 2.8)
33.3
(24.4 to 43.2)
OG00438.3(29.1 to 48.2)
OG00535.8(29.4 to 42.7)
OG0066.3(1.8 to 15.5)
OG0079.2(3.5 to 19.0)
OG0087.8(3.8 to 13.9)
21.9
(14.4 to 31.0)
OG00423.4(15.7 to 32.5)
OG00522.6(17.2 to 28.9)
OG0066.3(1.8 to 15.5)
OG0079.2(3.5 to 19.0)
OG0087.8(3.8 to 13.9)
11.4
(6.0 to 19.1)
OG00415.0(8.8 to 23.1)
OG00513.2(9.0 to 18.5)
OG0060.0(0.0 to 5.7)
OG0070.0(0.0 to 5.5)
OG0080.0(0.0 to 2.8)
0.0
(0.0 to 3.5)
OG0040.0(0.0 to 3.4)
OG0050.0(0.0 to 1.7)
OG0060.0(0.0 to 5.7)
OG0070.0(0.0 to 5.5)
OG0080.0(0.0 to 2.8)
21.0
(13.6 to 30.0)
OG00419.6(12.6 to 28.4)
OG00520.3(15.1 to 26.3)
OG0061.6(0.0 to 8.5)
OG0077.7(2.5 to 17.0)
OG0084.7(1.7 to 9.9)
14.3
(8.2 to 22.5)
OG00413.1(7.3 to 21.0)
OG00513.7(9.4 to 19.1)
OG0061.6(0.0 to 8.5)
OG0077.7(2.5 to 17.0)
OG0084.7(1.7 to 9.9)
6.7
(2.7 to 13.3)
OG0045.6(2.1 to 11.8)
OG0056.1(3.3 to 10.3)
OG0060.0(0.0 to 5.7)
OG0070.0(0.0 to 5.5)
OG0080.0(0.0 to 2.8)
0.0
(0.0 to 3.5)
OG0040.9(0.0 to 5.1)
OG0050.5(0.0 to 2.6)
OG0060.0(0.0 to 5.7)
OG0070.0(0.0 to 5.5)
OG0080.0(0.0 to 2.8)
29.8
(21.2 to 39.6)
OG00434.3(25.4 to 44.0)
OG00532.1(25.8 to 38.8)
OG00612.3(5.5 to 22.8)
OG00712.7(5.6 to 23.5)
OG00812.5(7.3 to 19.5)
17.3
(10.6 to 26.0)
OG00422.2(14.8 to 31.2)
OG00519.8(14.7 to 25.8)
OG0064.6(1.0 to 12.9)
OG0071.6(0.0 to 8.5)
OG0083.1(0.9 to 7.8)
4.8
(1.6 to 10.9)
OG0045.6(2.1 to 11.7)
OG0055.2(2.6 to 9.1)
OG0060.0(0.0 to 5.5)
OG0070.0(0.0 to 5.7)
OG0080.0(0.0 to 2.8)
32.7
(23.8 to 42.6)
OG00433.3(24.6 to 43.1)
OG00533.0(26.7 to 39.8)
OG0067.7(2.5 to 17.0)
OG0077.9(2.6 to 17.6)
OG0087.8(3.8 to 13.9)
23.1
(15.4 to 32.4)
OG00418.5(11.7 to 27.1)
OG00520.8(15.5 to 26.8)
OG0066.2(1.7 to 15.0)
OG0077.9(2.6 to 17.6)
OG0087.0(3.3 to 12.9)
8.7
(4.0 to 15.8)
OG00414.8(8.7 to 22.9)
OG00511.8(7.8 to 16.9)
OG0061.5(0.0 to 8.3)
OG0070.0(0.0 to 5.7)
OG0080.8(0.0 to 4.3)
1.0
(0.0 to 5.2)
OG0040.0(0.0 to 3.4)
OG0050.5(0.0 to 2.6)
OG0060.0(0.0 to 5.5)
OG0070.0(0.0 to 5.7)
OG0080.0(0.0 to 2.8)
23.1
(15.4 to 32.4)
OG00422.2(14.8 to 31.2)
OG00522.6(17.2 to 28.9)
OG0064.6(1.0 to 12.9)
OG0076.3(1.8 to 15.5)
OG0085.5(2.2 to 10.9)
16.3
(9.8 to 24.9)
OG00411.1(5.9 to 18.6)
OG00513.7(9.4 to 19.1)
OG0064.6(1.0 to 12.9)
OG0074.8(1.0 to 13.3)
OG0084.7(1.7 to 9.9)
5.8
(2.1 to 12.1)
OG00411.1(5.9 to 18.6)
OG0058.5(5.1 to 13.1)
OG0060.0(0.0 to 5.5)
OG0071.6(0.0 to 8.5)
OG0080.8(0.0 to 4.3)
1.0
(0.0 to 5.2)
OG0040.0(0.0 to 3.4)
OG0050.5(0.0 to 2.6)
OG0060.0(0.0 to 5.5)
OG0070.0(0.0 to 5.7)
OG0080.0(0.0 to 2.8)
7.3
(3.2 to 13.8)
OG0047.3(3.2 to 13.8)
OG0057.3(4.2 to 11.5)
OG0066.1(1.7 to 14.8)
OG0071.5(0.0 to 8.2)
OG0083.8(1.2 to 8.6)
14.5
(8.5 to 22.5)
OG00413.6(7.8 to 21.5)
OG00514.1(9.8 to 19.4)
OG0061.5(0.0 to 8.2)
OG0070.0(0.0 to 5.4)
OG0080.8(0.0 to 4.1)
4.5
(1.5 to 10.3)
OG0043.6(1.0 to 9.0)
OG0054.1(1.9 to 7.6)
OG0063.0(0.4 to 10.5)
OG0070.0(0.0 to 5.4)
OG0081.5(0.2 to 5.4)
1.8
(0.2 to 6.4)
OG0041.8(0.2 to 6.4)
OG0051.8(0.5 to 4.6)
OG0060.0(0.0 to 5.4)
OG0070.0(0.0 to 5.4)
OG0080.0(0.0 to 2.8)
0.0
(0.0 to 3.3)
OG0040.9(0.0 to 5.0)
OG0050.5(0.0 to 2.5)
OG0060.0(0.0 to 5.4)
OG0070.0(0.0 to 5.4)
OG0080.0(0.0 to 2.8)
71.8
(62.4 to 80.0)
OG00460.9(51.1 to 70.1)
OG00566.4(59.7 to 72.6)
OG00640.9(29.0 to 53.7)
OG00733.3(22.2 to 46.0)
OG00837.1(28.9 to 46.0)
19.1
(12.2 to 27.7)
OG00416.4(10.0 to 24.6)
OG00517.7(12.9 to 23.4)
OG00610.6(4.4 to 20.6)
OG00713.6(6.4 to 24.3)
OG00812.1(7.1 to 18.9)
46.4
(36.8 to 56.1)
OG00439.1(29.9 to 48.9)
OG00542.7(36.1 to 49.6)
OG00630.3(19.6 to 42.9)
OG00716.7(8.6 to 27.9)
OG00823.5(16.5 to 31.6)
6.4
(2.6 to 12.7)
OG0045.5(2.0 to 11.5)
OG0055.9(3.2 to 9.9)
OG0060.0(0.0 to 5.4)
OG0073.0(0.4 to 10.5)
OG0081.5(0.2 to 5.4)
45.5
(35.9 to 55.2)
OG00442.7(33.3 to 52.5)
OG00544.1(37.4 to 50.9)
OG00625.8(15.8 to 38.0)
OG00710.6(4.4 to 20.6)
OG00818.2(12.0 to 25.8)
28.2
(20.0 to 37.6)
OG00424.5(16.8 to 33.7)
OG00526.4(20.7 to 32.7)
OG00616.7(8.6 to 27.9)
OG0076.1(1.7 to 14.8)
OG00811.4(6.5 to 18.0)
11.8
(6.4 to 19.4)
OG00415.5(9.3 to 23.6)
OG00513.6(9.4 to 18.9)
OG0067.6(2.5 to 16.8)
OG0074.5(0.9 to 12.7)
OG0086.1(2.7 to 11.6)
5.5
(2.0 to 11.5)
OG0042.7(0.6 to 7.8)
OG0054.1(1.9 to 7.6)
OG0061.5(0.0 to 8.2)
OG0070.0(0.0 to 15.4)
OG0080.8(0.0 to 4.1)
44.5
(35.1 to 54.3)
OG00446.4(36.8 to 56.1)
OG00545.5(38.7 to 52.3)
OG00634.8(23.5 to 47.6)
OG00710.6(4.4 to 20.6)
OG00822.7(15.9 to 30.8)
16.4
(10.0 to 24.6)
OG00424.5(16.8 to 33.7)
OG00520.5(15.3 to 26.4)
OG00613.6(6.4 to 24.3)
OG0077.6(2.5 to 16.8)
OG00810.6(5.9 to 17.2)
25.5
(17.6 to 34.6)
OG00414.5(8.5 to 22.5)
OG00520.0(14.9 to 25.9)
OG00618.2(9.8 to 29.6)
OG0071.5(0.0 to 8.2)
OG0089.8(5.3 to 16.3)
2.7
(0.6 to 7.8)
OG0047.3(3.2 to 13.8)
OG0055.0(2.5 to 8.8)
OG0063.0(0.4 to 10.5)
OG0071.5(0.0 to 8.2)
OG0082.3(0.5 to 6.5)
52.7
(43.0 to 62.3)
OG00440.9(31.6 to 50.7)
OG00546.8(40.1 to 53.6)
OG00624.2(14.5 to 36.4)
OG00715.2(7.5 to 26.1)
OG00819.7(13.3 to 27.5)
4.8
(1.6 to 10.8)
OG0048.4(3.9 to 15.4)
OG0056.6(3.7 to 10.8)
OG0064.8(1.0 to 13.3)
OG0073.1(0.4 to 10.7)
OG0083.9(1.3 to 8.9)
6.7
(2.7 to 13.3)
OG0042.8(0.6 to 8.0)
OG0054.7(2.3 to 8.5)
OG0061.6(0.0 to 8.5)
OG0070.0(0.0 to 5.5)
OG0080.8(0.0 to 4.3)
1.9
(0.2 to 6.7)
OG0041.9(0.2 to 6.6)
OG0051.9(0.5 to 4.8)
OG0060.0(0.0 to 5.7)
OG0070.0(0.0 to 5.5)
OG0080.0(0.0 to 2.8)
1.0
(0.0 to 5.2)
OG0040.9(0.0 to 5.1)
OG0050.9(0.1 to 3.4)
OG0060.0(0.0 to 5.7)
OG0070.0(0.0 to 5.5)
OG0080.0(0.0 to 2.8)
0.0
(0.0 to 3.5)
OG0040.0(0.0 to 3.4)
OG0050.0(0.0 to 1.7)
OG0060.0(0.0 to 5.7)
OG0070.0(0.0 to 5.5)
OG0080.0(0.0 to 2.8)
54.3
(44.3 to 64.0)
OG00455.1(45.2 to 64.8)
OG00554.7(47.8 to 61.5)
OG00631.7(20.6 to 44.7)
OG00718.5(9.9 to 30.0)
OG00825.0(17.8 to 33.4)
19.0
(12.0 to 27.9)
OG00418.7(11.8 to 27.4)
OG00518.9(13.8 to 24.8)
OG0067.9(2.6 to 17.6)
OG0076.2(1.7 to 15.0)
OG0087.0(3.3 to 12.9)
31.4
(22.7 to 41.2)
OG00434.6(25.6 to 44.4)
OG00533.0(26.7 to 39.8)
OG00622.2(12.7 to 34.5)
OG0079.2(3.5 to 19.0)
OG00815.6(9.8 to 23.1)
3.8
(1.0 to 9.5)
OG0041.9(0.2 to 6.6)
OG0052.8(1.0 to 6.1)
OG0061.6(0.0 to 8.5)
OG0073.1(0.4 to 10.7)
OG0082.3(0.5 to 6.7)
37.1
(27.9 to 47.1)
OG00424.3(16.5 to 33.5)
OG00530.7(24.5 to 37.3)
OG00619.0(10.2 to 30.9)
OG0074.6(1.0 to 12.9)
OG00811.7(6.7 to 18.6)
22.9
(15.2 to 32.1)
OG00414.0(8.1 to 22.1)
OG00518.4(13.4 to 24.3)
OG0069.5(3.6 to 19.6)
OG0074.6(1.0 to 12.9)
OG0087.0(3.3 to 12.9)
13.3
(7.5 to 21.4)
OG0048.4(3.9 to 15.4)
OG00510.8(7.0 to 15.8)
OG0067.9(2.6 to 17.6)
OG0070.0(0.0 to 5.5)
OG0083.9(1.3 to 8.9)
1.0
(0.0 to 5.2)
OG0041.9(0.2 to 6.6)
OG0051.4(0.3 to 4.1)
OG0061.6(0.0 to 8.5)
OG0070.0(0.0 to 5.5)
OG0080.8(0.0 to 4.3)
41.0
(31.5 to 51.0)
OG00431.8(23.1 to 41.5)
OG00536.3(29.8 to 43.2)
OG00622.2(12.7 to 34.5)
OG00713.8(6.5 to 24.7)
OG00818.0(11.7 to 25.7)
19.0
(12.0 to 27.9)
OG00419.6(12.6 to 28.4)
OG00519.3(14.3 to 25.3)
OG00611.1(4.6 to 21.6)
OG0077.7(2.5 to 17.0)
OG0089.4(4.9 to 15.8)
17.1
(10.5 to 25.7)
OG0047.5(3.3 to 14.2)
OG00512.3(8.2 to 17.5)
OG0069.5(3.6 to 19.6)
OG0076.2(1.7 to 15.0)
OG0087.8(3.8 to 13.9)
4.8
(1.6 to 10.8)
OG0044.7(1.5 to 10.6)
OG0054.7(2.3 to 8.5)
OG0061.6(0.0 to 8.5)
OG0070.0(0.0 to 5.5)
OG0080.8(0.0 to 4.3)
35.2
(26.2 to 45.2)
OG00431.8(23.1 to 41.5)
OG00533.5(27.2 to 40.3)
OG00619.0(10.2 to 30.9)
OG00710.8(4.4 to 20.9)
OG00814.8(9.2 to 22.2)
6.7
(2.7 to 13.4)
OG0046.5(2.6 to 12.9)
OG0056.6(3.7 to 10.8)
OG0063.1(0.4 to 10.7)
OG0074.8(1.0 to 13.3)
OG0083.9(1.3 to 8.9)
2.9
(0.6 to 8.2)
OG0041.9(0.2 to 6.5)
OG0052.4(0.8 to 5.4)
OG0061.5(0.0 to 8.3)
OG0071.6(0.0 to 8.5)
OG0081.6(0.2 to 5.5)
1.0
(0.0 to 5.2)
OG0043.7(1.0 to 9.2)
OG0052.4(0.8 to 5.4)
OG0060.0(0.0 to 5.5)
OG0071.6(0.0 to 8.5)
OG0080.8(0.0 to 4.3)
0.0
(0.0 to 3.5)
OG0042.8(0.6 to 7.9)
OG0051.4(0.3 to 4.1)
OG0060.0(0.0 to 5.5)
OG0070.0(0.0 to 5.7)
OG0080.0(0.0 to 2.8)
0.0
(0.0 to 3.5)
OG0040.0(0.0 to 3.4)
OG0050.0(0.0 to 1.7)
OG0060.0(0.0 to 5.5)
OG0070.0(0.0 to 5.7)
OG0080.0(0.0 to 2.8)
56.7
(46.7 to 66.4)
OG00444.4(34.9 to 54.3)
OG00550.5(43.5 to 57.4)
OG00624.6(14.8 to 36.9)
OG00730.2(19.2 to 43.0)
OG00827.3(19.8 to 35.9)
27.9
(19.5 to 37.5)
OG00419.4(12.5 to 28.2)
OG00523.6(18.0 to 29.9)
OG0069.2(3.5 to 19.0)
OG00715.9(7.9 to 27.3)
OG00812.5(7.3 to 19.5)
26.0
(17.9 to 35.5)
OG00424.1(16.4 to 33.3)
OG00525.0(19.3 to 31.4)
OG00613.8(6.5 to 24.7)
OG00712.7(5.6 to 23.5)
OG00813.3(7.9 to 20.4)
2.9
(0.6 to 8.2)
OG0040.9(0.0 to 5.1)
OG0051.9(0.5 to 4.8)
OG0061.5(0.0 to 8.3)
OG0071.6(0.0 to 8.5)
OG0081.6(0.2 to 5.5)
37.5
(28.2 to 47.5)
OG00430.6(22.1 to 40.2)
OG00534.0(27.6 to 40.8)
OG00613.8(6.5 to 24.7)
OG00712.7(5.6 to 23.5)
OG00813.3(7.9 to 20.4)
24.0
(16.2 to 33.4)
OG00423.1(15.6 to 32.2)
OG00523.6(18.0 to 29.9)
OG00610.8(4.4 to 20.9)
OG0079.5(3.6 to 19.6)
OG00810.2(5.5 to 16.7)
10.6
(5.4 to 18.1)
OG0046.5(2.6 to 12.9)
OG0058.5(5.1 to 13.1)
OG0063.1(0.4 to 10.7)
OG0071.6(0.0 to 8.5)
OG0082.3(0.5 to 6.7)
2.9
(0.6 to 8.2)
OG0040.9(0.0 to 5.1)
OG0051.9(0.5 to 4.8)
OG0060.0(0.0 to 5.5)
OG0071.6(0.0 to 8.5)
OG0080.8(0.0 to 4.3)
33.7
(24.7 to 43.6)
OG00435.2(26.2 to 45.0)
OG00534.4(28.1 to 41.2)
OG00616.9(8.8 to 28.3)
OG00719.0(10.2 to 30.9)
OG00818.0(11.7 to 25.7)
15.4
(9.1 to 23.8)
OG00418.5(11.7 to 27.1)
OG00517.0(12.2 to 22.7)
OG0069.2(3.5 to 19.0)
OG00715.9(7.9 to 27.3)
OG00812.5(7.3 to 19.5)
14.4
(8.3 to 22.7)
OG00414.8(8.7 to 22.9)
OG00514.6(10.2 to 20.1)
OG0067.7(2.5 to 17.0)
OG0071.6(0.0 to 8.5)
OG0084.7(1.7 to 9.9)
3.8
(1.1 to 9.6)
OG0041.9(0.2 to 6.5)
OG0052.8(1.0 to 6.1)
OG0060.0(0.0 to 5.5)
OG0071.6(0.0 to 8.5)
OG0080.8(0.0 to 4.3)
34.6
(25.6 to 44.6)
OG00433.3(24.6 to 43.1)
OG00534.0(27.6 to 40.8)
OG00613.8(6.5 to 24.7)
OG00715.9(7.9 to 27.3)
OG00814.8(9.2 to 22.2)
0.9
(0.0 to 5.0)
OG0041.8(0.2 to 6.4)
OG0051.4(0.3 to 3.9)
OG0061.5(0.0 to 8.2)
OG0071.5(0.0 to 8.2)
OG0081.5(0.2 to 5.4)
18.2
(11.5 to 26.7)
OG00419.1(12.2 to 27.7)
OG00518.6(13.7 to 24.4)
OG00618.2(9.8 to 29.6)
OG00716.7(8.6 to 27.9)
OG00817.4(11.4 to 25.0)
0.0
(0.0 to 3.3)
OG0040.0(0.0 to 3.3)
OG0050.0(0.0 to 1.7)
OG0060.0(0.0 to 5.4)
OG0070.0(0.0 to 5.4)
OG0080.0(0.0 to 2.8)
0.0
(0.0 to 3.3)
OG0040.0(0.0 to 3.3)
OG0050.0(0.0 to 1.7)
OG0060.0(0.0 to 5.4)
OG0070.0(0.0 to 5.4)
OG0080.0(0.0 to 2.8)
3.8
(1.0 to 9.5)
OG0040.0(0.0 to 3.4)
OG0051.9(0.5 to 4.7)
OG0061.5(0.0 to 8.2)
OG0070.0(0.0 to 5.5)
OG0080.8(0.0 to 4.2)
16.2
(9.7 to 24.7)
OG00418.5(11.7 to 27.1)
OG00517.4(12.5 to 23.1)
OG00613.6(6.4 to 24.3)
OG00723.1(13.5 to 35.2)
OG00818.3(12.1 to 26.0)
0.0
(0.0 to 3.5)
OG0040.0(0.0 to 3.4)
OG0050.0(0.0 to 1.7)
OG0060.0(0.0 to 5.4)
OG0070.0(0.0 to 5.5)
OG0080.0(0.0 to 2.8)
0.0
(0.0 to 5.2)
OG0040.0(0.0 to 3.4)
OG0050.5(0.0 to 2.6)
OG0060.0(0.0 to 5.4)
OG0070.0(0.0 to 5.5)
OG0080.0(0.0 to 2.8)
1.0
(0.0 to 5.2)
OG0040.0(0.0 to 3.4)
OG0050.5(0.0 to 2.6)
OG0061.5(0.0 to 8.3)
OG0070.0(0.0 to 5.6)
OG0080.8(0.0 to 4.2)
13.5
(7.6 to 21.6)
OG00416.7(10.2 to 25.1)
OG00515.1(10.6 to 20.6)
OG00612.3(5.5 to 22.8)
OG00720.3(11.3 to 32.2)
OG00816.3(10.4 to 23.8)
0.0
(0.0 to 3.5)
OG0040.0(0.0 to 3.4)
OG0050.0(0.0 to 1.7)
OG0060.0(0.0 to 5.5)
OG0070.0(0.0 to 5.6)
OG0080.0(0.0 to 2.8)
0.0
(0.0 to 3.5)
OG0040.0(0.0 to 5.1)
OG0050.5(0.0 to 2.6)
OG0060.0(0.0 to 5.5)
OG0070.0(0.0 to 5.6)
OG0080.0(0.0 to 2.8)
5.5
(2.0 to 11.5)
OG0041.8(0.2 to 6.4)
OG0053.6(1.6 to 7.0)
OG0064.5(0.9 to 12.7)
OG0071.5(0.0 to 8.2)
OG0083.0(0.8 to 7.6)
32.7
(24.1 to 42.3)
OG00440.0(30.8 to 49.8)
OG00536.4(30.0 to 43.1)
OG00631.8(20.9 to 44.4)
OG00739.4(27.6 to 52.2)
OG00835.6(27.5 to 44.4)
0.0
(0.0 to 3.3)
OG0040.0(0.0 to 3.3)
OG0050.0(0.0 to 1.7)
OG0060.0(0.0 to 5.4)
OG0070.0(0.0 to 5.4)
OG0080.0(0.0 to 2.8)
10.9
(5.8 to 18.3)
OG0043.6(1.0 to 9.0)
OG0057.3(4.2 to 11.5)
OG0064.5(0.9 to 12.7)
OG0076.1(1.7 to 14.8)
OG0085.3(2.2 to 10.6)
47.3
(37.7 to 57.0)
OG00454.5(44.8 to 64.1)
OG00550.9(44.1 to 57.7)
OG00642.4(30.3 to 55.2)
OG00743.9(31.7 to 56.7)
OG00843.2(34.6 to 52.1)
0.0
(0.0 to 3.3)
OG0040.0(0.0 to 5.0)
OG0050.5(0.0 to 2.5)
OG0060.0(0.0 to 5.4)
OG0070.0(0.0 to 5.4)
OG0080.0(0.0 to 2.8)
29.6
(21.2 to 39.2)
OG00432.7(24.0 to 42.5)
OG00531.2(25.0 to 37.8)
OG00630.8(19.9 to 43.4)
OG00728.6(17.9 to 41.3)
OG00829.7(21.9 to 38.4)
0.0
(0.0 to 3.4)
OG0040.0(0.0 to 3.4)
OG0050.0(0.0 to 1.7)
OG0060.0(0.0 to 5.5)
OG0070.0(0.0 to 5.7)
OG0080.0(0.0 to 2.8)
54.5
(44.8 to 64.1)
OG00462.7(53.0 to 71.8)
OG00558.6(51.8 to 65.2)
OG00659.1(46.3 to 71.0)
OG00753.0(40.3 to 65.4)
OG00856.1(42.7 to 64.7)
0.0
(0.0 to 3.3)
OG0040.9(0.0 to 5.0)
OG0050.5(0.0 to 2.5)
OG0060.0(0.0 to 5.4)
OG0070.0(0.0 to 5.4)
OG0080.0(0.0 to 2.8)
10.0
(1.2 to 31.7)
OG00112.4(6.6 to 20.6)
OG0023.4(0.4 to 11.9)
14.3
(3.0 to 36.3)
OG0016.3(2.4 to 13.2)
OG0021.8(0.0 to 9.7)
0.0
(0.0 to 17.6)
OG0013.7(0.8 to 10.4)
100.0
(82.4 to 100.0)
OG001100.0(96.2 to 100.0)
OG0021.9(0.0 to 9.9)
61.1
(35.7 to 82.7)
OG00159.1(48.1 to 69.5)
OG0023.8(0.5 to 13.2)
56.3
(29.9 to 80.2)
OG00138.7(28.8 to 49.4)
OG0025.7(1.2 to 15.7)
41.2
(18.4 to 67.1)
OG00122.8(14.1 to 33.6)
85.0
(62.1 to 96.8)
OG00171.6(61.4 to 80.4)
OG0025.0(1.0 to 13.9)
15.0
(3.2 to 37.9)
OG00110.3(5.1 to 18.1)
OG0023.4(0.4 to 11.9)
9.5
(1.2 to 30.4)
OG0013.2(0.7 to 9.1)
OG0023.6(0.4 to 12.5)
5.3
(0.1 to 26.0)
OG0013.7(0.8 to 10.3)
89.5
(66.9 to 98.7)
OG00186.2(77.5 to 92.4)
OG0020.0(0.0 to 6.6)
25.0
(7.3 to 52.4)
OG00140.4(30.2 to 51.4)
OG0021.9(0.0 to 10.1)
12.5
(1.6 to 38.3)
OG00117.8(10.5 to 27.3)
OG0022.0(0.0 to 10.4)
11.8
(1.5 to 36.4)
OG00112.5(6.2 to 21.8)
64.4
(48.8 to 78.1)
OG00484.0(70.9 to 92.8)
OG00574.7(64.8 to 83.1)
OG0060.0(0.0 to 11.6)
OG0073.4(0.1 to 17.8)
OG0081.7(0.0 to 9.1)
ParticipantsOG00448
ParticipantsOG00595
ParticipantsOG00623
ParticipantsOG00729
ParticipantsOG00852
Title
Measurements
OG000100.0(66.4 to 100.0)
OG00190.0(55.5 to 99.7)
OG00294.7(74.0 to 99.9)
OG003100.0(92.5 to 100.0)
OG004100.0(92.6 to 100.0)
OG005100.0(96.2 to 100.0)
OG0060.0(0.0 to 14.8)
OG0070.0(0.0 to 11.9)
OG0080.0(0.0 to 6.8)
ParticipantsOG00444
ParticipantsOG00586
ParticipantsOG00630
ParticipantsOG00729
ParticipantsOG00859
Title
Measurements
OG00070.0(34.8 to 93.3)
OG00144.4(13.7 to 78.8)
OG00257.9(33.5 to 79.7)
OG00323.8(12.1 to 39.5)
OG00443.2(28.3 to 59.0)
OG00533.7(23.9 to 44.7)
OG0060.0(0.0 to 11.6)
OG0073.4(0.1 to 17.8)
OG0081.7(0.0 to 9.1)
ParticipantsOG00447
ParticipantsOG00594
ParticipantsOG00623
ParticipantsOG00729
ParticipantsOG00852
Title
Measurements
OG00077.8(40.0 to 97.2)
OG00160.0(26.2 to 87.8)
OG00268.4(43.4 to 87.4)
OG00372.3(57.4 to 84.4)
OG00463.8(48.5 to 77.3)
OG00568.1(57.7 to 77.3)
OG0060.0(0.0 to 14.8)
OG0070.0(0.0 to 11.9)
OG0080.0(0.0 to 6.8)
4.3
(0.5 to 14.8)
OG0043.9(0.5 to 13.5)
OG0054.1(1.1 to 10.2)
OG0060.0(0.0 to 11.2)
OG0073.3(0.1 to 17.2)
OG0081.6(0.0 to 8.8)
ParticipantsOG00451
ParticipantsOG00597
ParticipantsOG00631
ParticipantsOG00730
ParticipantsOG00861
Title
Measurements
OG0000.0(0.0 to 33.6)
OG0010.0(0.0 to 28.5)
OG0020.0(0.0 to 16.8)
OG0032.2(0.1 to 11.5)
OG0043.9(0.5 to 13.5)
OG0053.1(0.6 to 8.8)
OG0060.0(0.0 to 11.2)
OG0073.3(0.1 to 17.2)
OG0081.6(0.0 to 8.8)
ParticipantsOG00451
ParticipantsOG00597
ParticipantsOG00631
ParticipantsOG00730
ParticipantsOG00861
Title
Measurements
OG0000.0(0.0 to 33.6)
OG0010.0(0.0 to 28.5)
OG0020.0(0.0 to 16.8)
OG0032.2(0.1 to 11.5)
OG0043.9(0.5 to 13.5)
OG0053.1(0.6 to 8.8)
OG0060.0(0.0 to 11.2)
OG0073.3(0.1 to 17.2)
OG0081.6(0.0 to 8.8)
ParticipantsOG00451
ParticipantsOG00597
ParticipantsOG00631
ParticipantsOG00730
ParticipantsOG00861
Title
Measurements
OG0000.0(0.0 to 33.6)
OG0010.0(0.0 to 28.5)
OG0020.0(0.0 to 16.8)
OG0032.2(0.1 to 11.5)
OG0042.0(0.0 to 10.4)
OG0052.1(0.3 to 7.3)
OG0060.0(0.0 to 11.2)
OG0070.0(0.0 to 11.6)
OG0080.0(0.0 to 5.9)
ParticipantsOG00451
ParticipantsOG00597
ParticipantsOG00631
ParticipantsOG00730
ParticipantsOG00861
Title
Measurements
OG0000.0(0.0 to 33.6)
OG0010.0(0.0 to 28.5)
OG0020.0(0.0 to 16.8)
OG0032.2(0.1 to 11.5)
OG0040.0(0.0 to 7.0)
OG0051.0(0.0 to 5.6)
OG0060.0(0.0 to 11.2)
OG0070.0(0.0 to 11.6)
OG0080.0(0.0 to 5.9)
ParticipantsOG00451
ParticipantsOG00597
ParticipantsOG00631
ParticipantsOG00730
ParticipantsOG00861
Title
Measurements
OG0000.0(0.0 to 33.6)
OG0010.0(0.0 to 28.5)
OG0020.0(0.0 to 16.8)
OG0032.2(0.1 to 11.5)
OG0040.0(0.0 to 7.0)
OG0051.0(0.0 to 5.6)
OG0060.0(0.0 to 11.2)
OG0070.0(0.0 to 11.6)
OG0080.0(0.0 to 5.9)
ParticipantsOG00449
ParticipantsOG00595
ParticipantsOG00624
ParticipantsOG00729
ParticipantsOG00853
Title
Measurements
OG0000.0(0.0 to 33.6)
OG0010.0(0.0 to 30.8)
OG0020.0(0.0 to 17.6)
OG0030.0(0.0 to 7.7)
OG0044.1(0.5 to 14.0)
OG0052.1(0.3 to 7.4)
OG0064.2(0.1 to 21.1)
OG0070.0(0.0 to 11.9)
OG0081.9(0.0 to 10.1)
ParticipantsOG00449
ParticipantsOG00595
ParticipantsOG00624
ParticipantsOG00729
ParticipantsOG00853
Title
Measurements
OG0000.0(0.0 to 33.6)
OG0010.0(0.0 to 30.8)
OG0020.0(0.0 to 17.6)
OG0030.0(0.0 to 7.7)
OG0042.0(0.1 to 10.9)
OG0051.1(0.0 to 5.7)
OG0060.0(0.0 to 14.2)
OG0070.0(0.0 to 11.9)
OG0080.0(0.0 to 6.7)
ParticipantsOG00449
ParticipantsOG00595
ParticipantsOG00624
ParticipantsOG00729
ParticipantsOG00853
Title
Measurements
OG0000.0(0.0 to 33.6)
OG0010.0(0.0 to 30.8)
OG0020.0(0.0 to 17.6)
OG0030.0(0.0 to 7.7)
OG0042.0(0.1 to 10.9)
OG0051.1(0.0 to 5.7)
OG0060.0(0.0 to 14.2)
OG0070.0(0.0 to 11.9)
OG0080.0(0.0 to 6.7)
ParticipantsOG00449
ParticipantsOG00595
ParticipantsOG00624
ParticipantsOG00729
ParticipantsOG00853
Title
Measurements
OG0000.0(0.0 to 33.6)
OG0010.0(0.0 to 30.8)
OG0020.0(0.0 to 17.6)
OG0030.0(0.0 to 7.7)
OG0042.0(0.1 to 10.9)
OG0051.1(0.0 to 5.7)
OG0060.0(0.0 to 14.2)
OG0070.0(0.0 to 11.9)
OG0080.0(0.0 to 6.7)
ParticipantsOG00449
ParticipantsOG00595
ParticipantsOG00624
ParticipantsOG00729
ParticipantsOG00853
Title
Measurements
OG0000.0(0.0 to 33.6)
OG0010.0(0.0 to 30.8)
OG0020.0(0.0 to 17.6)
OG0030.0(0.0 to 7.7)
OG0040.0(0.0 to 7.3)
OG0050.0(0.0 to 3.8)
OG0060.0(0.0 to 14.2)
OG0070.0(0.0 to 11.9)
OG0080.0(0.0 to 6.7)
ParticipantsOG00449
ParticipantsOG00595
ParticipantsOG00624
ParticipantsOG00729
ParticipantsOG00853
Title
Measurements
OG0000.0(0.0 to 33.6)
OG0010.0(0.0 to 30.8)
OG0020.0(0.0 to 17.6)
OG0030.0(0.0 to 7.7)
OG0040.0(0.0 to 7.3)
OG0050.0(0.0 to 3.8)
OG0060.0(0.0 to 14.2)
OG0070.0(0.0 to 11.9)
OG0080.0(0.0 to 6.7)
ParticipantsOG00451
ParticipantsOG00597
ParticipantsOG00631
ParticipantsOG00730
ParticipantsOG00861
Title
Measurements
OG0000.0(0.0 to 30.8)
OG0019.1(0.2 to 41.3)
OG0024.8(0.1 to 23.8)
OG0032.2(0.1 to 11.5)
OG0042.0(0.0 to 10.4)
OG0052.1(0.3 to 7.3)
OG0060.0(0.0 to 11.2)
OG0073.3(0.1 to 17.2)
OG0081.6(0.0 to 8.8)
ParticipantsOG00451
ParticipantsOG00597
ParticipantsOG00631
ParticipantsOG00730
ParticipantsOG00861
Title
Measurements
OG0000.0(0.0 to 30.8)
OG0019.1(0.2 to 41.3)
OG0024.8(0.1 to 23.8)
OG0032.2(0.1 to 11.5)
OG0042.0(0.0 to 10.4)
OG0052.1(0.3 to 7.3)
OG0060.0(0.0 to 11.2)
OG0073.3(0.1 to 17.2)
OG0081.6(0.0 to 8.8)
ParticipantsOG00451
ParticipantsOG00597
ParticipantsOG00631
ParticipantsOG00730
ParticipantsOG00861
Title
Measurements
OG0000.0(0.0 to 30.8)
OG0019.1(0.2 to 41.3)
OG0024.8(0.1 to 23.8)
OG0032.2(0.1 to 11.5)
OG0042.0(0.0 to 10.4)
OG0052.1(0.3 to 7.3)
OG0060.0(0.0 to 11.2)
OG0073.3(0.1 to 17.2)
OG0081.6(0.0 to 8.8)
ParticipantsOG00451
ParticipantsOG00597
ParticipantsOG00631
ParticipantsOG00730
ParticipantsOG00861
Title
Measurements
OG0000.0(0.0 to 30.8)
OG0019.1(0.2 to 14.3)
OG0024.8(0.1 to 23.8)
OG0030.0(0.0 to 7.7)
OG0040.0(0.0 to 7.0)
OG0050.0(0.0 to 3.7)
OG0060.0(0.0 to 11.2)
OG0073.3(0.1 to 17.2)
OG0081.6(0.0 to 8.8)
ParticipantsOG00451
ParticipantsOG00597
ParticipantsOG00631
ParticipantsOG00730
ParticipantsOG00861
Title
Measurements
OG0000.0(0.0 to 30.8)
OG0010.0(0.0 to 28.5)
OG0020.0(0.0 to 16.1)
OG0030.0(0.0 to 7.7)
OG0040.0(0.0 to 7.0)
OG0050.0(0.0 to 3.7)
OG0060.0(0.0 to 11.2)
OG0073.3(0.1 to 17.2)
OG0081.6(0.0 to 8.8)
ParticipantsOG00451
ParticipantsOG00597
ParticipantsOG00631
ParticipantsOG00730
ParticipantsOG00861
Title
Measurements
OG0000.0(0.0 to 30.8)
OG0010.0(0.0 to 28.5)
OG0020.0(0.0 to 16.1)
OG0030.0(0.0 to 7.7)
OG0040.0(0.0 to 7.0)
OG0050.0(0.0 to 3.7)
OG0060.0(0.0 to 11.2)
OG0070.0(0.0 to 11.6)
OG0080.0(0.0 to 5.9)
ParticipantsOG00449
ParticipantsOG00595
ParticipantsOG00624
ParticipantsOG00730
ParticipantsOG00854
Title
Measurements
OG0000.0(0.0 to 33.6)
OG0010.0(0.0 to 30.8)
OG0020.0(0.0 to 17.6)
OG0032.2(0.1 to 11.5)
OG0040.0(0.0 to 7.3)
OG0051.1(0.0 to 5.7)
OG0060.0(0.0 to 14.2)
OG0070.0(0.0 to 11.6)
OG0080.0(0.0 to 6.6)
ParticipantsOG00449
ParticipantsOG00595
ParticipantsOG00624
ParticipantsOG00730
ParticipantsOG00854
Title
Measurements
OG0000.0(0.0 to 33.6)
OG0010.0(0.0 to 30.8)
OG0020.0(0.0 to 17.6)
OG0032.2(0.1 to 11.5)
OG0040.0(0.0 to 7.3)
OG0051.1(0.0 to 5.7)
OG0060.0(0.0 to 14.2)
OG0070.0(0.0 to 11.6)
OG0080.0(0.0 to 6.6)
ParticipantsOG00449
ParticipantsOG00595
ParticipantsOG00624
ParticipantsOG00730
ParticipantsOG00854
Title
Measurements
OG0000.0(0.0 to 33.6)
OG0010.0(0.0 to 30.8)
OG0020.0(0.0 to 17.6)
OG0030.0(0.0 to 7.7)
OG0040.0(0.0 to 7.3)
OG0050.0(0.0 to 3.8)
OG0060.0(0.0 to 14.2)
OG0070.0(0.0 to 11.6)
OG0080.0(0.0 to 6.6)
ParticipantsOG00449
ParticipantsOG00595
ParticipantsOG00624
ParticipantsOG00730
ParticipantsOG00854
Title
Measurements
OG0000.0(0.0 to 33.6)
OG0010.0(0.0 to 30.8)
OG0020.0(0.0 to 17.6)
OG0030.0(0.0 to 7.7)
OG0040.0(0.0 to 7.3)
OG0050.0(0.0 to 3.8)
OG0060.0(0.0 to 14.2)
OG0070.0(0.0 to 11.6)
OG0080.0(0.0 to 6.6)
ParticipantsOG00449
ParticipantsOG00595
ParticipantsOG00624
ParticipantsOG00730
ParticipantsOG00854
Title
Measurements
OG0000.0(0.0 to 33.6)
OG0010.0(0.0 to 30.8)
OG0020.0(0.0 to 17.6)
OG0030.0(0.0 to 7.7)
OG0040.0(0.0 to 7.3)
OG0050.0(0.0 to 3.8)
OG0060.0(0.0 to 14.2)
OG0070.0(0.0 to 11.6)
OG0080.0(0.0 to 6.6)
ParticipantsOG00449
ParticipantsOG00595
ParticipantsOG00624
ParticipantsOG00730
ParticipantsOG00854
Title
Measurements
OG0000.0(0.0 to 33.6)
OG0010.0(0.0 to 30.8)
OG0020.0(0.0 to 17.6)
OG0030.0(0.0 to 7.7)
OG0040.0(0.0 to 7.3)
OG0050.0(0.0 to 3.8)
OG0060.0(0.0 to 14.2)
OG0070.0(0.0 to 11.6)
OG0080.0(0.0 to 6.6)
ParticipantsOG00450
ParticipantsOG00595
ParticipantsOG00630
ParticipantsOG00729
ParticipantsOG00859
Title
Measurements
OG00090.0(55.5 to 99.7)
OG00166.7(29.9 to 92.5)
OG00278.9(54.4 to 93.9)
OG00364.4(48.8 to 78.1)
OG00486.0(73.3 to 94.2)
OG00575.8(65.9 to 84.0)
OG0060.0(0.0 to 11.6)
OG0073.4(0.1 to 17.8)
OG0081.7(0.0 to 9.1)
ParticipantsOG00450
ParticipantsOG00595
ParticipantsOG00630
ParticipantsOG00729
ParticipantsOG00859
Title
Measurements
OG00090.0(55.5 to 99.7)
OG00166.7(29.9 to 92.5)
OG00278.9(54.4 to 93.9)
OG00364.4(48.8 to 78.1)
OG00486.0(73.3 to 94.2)
OG00575.8(65.9 to 84.0)
OG0060.0(0.0 to 11.6)
OG0073.4(0.1 to 17.8)
OG0081.7(0.0 to 9.1)
ParticipantsOG00450
ParticipantsOG00595
ParticipantsOG00630
ParticipantsOG00729
ParticipantsOG00859
Title
Measurements
OG00080.0(44.4 to 97.5)
OG00144.4(13.7 to 78.8)
OG00263.2(38.4 to 83.7)
OG00351.1(35.8 to 66.3)
OG00466.0(51.2 to 78.8)
OG00558.9(48.4 to 68.9)
OG0060.0(0.0 to 11.6)
OG0073.4(0.1 to 17.8)
OG0081.7(0.0 to 9.1)
ParticipantsOG00450
ParticipantsOG00595
ParticipantsOG00630
ParticipantsOG00729
ParticipantsOG00859
Title
Measurements
OG00050.0(18.7 to 81.3)
OG00122.2(2.8 to 60.0)
OG00236.8(16.3 to 61.6)
OG00328.9(16.4 to 44.3)
OG00440.0(26.4 to 54.8)
OG00534.7(25.3 to 45.2)
OG0060.0(0.0 to 11.6)
OG0073.4(0.1 to 17.8)
OG0081.7(0.0 to 9.1)
ParticipantsOG00450
ParticipantsOG00595
ParticipantsOG00630
ParticipantsOG00729
ParticipantsOG00859
Title
Measurements
OG00020.0(2.5 to 55.6)
OG00122.2(2.8 to 60.0)
OG00221.1(6.1 to 45.6)
OG00311.1(3.7 to 24.1)
OG00416.0(7.2 to 29.1)
OG00513.7(7.5 to 22.3)
OG0060.0(0.0 to 11.6)
OG0070.0(0.0 to 11.9)
OG0080.0(0.0 to 6.1)
ParticipantsOG00448
ParticipantsOG00595
ParticipantsOG00623
ParticipantsOG00729
ParticipantsOG00852
Title
Measurements
OG000100.0(66.4 to 100.0)
OG001100.0(69.2 to 100.0)
OG002100.0(82.4 to 100.0)
OG003100.0(92.5 to 100.0)
OG004100.0(92.6 to 100.0)
OG005100.0(96.2 to 100.0)
OG0064.3(0.1 to 21.9)
OG0070.0(0.0 to 11.9)
OG0081.9(0.0 to 10.3)
ParticipantsOG00448
ParticipantsOG00595
ParticipantsOG00623
ParticipantsOG00729
ParticipantsOG00852
Title
Measurements
OG000100.0(66.4 to 100.0)
OG00190.0(55.5 to 99.7)
OG00294.7(74.0 to 99.9)
OG003100.0(92.5 to 100.0)
OG004100.0(92.6 to 100.0)
OG005100.0(96.2 to 100.0)
OG0060.0(0.0 to 14.8)
OG0070.0(0.0 to 11.9)
OG0080.0(0.0 to 6.8)
ParticipantsOG00448
ParticipantsOG00595
ParticipantsOG00623
ParticipantsOG00729
ParticipantsOG00852
Title
Measurements
OG000100.0(66.4 to 100.0)
OG00190.0(55.5 to 99.7)
OG00294.7(74.0 to 99.9)
OG00395.7(85.5 to 99.5)
OG00495.8(85.7 to 99.5)
OG00595.8(89.6 to 98.8)
OG0060.0(0.0 to 14.8)
OG0070.0(0.0 to 11.9)
OG0080.0(0.0 to 6.8)
ParticipantsOG00448
ParticipantsOG00595
ParticipantsOG00623
ParticipantsOG00729
ParticipantsOG00852
Title
Measurements
OG000100.0(66.4 to 100.0)
OG00170.0(34.8 to 93.3)
OG00284.2(60.4 to 96.6)
OG00387.2(74.3 to 95.2)
OG00485.4(72.2 to 93.9)
OG00586.3(77.7 to 92.5)
OG0060.0(0.0 to 14.8)
OG0070.0(0.0 to 11.9)
OG0080.0(0.0 to 6.8)
ParticipantsOG00448
ParticipantsOG00595
ParticipantsOG00623
ParticipantsOG00729
ParticipantsOG00852
Title
Measurements
OG00044.4(13.7 to 78.8)
OG00150.0(18.7 to 81.3)
OG00247.4(24.4 to 71.1)
OG00359.6(44.3 to 73.6)
OG00454.2(39.2 to 68.8)
OG00556.8(46.3 to 67.0)
OG0060.0(0.0 to 14.8)
OG0070.0(0.0 to 11.9)
OG0080.0(0.0 to 6.8)
ParticipantsOG00444
ParticipantsOG00586
ParticipantsOG00630
ParticipantsOG00729
ParticipantsOG00859
Title
Measurements
OG00070.0(34.8 to 93.3)
OG00144.4(13.7 to 78.8)
OG00257.9(33.5 to 79.7)
OG00328.6(15.7 to 44.6)
OG00443.2(28.3 to 59.0)
OG00536.0(26.0 to 47.1)
OG0060.0(0.0 to 11.6)
OG0073.4(0.1 to 17.8)
OG0081.7(0.0 to 9.1)
ParticipantsOG00444
ParticipantsOG00586
ParticipantsOG00630
ParticipantsOG00729
ParticipantsOG00859
Title
Measurements
OG00060.0(26.2 to 87.8)
OG00133.3(7.5 to 70.1)
OG00247.4(24.4 to 71.7)
OG00321.4(10.3 to 36.8)
OG00443.2(28.3 to 59.0)
OG00532.6(22.8 to 43.5)
OG0060.0(0.0 to 11.6)
OG0073.4(0.1 to 17.8)
OG0081.7(0.0 to 9.1)
ParticipantsOG00444
ParticipantsOG00586
ParticipantsOG00630
ParticipantsOG00729
ParticipantsOG00859
Title
Measurements
OG00010.0(0.3 to 44.5)
OG0010.0(0.0 to 33.6)
OG0025.3(0.1 to 26.0)
OG0039.5(2.7 to 22.6)
OG00418.2(8.2 to 32.7)
OG00514.0(7.4 to 23.1)
OG0060.0(0.0 to 11.6)
OG0073.4(0.1 to 17.8)
OG0081.7(0.0 to 9.1)
ParticipantsOG00444
ParticipantsOG00586
ParticipantsOG00630
ParticipantsOG00729
ParticipantsOG00859
Title
Measurements
OG0000.0(0.0 to 30.8)
OG0010.0(0.0 to 33.6)
OG0020.0(0.0 to 17.6)
OG0032.4(0.1 to 12.6)
OG0044.5(0.6 to 15.5)
OG0053.5(0.7 to 9.9)
OG0060.0(0.0 to 11.6)
OG0070.0(0.0 to 11.9)
OG0080.0(0.0 to 6.1)
ParticipantsOG00444
ParticipantsOG00586
ParticipantsOG00630
ParticipantsOG00729
ParticipantsOG00859
Title
Measurements
OG0000.0(0.0 to 30.8)
OG0010.0(0.0 to 33.6)
OG0020.0(0.0 to 17.6)
OG0032.4(0.1 to 12.6)
OG0040.0(0.0 to 8.0)
OG0051.2(0.0 to 6.3)
OG0060.0(0.0 to 11.6)
OG0070.0(0.0 to 11.9)
OG0080.0(0.0 to 6.1)
ParticipantsOG00447
ParticipantsOG00594
ParticipantsOG00623
ParticipantsOG00729
ParticipantsOG00852
Title
Measurements
OG00077.8(40.0 to 97.2)
OG00170.0(34.8 to 93.3)
OG00273.7(48.8 to 90.9)
OG00372.3(57.4 to 84.4)
OG00463.8(48.5 to 77.3)
OG00568.1(57.7 to 77.3)
OG0060.0(0.0 to 14.8)
OG0070.0(0.0 to 11.9)
OG0080.0(0.0 to 6.8)
ParticipantsOG00447
ParticipantsOG00594
ParticipantsOG00623
ParticipantsOG00729
ParticipantsOG00852
Title
Measurements
OG00077.8(40.0 to 97.2)
OG00160.0(26.2 to 87.8)
OG00268.4(43.4 to 87.4)
OG00372.3(57.4 to 84.4)
OG00461.7(46.4 to 75.5)
OG00567.0(56.6 to 76.4)
OG0060.0(0.0 to 14.8)
OG0070.0(0.0 to 11.9)
OG0080.0(0.0 to 6.8)
ParticipantsOG00447
ParticipantsOG00594
ParticipantsOG00623
ParticipantsOG00729
ParticipantsOG00852
Title
Measurements
OG00055.6(21.2 to 86.3)
OG00160.0(26.2 to 87.8)
OG00257.9(33.5 to 79.7)
OG00361.7(46.4 to 75.5)
OG00451.1(36.1 to 65.9)
OG00556.4(45.8 to 66.6)
OG0060.0(0.0 to 14.8)
OG0070.0(0.0 to 11.9)
OG0080.0(0.0 to 6.8)
ParticipantsOG00447
ParticipantsOG00594
ParticipantsOG00623
ParticipantsOG00729
ParticipantsOG00852
Title
Measurements
OG00033.3(7.5 to 70.1)
OG00130.0(6.7 to 65.2)
OG00231.6(12.6 to 56.6)
OG00327.7(15.6 to 42.6)
OG00421.3(10.7 to 35.7)
OG00524.5(16.2 to 34.4)
OG0060.0(0.0 to 14.8)
OG0070.0(0.0 to 11.9)
OG0080.0(0.0 to 6.8)
ParticipantsOG00447
ParticipantsOG00594
ParticipantsOG00623
ParticipantsOG00729
ParticipantsOG00852
Title
Measurements
OG00011.1(0.3 to 48.2)
OG00110.0(0.3 to 44.5)
OG00210.5(1.3 to 33.1)
OG00310.6(3.5 to 23.1)
OG00410.6(3.5 to 23.1)
OG00510.6(5.2 to 18.7)
OG0060.0(0.0 to 14.8)
OG0070.0(0.0 to 11.9)
OG0080.0(0.0 to 6.8)
ParticipantsOG00451
ParticipantsOG00596
ParticipantsOG00631
ParticipantsOG00729
ParticipantsOG00860
Title
Measurements
OG00088.9(51.8 to 99.7)
OG00190.9(58.7 to 99.8)
OG00290.0(68.3 to 98.8)
OG00391.1(78.8 to 97.5)
OG00488.2(76.1 to 95.6)
OG00589.6(81.7 to 94.9)
OG0066.5(0.8 to 21.4)
OG0076.9(0.8 to 22.8)
OG0086.7(1.8 to 16.2)
ParticipantsOG00451
ParticipantsOG00596
ParticipantsOG00631
ParticipantsOG00729
ParticipantsOG00860
Title
Measurements
OG00088.9(51.8 to 99.7)
OG00190.9(58.7 to 99.8)
OG00290.0(68.3 to 98.8)
OG00391.1(78.8 to 97.5)
OG00488.2(76.1 to 95.6)
OG00589.6(81.7 to 94.9)
OG0066.5(0.8 to 21.4)
OG0076.9(0.8 to 22.8)
OG0086.7(1.8 to 16.2)
ParticipantsOG00451
ParticipantsOG00596
ParticipantsOG00631
ParticipantsOG00729
ParticipantsOG00860
Title
Measurements
OG00088.9(51.8 to 99.7)
OG00181.8(48.2 to 97.7)
OG00285.0(62.1 to 96.8)
OG00382.2(67.9 to 92.0)
OG00486.3(73.7 to 94.3)
OG00584.4(75.5 to 91.0)
OG0063.2(0.1 to 16.7)
OG0073.4(0.1 to 17.8)
OG0083.3(0.4 to 11.5)
ParticipantsOG00451
ParticipantsOG00596
ParticipantsOG00631
ParticipantsOG00729
ParticipantsOG00860
Title
Measurements
OG00066.7(29.9 to 92.5)
OG00172.7(39.0 to 94.0)
OG00270.0(45.7 to 88.1)
OG00360.0(44.3 to 74.3)
OG00472.5(58.3 to 84.1)
OG00566.7(56.3 to 76.0)
OG0063.2(0.1 to 16.7)
OG0070.0(0.0 to 11.9)
OG0081.7(0.0 to 8.9)
ParticipantsOG00451
ParticipantsOG00596
ParticipantsOG00631
ParticipantsOG00729
ParticipantsOG00860
Title
Measurements
OG00044.4(13.7 to 78.8)
OG00154.5(23.4 to 83.3)
OG00250.0(27.2 to 72.8)
OG00337.8(23.8 to 53.5)
OG00449.0(34.8 to 63.4)
OG00543.8(33.6 to 54.3)
OG0060.0(0.0 to 11.2)
OG0070.0(0.0 to 11.9)
OG0080.0(0.0 to 6.0)
ParticipantsOG00448
ParticipantsOG00595
ParticipantsOG00624
ParticipantsOG00730
ParticipantsOG00854
Title
Measurements
OG000100.0(66.4 to 100.0)
OG001100.0(69.2 to 100.0)
OG002100.0(82.4 to 100.0)
OG003100.0(92.5 to 100.0)
OG004100.0(92.6 to 100.0)
OG005100.0(96.2 to 100.0)
OG0068.3(1.0 to 27.0)
OG00710.0(2.1 to 26.5)
OG0089.3(3.1 to 20.3)
ParticipantsOG00448
ParticipantsOG00595
ParticipantsOG00624
ParticipantsOG00730
ParticipantsOG00854
Title
Measurements
OG000100.0(66.4 to 100.0)
OG001100.0(69.2 to 100.0)
OG002100.0(82.4 to 100.0)
OG00397.9(88.7 to 99.9)
OG004100.0(92.6 to 100.0)
OG00598.9(94.3 to 100.0)
OG0060.0(0.0 to 14.2)
OG0073.3(0.1 to 7.2)
OG0081.9(0.0 to 9.9)
ParticipantsOG00448
ParticipantsOG00595
ParticipantsOG00624
ParticipantsOG00730
ParticipantsOG00854
Title
Measurements
OG000100.0(66.4 to 100.0)
OG00190.0(55.5 to 99.7)
OG00294.7(74.0 to 99.9)
OG00397.9(88.7 to 99.9)
OG00493.8(82.8 to 98.7)
OG00595.8(89.6 to 98.8)
OG0060.0(0.0 to 14.2)
OG0073.3(0.1 to 17.2)
OG0081.9(0.0 to 9.9)
ParticipantsOG00448
ParticipantsOG00595
ParticipantsOG00624
ParticipantsOG00730
ParticipantsOG00854
Title
Measurements
OG000100.0(66.4 to 100.0)
OG00180.0(44.4 to 97.5)
OG00289.5(66.9 to 98.7)
OG00393.6(82.5 to 98.7)
OG00485.4(72.2 to 93.9)
OG00589.5(81.5 to 94.8)
OG0060.0(0.0 to 14.2)
OG0070.0(0.0 to 11.6)
OG0080.0(0.0 to 6.6)
ParticipantsOG00448
ParticipantsOG00595
ParticipantsOG00624
ParticipantsOG00730
ParticipantsOG00854
Title
Measurements
OG00055.6(21.2 to 86.3)
OG00180.0(44.4 to 97.5)
OG00268.4(43.4 to 87.4)
OG00389.4(76.9 to 96.5)
OG00477.1(62.7 to 88.0)
OG00583.2(74.1 to 90.1)
OG0060.0(0.0 to 14.2)
OG0070.0(0.0 to 11.6)
OG0080.0(0.0 to 6.6)
ParticipantsOG00450
ParticipantsOG00595
ParticipantsOG00631
ParticipantsOG00729
ParticipantsOG00860
Title
Measurements
OG00088.9(51.8 to 99.7)
OG00181.8(48.2 to 97.7)
OG00285.0(62.1 to 96.8)
OG00371.1(55.7 to 83.6)
OG00472.0(57.5 to 83.8)
OG00571.6(61.4 to 80.4)
OG0063.2(0.1 to 16.7)
OG0076.9(0.8 to 22.8)
OG0085.0(1.0 to 13.9)
ParticipantsOG00450
ParticipantsOG00595
ParticipantsOG00631
ParticipantsOG00729
ParticipantsOG00860
Title
Measurements
OG00088.9(51.8 to 99.7)
OG00163.6(30.8 to 89.1)
OG00275.0(50.9 to 91.3)
OG00366.7(51.0 to 80.0)
OG00468.0(53.3 to 80.5)
OG00567.4(57.0 to 76.6)
OG0063.2(0.1 to 16.7)
OG0076.9(0.8 to 22.8)
OG0085.0(1.0 to 13.9)
ParticipantsOG00450
ParticipantsOG00595
ParticipantsOG00631
ParticipantsOG00729
ParticipantsOG00860
Title
Measurements
OG00044.4(13.7 to 78.8)
OG00136.4(10.9 to 69.2)
OG00240.0(19.1 to 63.9)
OG00337.8(23.8 to 53.5)
OG00434.0(21.2 to 48.8)
OG00535.8(26.2 to 46.3)
OG0063.2(0.1 to 16.7)
OG0070.0(0.0 to 11.9)
OG0081.7(0.0 to 8.9)
ParticipantsOG00450
ParticipantsOG00595
ParticipantsOG00631
ParticipantsOG00729
ParticipantsOG00860
Title
Measurements
OG00011.1(0.3 to 48.2)
OG00118.2(2.3 to 51.8)
OG00215.0(3.2 to 37.9)
OG00317.8(8.0 to 32.1)
OG00410.0(3.3 to 21.8)
OG00513.7(7.5 to 22.3)
OG0060.0(0.0 to 11.2)
OG0070.0(0.0 to 11.9)
OG0080.0(0.0 to 6.0)
ParticipantsOG00450
ParticipantsOG00595
ParticipantsOG00631
ParticipantsOG00729
ParticipantsOG00860
Title
Measurements
OG0000.0(0.0 to 33.6)
OG0019.1(0.2 to 41.3)
OG0025.0(0.1 to 24.9)
OG0032.2(0.1 to 11.8)
OG0042.0(0.1 to 10.6)
OG0052.1(0.3 to 7.4)
OG0060.0(0.0 to 11.2)
OG0070.0(0.0 to 11.9)
OG0080.0(0.0 to 6.0)
ParticipantsOG00447
ParticipantsOG00594
ParticipantsOG00624
ParticipantsOG00730
ParticipantsOG00854
Title
Measurements
OG00088.9(51.8 to 99.7)
OG00190.0(55.5 to 99.7)
OG00289.5(66.9 to 98.7)
OG00387.2(74.3 to 95.2)
OG00487.2(74.3 to 95.2)
OG00587.2(78.8 to 93.2)
OG0060.0(0.0 to 14.2)
OG0070.0(0.0 to 11.6)
OG0080.0(0.0 to 6.6)
ParticipantsOG00447
ParticipantsOG00594
ParticipantsOG00624
ParticipantsOG00730
ParticipantsOG00854
Title
Measurements
OG00077.8(40.0 to 97.2)
OG00190.0(55.5 to 99.7)
OG00284.2(60.4 to 96.6)
OG00387.2(74.3 to 95.2)
OG00485.1(71.7 to 93.8)
OG00586.2(77.5 to 92.4)
OG0060.0(0.0 to 14.2)
OG0070.0(0.0 to 11.6)
OG0080.0(0.0 to 6.6)
ParticipantsOG00447
ParticipantsOG00594
ParticipantsOG00624
ParticipantsOG00730
ParticipantsOG00854
Title
Measurements
OG00055.6(21.2 to 86.3)
OG00170.0(34.8 to 93.3)
OG00263.2(38.4 to 83.7)
OG00374.5(59.7 to 86.1)
OG00478.7(64.3 to 89.3)
OG00576.6(66.7 to 84.7)
OG0060.0(0.0 to 14.2)
OG0070.0(0.0 to 11.6)
OG0080.0(0.0 to 6.6)
ParticipantsOG00447
ParticipantsOG00594
ParticipantsOG00624
ParticipantsOG00730
ParticipantsOG00854
Title
Measurements
OG00044.4(13.7 to 78.8)
OG00130.0(6.7 to 65.2)
OG00236.8(16.3 to 61.6)
OG00357.4(42.2 to 71.7)
OG00459.6(44.3 to 73.6)
OG00558.5(47.9 to 68.6)
OG0060.0(0.0 to 14.2)
OG0070.0(0.0 to 11.6)
OG0080.0(0.0 to 6.6)
ParticipantsOG00447
ParticipantsOG00594
ParticipantsOG00624
ParticipantsOG00730
ParticipantsOG00854
Title
Measurements
OG00022.2(2.8 to 60.0)
OG00120.0(2.5 to 55.6)
OG00221.1(6.1 to 45.6)
OG00329.8(17.3 to 44.9)
OG00434.0(20.9 to 49.3)
OG00531.9(22.7 to 42.3)
OG0060.0(0.0 to 14.2)
OG0070.0(0.0 to 11.6)
OG0080.0(0.0 to 6.6)
ParticipantsOG00451
ParticipantsOG00597
ParticipantsOG00630
ParticipantsOG00728
ParticipantsOG00858
Title
Measurements
OG00020.0(2.5 to 55.6)
OG0010.0(0.0 to 30.8)
OG00210.0(1.2 to 31.7)
OG00317.4(7.8 to 31.4)
OG0047.8(2.2 to 18.9)
OG00512.4(6.6 to 20.6)
OG0060.0(0.0 to 11.6)
OG0077.1(0.9 to 23.5)
OG0083.4(0.4 to 11.9)
ParticipantsOG00451
ParticipantsOG00597
ParticipantsOG00630
ParticipantsOG00728
ParticipantsOG00858
Title
Measurements
OG00020.0(2.5 to 55.6)
OG0010.0(0.0 to 30.8)
OG00210.0(1.2 to 31.7)
OG00317.4(7.8 to 31.4)
OG0047.8(2.2 to 18.9)
OG00512.4(6.6 to 20.6)
OG0060.0(0.0 to 11.6)
OG0077.1(0.9 to 23.5)
OG0083.4(0.4 to 11.9)
ParticipantsOG00451
ParticipantsOG00597
ParticipantsOG00630
ParticipantsOG00728
ParticipantsOG00858
Title
Measurements
OG00020.0(2.5 to 55.6)
OG0010.0(0.0 to 30.8)
OG00210.0(1.2 to 31.7)
OG00317.4(7.8 to 31.4)
OG0047.8(2.2 to 18.9)
OG00512.4(6.6 to 20.6)
OG0060.0(0.0 to 11.6)
OG0077.1(0.9 to 23.5)
OG0083.4(0.4 to 11.9)
ParticipantsOG00451
ParticipantsOG00597
ParticipantsOG00630
ParticipantsOG00728
ParticipantsOG00858
Title
Measurements
OG00010.0(0.3 to 44.5)
OG0010.0(0.0 to 30.8)
OG0025.0(0.1 to 24.9)
OG00315.2(6.3 to 28.9)
OG0045.9(1.2 to 16.2)
OG00510.3(5.1 to 18.1)
OG0060.0(0.0 to 11.6)
OG0073.6(0.1 to 18.3)
OG0081.7(0.0 to 9.2)
ParticipantsOG00451
ParticipantsOG00597
ParticipantsOG00630
ParticipantsOG00728
ParticipantsOG00858
Title
Measurements
OG00010.0(0.3 to 44.5)
OG0010.0(0.0 to 30.8)
OG0025.0(0.1 to 24.9)
OG0036.5(1.4 to 17.9)
OG0042.0(0.0 to 10.4)
OG0054.1(1.1 to 10.2)
OG0060.0(0.0 to 11.6)
OG0073.6(0.1 to 18.3)
OG0081.7(0.0 to 9.2)
ParticipantsOG00451
ParticipantsOG00597
ParticipantsOG00630
ParticipantsOG00728
ParticipantsOG00858
Title
Measurements
OG0000.0(0.0 to 30.8)
OG0010.0(0.0 to 30.8)
OG0020.0(0.0 to 16.8)
OG0032.2(0.1 to 11.5)
OG0042.0(0.0 to 10.4)
OG0052.1(0.3 to 7.3)
OG0060.0(0.0 to 11.6)
OG0070.0(0.0 to 12.3)
OG0080.0(0.0 to 6.2)
ParticipantsOG00447
ParticipantsOG00588
ParticipantsOG00624
ParticipantsOG00728
ParticipantsOG00852
Title
Measurements
OG00062.5(24.5 to 91.5)
OG00180.0(44.4 to 97.5)
OG00272.2(46.5 to 90.3)
OG00365.9(49.4 to 79.9)
OG00463.8(48.5 to 77.3)
OG00564.8(53.9 to 74.7)
OG0064.2(0.1 to 21.1)
OG0073.6(0.1 to 18.3)
OG0083.8(0.5 to 13.2)
ParticipantsOG00447
ParticipantsOG00588
ParticipantsOG00624
ParticipantsOG00728
ParticipantsOG00852
Title
Measurements
OG00037.5(8.5 to 75.5)
OG00180.0(44.4 to 97.5)
OG00261.1(35.7 to 82.7)
OG00361.0(44.5 to 75.8)
OG00457.4(42.2 to 71.7)
OG00559.1(48.1 to 69.5)
OG0064.2(0.1 to 21.1)
OG0073.6(0.1 to 18.3)
OG0083.8(0.5 to 13.2)
ParticipantsOG00447
ParticipantsOG00588
ParticipantsOG00624
ParticipantsOG00728
ParticipantsOG00852
Title
Measurements
OG00025.0(3.2 to 65.1)
OG00180.0(44.4 to 97.5)
OG00255.6(30.8 to 78.5)
OG00358.5(42.1 to 73.7)
OG00444.7(30.2 to 59.9)
OG00551.1(40.2 to 61.9)
OG0060.0(0.0 to 14.2)
OG0073.6(0.1 to 18.3)
OG0081.9(0.0 to 10.3)
ParticipantsOG00447
ParticipantsOG00588
ParticipantsOG00624
ParticipantsOG00728
ParticipantsOG00852
Title
Measurements
OG00025.0(3.2 to 65.1)
OG00160.0(26.2 to 87.8)
OG00244.5(21.5 to 69.2)
OG00334.1(20.1 to 50.6)
OG00431.9(19.1 to 47.1)
OG00533.0(23.3 to 43.8)
OG0060.0(0.0 to 14.2)
OG0073.6(0.1 to 18.3)
OG0081.9(0.0 to 10.3)
ParticipantsOG00447
ParticipantsOG00588
ParticipantsOG00624
ParticipantsOG00728
ParticipantsOG00852
Title
Measurements
OG0000.0(0.0 to 36.9)
OG00140.0(12.2 to 73.8)
OG00222.2(6.4 to 47.6)
OG00314.6(5.6 to 29.2)
OG00421.3(10.7 to 35.7)
OG00518.2(10.8 to 27.8)
OG0060.0(0.0 to 14.2)
OG0073.6(0.1 to 18.3)
OG0081.9(0.0 to 10.3)
ParticipantsOG00447
ParticipantsOG00588
ParticipantsOG00624
ParticipantsOG00728
ParticipantsOG00852
Title
Measurements
OG0000.0(0.0 to 36.9)
OG00120.0(2.5 to 55.6)
OG00211.1(1.4 to 34.7)
OG0034.9(0.6 to 16.5)
OG0048.5(2.4 to 20.4)
OG0056.8(2.5 to 14.3)
OG0060.0(0.0 to 14.2)
OG0073.6(0.1 to 18.3)
OG0081.9(0.0 to 10.3)
ParticipantsOG00451
ParticipantsOG00597
ParticipantsOG00630
ParticipantsOG00728
ParticipantsOG00858
Title
Measurements
OG00020.0(2.5 to 55.6)
OG00110.0(0.3 to 44.5)
OG00215.0(3.2 to 37.9)
OG00310.9(3.6 to 23.6)
OG00415.7(7.0 to 28.6)
OG00513.4(7.3 to 21.8)
OG0063.3(0.1 to 17.2)
OG0073.6(0.1 to 18.3)
OG0083.4(0.4 to 11.9)
ParticipantsOG00451
ParticipantsOG00597
ParticipantsOG00630
ParticipantsOG00728
ParticipantsOG00858
Title
Measurements
OG00020.0(2.5 to 55.6)
OG00110.0(0.3 to 44.5)
OG00215.0(3.2 to 37.9)
OG0038.7(2.4 to 20.8)
OG00411.8(4.4 to 23.9)
OG00510.3(5.1 to 18.1)
OG0063.3(0.1 to 17.2)
OG0073.6(0.1 to 18.3)
OG0083.4(0.4 to 11.9)
ParticipantsOG00451
ParticipantsOG00597
ParticipantsOG00630
ParticipantsOG00728
ParticipantsOG00858
Title
Measurements
OG00010.0(0.3 to 44.5)
OG00110.0(0.3 to 44.5)
OG00210.0(1.2 to 31.7)
OG0036.5(1.4 to 17.9)
OG00411.8(4.4 to 23.9)
OG0059.3(4.3 to 16.9)
OG0060.0(0.0 to 11.6)
OG0073.6(0.1 to 18.3)
OG0081.7(0.0 to 9.2)
ParticipantsOG00451
ParticipantsOG00597
ParticipantsOG00630
ParticipantsOG00728
ParticipantsOG00858
Title
Measurements
OG0000.0(0.0 to 30.8)
OG0010.0(0.0 to 30.8)
OG0020.0(0.0 to 16.8)
OG0030.0(0.0 to 7.7)
OG0043.9(0.5 to 13.5)
OG0052.1(0.3 to 7.3)
OG0060.0(0.0 to 11.6)
OG0073.6(0.1 to 18.3)
OG0081.7(0.0 to 9.2)
ParticipantsOG00451
ParticipantsOG00597
ParticipantsOG00630
ParticipantsOG00728
ParticipantsOG00858
Title
Measurements
OG0000.0(0.0 to 30.8)
OG0010.0(0.0 to 30.8)
OG0020.0(0.0 to 16.8)
OG0030.0(0.0 to 7.7)
OG0042.0(0.0 to 10.4)
OG0051.0(0.0 to 5.6)
OG0060.0(0.0 to 11.6)
OG0070.0(0.0 to 12.3)
OG0080.0(0.0 to 6.2)
ParticipantsOG00451
ParticipantsOG00597
ParticipantsOG00630
ParticipantsOG00728
ParticipantsOG00858
Title
Measurements
OG0000.0(0.0 to 30.8)
OG0010.0(0.0 to 30.8)
OG0020.0(0.0 to 16.8)
OG0030.0(0.0 to 7.7)
OG0040.0(0.0 to 7.0)
OG0050.0(0.0 to 3.7)
OG0060.0(0.0 to 11.6)
OG0070.0(0.0 to 12.3)
OG0080.0(0.0 to 6.2)
ParticipantsOG00446
ParticipantsOG00589
ParticipantsOG00624
ParticipantsOG00729
ParticipantsOG00853
Title
Measurements
OG00012.5(0.3 to 52.7)
OG00137.5(8.5 to 75.5)
OG00225.0(7.3 to 52.4)
OG00344.2(29.1 to 60.1)
OG00447.8(32.9 to 63.1)
OG00546.1(35.4 to 57.0)
OG0064.2(0.1 to 21.1)
OG0070.0(0.0 to 11.9)
OG0081.9(0.0 to 10.1)
ParticipantsOG00446
ParticipantsOG00589
ParticipantsOG00624
ParticipantsOG00729
ParticipantsOG00853
Title
Measurements
OG00012.5(0.3 to 52.7)
OG00137.5(8.5 to 75.5)
OG00225.0(7.3 to 52.4)
OG00339.5(25.0 to 55.6)
OG00441.3(27.0 to 56.8)
OG00540.4(30.2 to 51.4)
OG0064.2(0.1 to 21.1)
OG0070.0(0.0 to 11.9)
OG0081.9(0.0 to 10.1)
ParticipantsOG00446
ParticipantsOG00589
ParticipantsOG00624
ParticipantsOG00729
ParticipantsOG00853
Title
Measurements
OG00012.5(0.3 to 52.7)
OG00125.0(3.2 to 65.1)
OG00218.8(4.0 to 45.6)
OG00334.9(21.0 to 50.9)
OG00432.6(19.5 to 48.0)
OG00533.7(24.0 to 44.5)
OG0060.0(0.0 to 14.2)
OG0070.0(0.0 to 11.9)
OG0080.0(0.0 to 6.7)
ParticipantsOG00446
ParticipantsOG00589
ParticipantsOG00624
ParticipantsOG00729
ParticipantsOG00853
Title
Measurements
OG0000.0(0.0 to 36.9)
OG00112.5(0.3 to 52.7)
OG0026.3(0.2 to 30.2)
OG00311.6(3.9 to 25.1)
OG00410.9(3.6 to 23.6)
OG00511.2(5.5 to 19.7)
OG0060.0(0.0 to 14.2)
OG0070.0(0.0 to 11.9)
OG0080.0(0.0 to 6.7)
ParticipantsOG00446
ParticipantsOG00589
ParticipantsOG00624
ParticipantsOG00729
ParticipantsOG00853
Title
Measurements
OG0000.0(0.0 to 36.9)
OG00112.5(0.3 to 52.7)
OG0026.3(0.2 to 30.2)
OG0039.3(2.6 to 22.1)
OG0042.2(0.1 to 11.5)
OG0055.6(1.8 to 12.6)
OG0060.0(0.0 to 14.2)
OG0070.0(0.0 to 11.9)
OG0080.0(0.0 to 6.7)
ParticipantsOG00446
ParticipantsOG00589
ParticipantsOG00624
ParticipantsOG00729
ParticipantsOG00853
Title
Measurements
OG0000.0(0.0 to 36.9)
OG00112.5(0.3 to 52.7)
OG0026.3(0.2 to 30.2)
OG0032.3(0.1 to 12.3)
OG0040.0(0.0 to 7.7)
OG0051.1(0.0 to 6.1)
OG0060.0(0.0 to 14.2)
OG0070.0(0.0 to 11.9)
OG0080.0(0.0 to 6.7)
ParticipantsOG00450
ParticipantsOG00595
ParticipantsOG00627
ParticipantsOG00728
ParticipantsOG00855
Title
Measurements
OG00010.0(0.3 to 44.5)
OG00118.2(2.3 to 51.8)
OG00214.3(3.0 to 36.3)
OG00313.3(5.1 to 26.8)
OG0046.0(1.3 to 16.5)
OG0059.5(4.4 to 17.2)
OG0063.7(0.1 to 19.0)
OG0073.6(0.1 to 18.3)
OG0083.6(0.4 to 12.5)
ParticipantsOG00450
ParticipantsOG00595
ParticipantsOG00627
ParticipantsOG00728
ParticipantsOG00855
Title
Measurements
OG00010.0(0.3 to 44.5)
OG00118.2(2.3 to 51.8)
OG00214.3(3.0 to 36.3)
OG00311.1(3.7 to 24.1)
OG0044.0(0.5 to 13.7)
OG0057.4(3.0 to 14.6)
OG0063.7(0.1 to 19.0)
OG0070.0(0.0 to 12.3)
OG0081.8(0.0 to 9.7)
ParticipantsOG00450
ParticipantsOG00595
ParticipantsOG00627
ParticipantsOG00728
ParticipantsOG00855
Title
Measurements
OG00010.0(0.3 to 44.5)
OG00118.2(2.3 to 51.8)
OG00214.3(3.0 to 36.3)
OG0038.9(2.5 to 21.2)
OG0044.0(0.5 to 13.7)
OG0056.3(2.4 to 13.22)
OG0063.7(0.1 to 19.0)
OG0070.0(0.0 to 12.3)
OG0081.8(0.0 to 9.7)
ParticipantsOG00450
ParticipantsOG00595
ParticipantsOG00627
ParticipantsOG00728
ParticipantsOG00855
Title
Measurements
OG0000.0(0.0 to 30.8)
OG0019.1(0.2 to 41.3)
OG0024.8(0.1 to 23.8)
OG0034.4(0.5 to 15.1)
OG0044.0(0.5 to 13.7)
OG0054.2(1.2 to 10.4)
OG0060.0(0.0 to 12.8)
OG0070.0(0.0 to 12.3)
OG0080.0(0.0 to 6.5)
ParticipantsOG00450
ParticipantsOG00595
ParticipantsOG00627
ParticipantsOG00728
ParticipantsOG00855
Title
Measurements
OG0000.0(0.0 to 30.8)
OG0010.0(0.0 to 28.5)
OG0020.0(0.0 to 16.1)
OG0032.2(0.1 to 11.8)
OG0042.0(0.1 to 10.6)
OG0052.1(0.3 to 7.4)
OG0060.0(0.0 to 12.8)
OG0070.0(0.0 to 12.3)
OG0080.0(0.0 to 6.5)
ParticipantsOG00450
ParticipantsOG00595
ParticipantsOG00627
ParticipantsOG00728
ParticipantsOG00855
Title
Measurements
OG0000.0(0.0 to 30.8)
OG0010.0(0.0 to 28.5)
OG0020.0(0.0 to 16.1)
OG0030.0(0.0 to 7.9)
OG0040.0(0.0 to 7.1)
OG0050.0(0.0 to 3.8)
OG0060.0(0.0 to 12.8)
OG0070.0(0.0 to 12.3)
OG0080.0(0.0 to 6.5)
ParticipantsOG00448
ParticipantsOG00593
ParticipantsOG00623
ParticipantsOG00730
ParticipantsOG00853
Title
Measurements
OG00033.3(7.5 to 70.1)
OG00185.7(42.1 to 99.6)
OG00256.3(29.9 to 80.2)
OG00353.3(37.9 to 68.3)
OG00452.1(37.2 to 66.7)
OG00552.7(42.1 to 63.1)
OG0068.7(1.1 to 28.0)
OG00710.0(2.1 to 26.5)
OG0089.4(3.1 to 20.7)
ParticipantsOG00448
ParticipantsOG00593
ParticipantsOG00623
ParticipantsOG00730
ParticipantsOG00853
Title
Measurements
OG00033.3(7.5 to 70.1)
OG00185.7(42.1 to 99.6)
OG00256.3(29.9 to 80.2)
OG00340.0(25.7 to 55.7)
OG00437.5(24.0 to 52.6)
OG00538.7(28.8 to 49.4)
OG0060.0(0.0 to 14.8)
OG00710.0(2.1 to 26.5)
OG0085.7(1.2 to 15.7)
ParticipantsOG00448
ParticipantsOG00593
ParticipantsOG00623
ParticipantsOG00730
ParticipantsOG00853
Title
Measurements
OG00033.3(7.5 to 70.1)
OG00185.7(42.1 to 99.6)
OG00256.3(29.9 to 80.2)
OG00326.7(14.6 to 41.9)
OG00431.3(18.7 to 46.3)
OG00529.0(20.1 to 39.4)
OG0060.0(0.0 to 14.8)
OG00710.0(2.1 to 26.5)
OG0085.7(1.2 to 15.7)
ParticipantsOG00448
ParticipantsOG00593
ParticipantsOG00623
ParticipantsOG00730
ParticipantsOG00853
Title
Measurements
OG00022.2(2.8 to 60.0)
OG00171.4(29.0 to 96.3)
OG00243.8(19.8 to 70.1)
OG00317.8(8.0 to 32.1)
OG00420.8(10.5 to 35.0)
OG00519.4(11.9 to 28.9)
OG0060.0(0.0 to 14.8)
OG00710.0(2.1 to 26.5)
OG0085.7(1.2 to 15.7)
ParticipantsOG00448
ParticipantsOG00593
ParticipantsOG00623
ParticipantsOG00730
ParticipantsOG00853
Title
Measurements
OG00022.2(2.8 to 60.0)
OG00142.9(9.9 to 81.6)
OG00231.3(11.0 to 58.7)
OG0038.9(2.5 to 21.2)
OG00412.5(4.7 to 25.2)
OG00510.8(5.3 to 18.9)
OG0060.0(0.0 to 14.8)
OG0076.7(0.8 to 22.1)
OG0083.8(0.5 to 13.0)
ParticipantsOG00448
ParticipantsOG00593
ParticipantsOG00623
ParticipantsOG00730
ParticipantsOG00853
Title
Measurements
OG0000.0(0.0 to 33.6)
OG00128.6(3.7 to 71.0)
OG00212.5(1.6 to 38.3)
OG0034.4(0.5 to 15.1)
OG0040.0(0.0 to 7.4)
OG0052.2(0.3 to 7.6)
OG0060.0(0.0 to 14.8)
OG0073.3(0.1 to 17.2)
OG0081.9(0.0 to 10.1)
ParticipantsOG00449
ParticipantsOG00593
ParticipantsOG00627
ParticipantsOG00728
ParticipantsOG00855
Title
Measurements
OG0000.0(0.0 to 30.8)
OG00127.3(6.0 to 61.0)
OG00214.3(3.0 to 36.3)
OG0032.3(0.1 to 12.0)
OG0046.1(1.3 to 16.9)
OG0054.3(1.2 to 10.6)
OG0060.0(0.0 to 12.8)
OG0077.1(0.9 to 23.5)
OG0083.6(0.4 to 12.5)
ParticipantsOG00449
ParticipantsOG00593
ParticipantsOG00627
ParticipantsOG00728
ParticipantsOG00855
Title
Measurements
OG0000.0(0.0 to 30.8)
OG00118.2(2.3 to 51.8)
OG0029.5(1.2 to 30.4)
OG0032.3(0.1 to 12.0)
OG0044.1(0.5 to 14.0)
OG0053.2(0.7 to 9.1)
OG0060.0(0.0 to 12.8)
OG0077.1(0.9 to 23.5)
OG0083.6(0.4 to 12.5)
ParticipantsOG00449
ParticipantsOG00593
ParticipantsOG00627
ParticipantsOG00728
ParticipantsOG00855
Title
Measurements
OG0000.0(0.0 to 30.8)
OG00118.2(2.3 to 51.8)
OG0029.5(1.2 to 30.4)
OG0030.0(0.0 to 8.0)
OG0042.0(0.1 to 10.9)
OG0051.1(0.0 to 5.8)
OG0060.0(0.0 to 12.8)
OG0077.1(0.9 to 23.5)
OG0083.6(0.4 to 12.5)
ParticipantsOG00449
ParticipantsOG00593
ParticipantsOG00627
ParticipantsOG00728
ParticipantsOG00855
Title
Measurements
OG0000.0(0.0 to 30.8)
OG0010.0(0.0 to 28.5)
OG0020.0(0.0 to 16.1)
OG0030.0(0.0 to 8.0)
OG0042.0(0.1 to 10.9)
OG0051.1(0.0 to 5.8)
OG0060.0(0.0 to 12.8)
OG0073.6(0.1 to 18.3)
OG0081.8(0.0 to 9.7)
ParticipantsOG00449
ParticipantsOG00593
ParticipantsOG00627
ParticipantsOG00728
ParticipantsOG00855
Title
Measurements
OG0000.0(0.0 to 30.8)
OG0010.0(0.0 to 28.5)
OG0020.0(0.0 to 16.1)
OG0030.0(0.0 to 8.0)
OG0042.0(0.1 to 10.9)
OG0051.1(0.0 to 5.8)
OG0060.0(0.0 to 12.8)
OG0073.6(0.1 to 18.3)
OG0081.8(0.0 to 9.7)
ParticipantsOG00449
ParticipantsOG00593
ParticipantsOG00627
ParticipantsOG00728
ParticipantsOG00855
Title
Measurements
OG0000.0(0.0 to 30.8)
OG0010.0(0.0 to 28.5)
OG0020.0(0.0 to 16.1)
OG0030.0(0.0 to 8.0)
OG0042.0(0.1 to 10.9)
OG0051.1(0.0 to 5.8)
OG0060.0(0.0 to 12.8)
OG0070.0(0.0 to 12.3)
OG0080.0(0.0 to 6.5)
ParticipantsOG00447
ParticipantsOG00590
ParticipantsOG00622
ParticipantsOG00729
ParticipantsOG00851
Title
Measurements
OG00011.1(0.3 to 48.2)
OG00114.3(0.4 to 57.9)
OG00212.5(1.6 to 38.3)
OG00320.9(10.0 to 36.0)
OG00421.3(10.7 to 35.7)
OG00521.1(13.2 to 31.0)
OG0064.5(0.1 to 22.8)
OG0073.4(0.1 to 17.8)
OG0083.9(0.5 to 13.5)
ParticipantsOG00447
ParticipantsOG00590
ParticipantsOG00622
ParticipantsOG00729
ParticipantsOG00851
Title
Measurements
OG00011.1(0.3 to 48.2)
OG00114.3(0.4 to 57.9)
OG00212.5(1.6 to 38.3)
OG00318.6(8.4 to 33.4)
OG00417.0(7.6 to 30.8)
OG00517.8(10.5 to 27.3)
OG0060.0(0.0 to 15.4)
OG0073.4(0.1 to 17.8)
OG0082.0(0.0 to 10.4)
ParticipantsOG00447
ParticipantsOG00590
ParticipantsOG00622
ParticipantsOG00729
ParticipantsOG00851
Title
Measurements
OG0000.0(0.0 to 33.6)
OG00114.3(0.4 to 57.9)
OG0026.3(0.2 to 30.2)
OG00316.3(6.8 to 30.7)
OG0048.5(2.4 to 20.4)
OG00512.2(6.3 to 20.8)
OG0060.0(0.0 to 15.4)
OG0070.0(0.0 to 11.9)
OG0080.0(0.0 to 7.0)
ParticipantsOG00447
ParticipantsOG00590
ParticipantsOG00622
ParticipantsOG00729
ParticipantsOG00851
Title
Measurements
OG0000.0(0.0 to 33.6)
OG0010.0(0.0 to 41.0)
OG0020.0(0.0 to 20.6)
OG0034.7(0.6 to 15.8)
OG0044.3(0.5 to 14.5)
OG0054.4(1.2 to 11.0)
OG0060.0(0.0 to 15.4)
OG0070.0(0.0 to 11.9)
OG0080.0(0.0 to 7.0)
ParticipantsOG00447
ParticipantsOG00590
ParticipantsOG00622
ParticipantsOG00729
ParticipantsOG00851
Title
Measurements
OG0000.0(0.0 to 33.6)
OG0010.0(0.0 to 41.0)
OG0020.0(0.0 to 20.6)
OG0032.3(0.1 to 12.3)
OG0042.1(0.1 to 11.3)
OG0052.2(0.3 to 7.8)
OG0060.0(0.0 to 15.4)
OG0070.0(0.0 to 11.9)
OG0080.0(0.0 to 7.0)
ParticipantsOG00447
ParticipantsOG00590
ParticipantsOG00622
ParticipantsOG00729
ParticipantsOG00851
Title
Measurements
OG0000.0(0.0 to 33.6)
OG0010.0(0.0 to 41.0)
OG0020.0(0.0 to 20.6)
OG0030.0(0.0 to 8.2)
OG0040.0(0.0 to 7.5)
OG0050.0(0.0 to 4.0)
OG0060.0(0.0 to 15.4)
OG0070.0(0.0 to 11.9)
OG0080.0(0.0 to 7.0)
ParticipantsOG00447
ParticipantsOG00581
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
Title
Measurements
OG0000.0(0.0 to 30.8)
OG0010.0(0.0 to 33.6)
OG0020.0(0.0 to 17.6)
OG0038.8(1.9 to 23.7)
OG0042.1(0.1 to 11.3)
OG0054.9(1.4 to 12.2)
ParticipantsOG00447
ParticipantsOG00581
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
Title
Measurements
OG0000.0(0.0 to 30.8)
OG0010.0(0.0 to 33.6)
OG0020.0(0.0 to 17.6)
OG0035.9(0.7 to 19.7)
OG0042.1(0.1 to 11.3)
OG0053.7(0.8 to 10.4)
ParticipantsOG00447
ParticipantsOG00581
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
Title
Measurements
OG0000.0(0.0 to 30.8)
OG0010.0(0.0 to 33.6)
OG0020.0(0.0 to 17.6)
OG0035.9(0.7 to 19.7)
OG0042.1(0.1 to 11.3)
OG0053.7(0.8 to 10.4)
ParticipantsOG00447
ParticipantsOG00581
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
Title
Measurements
OG0000.0(0.0 to 30.8)
OG0010.0(0.0 to 33.6)
OG0020.0(0.0 to 17.6)
OG0035.9(0.7 to 19.7)
OG0042.1(0.1 to 11.3)
OG0053.7(0.8 to 10.4)
ParticipantsOG00447
ParticipantsOG00581
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
Title
Measurements
OG0000.0(0.0 to 30.8)
OG0010.0(0.0 to 33.6)
OG0020.0(0.0 to 17.6)
OG0032.9(0.1 to 15.3)
OG0042.1(0.1 to 11.3)
OG0052.5(0.3 to 8.6)
ParticipantsOG00447
ParticipantsOG00581
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
Title
Measurements
OG0000.0(0.0 to 30.8)
OG0010.0(0.0 to 33.6)
OG0020.0(0.0 to 17.6)
OG0030.0(0.0 to 10.3)
OG0040.0(0.0 to 7.5)
OG0050.0(0.0 to 4.5)
ParticipantsOG00440
ParticipantsOG00579
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
Title
Measurements
OG00022.2(2.8 to 60.0)
OG00175.0(34.9 to 96.8)
OG00247.1(23.0 to 72.2)
OG00320.5(9.3 to 36.5)
OG00430.0(16.6 to 46.5)
OG00525.3(16.2 to 36.4)
ParticipantsOG00440
ParticipantsOG00579
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
Title
Measurements
OG00011.1(0.3 to 48.2)
OG00175.0(34.9 to 96.8)
OG00241.2(18.4 to 67.1)
OG00315.4(5.9 to 30.5)
OG00430.0(16.6 to 46.5)
OG00522.8(14.1 to 33.6)
ParticipantsOG00440
ParticipantsOG00579
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
Title
Measurements
OG00011.1(0.3 to 48.2)
OG00175.0(34.9 to 96.8)
OG00241.2(18.4 to 67.1)
OG00310.3(2.9 to 24.2)
OG00427.5(14.6 to 43.9)
OG00519.0(11.0 to 29.4)
ParticipantsOG00440
ParticipantsOG00579
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
Title
Measurements
OG00011.1(0.3 to 48.2)
OG00150.0(15.7 to 84.3)
OG00229.4(10.3 to 56.0)
OG0032.6(0.1 to 13.5)
OG00412.5(4.2 to 26.8)
OG0057.6(2.8 to 15.8)
ParticipantsOG00440
ParticipantsOG00579
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
Title
Measurements
OG00011.1(0.3 to 48.2)
OG0010.0(0.0 to 36.9)
OG0025.9(0.1 to 28.7)
OG0032.6(0.1 to 13.5)
OG0047.5(1.6 to 20.4)
OG0055.1(1.4 to 12.5)
ParticipantsOG00440
ParticipantsOG00579
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
Title
Measurements
OG00011.1(0.3 to 48.2)
OG0010.0(0.0 to 36.9)
OG0025.9(0.1 to 28.7)
OG0032.6(0.1 to 13.5)
OG0045.0(0.6 to 16.9)
OG0053.8(0.8 to 10.7)
ParticipantsOG00448
ParticipantsOG00582
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
Title
Measurements
OG0000.0(0.0 to 30.8)
OG00111.1(0.3 to 48.2)
OG0025.3(0.1 to 26.0)
OG0038.8(1.9 to 23.7)
OG0040.0(0.0 to 7.4)
OG0053.7(0.8 to 10.3)
ParticipantsOG00448
ParticipantsOG00582
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
Title
Measurements
OG0000.0(0.0 to 30.8)
OG00111.1(0.3 to 48.2)
OG0025.3(0.1 to 26.0)
OG0038.8(1.9 to 23.7)
OG0040.0(0.0 to 7.4)
OG0053.7(0.8 to 10.3)
ParticipantsOG00448
ParticipantsOG00582
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
Title
Measurements
OG0000.0(0.0 to 30.8)
OG00111.1(0.3 to 48.2)
OG0025.3(0.1 to 26.0)
OG0035.9(0.7 to 19.7)
OG0040.0(0.0 to 7.4)
OG0052.4(0.3 to 8.5)
ParticipantsOG00448
ParticipantsOG00582
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
Title
Measurements
OG0000.0(0.0 to 30.8)
OG00111.1(0.3 to 48.2)
OG0025.3(0.1 to 26.0)
OG0035.9(0.7 to 19.7)
OG0040.0(0.0 to 7.4)
OG0052.4(0.3 to 8.5)
ParticipantsOG00448
ParticipantsOG00582
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
Title
Measurements
OG0000.0(0.0 to 30.8)
OG00111.1(0.3 to 48.2)
OG0025.3(0.1 to 26.0)
OG0035.9(0.7 to 19.7)
OG0040.0(0.0 to 7.4)
OG0052.4(0.3 to 8.5)
ParticipantsOG00448
ParticipantsOG00582
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
Title
Measurements
OG0000.0(0.0 to 30.8)
OG0010.0(0.0 to 33.6)
OG0020.0(0.0 to 17.6)
OG0032.9(0.1 to 15.3)
OG0040.0(0.0 to 7.4)
OG0051.2(0.0 to 6.6)
ParticipantsOG00441
ParticipantsOG00580
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
Title
Measurements
OG0000.0(0.0 to 33.6)
OG00125.0(3.2 to 65.1)
OG00211.8(1.5 to 36.4)
OG00315.4(5.9 to 30.5)
OG00412.2(4.1 to 26.2)
OG00513.8(7.1 to 23.3)
ParticipantsOG00441
ParticipantsOG00580
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
Title
Measurements
OG0000.0(0.0 to 33.6)
OG00125.0(3.2 to 65.1)
OG00211.8(1.5 to 36.4)
OG00312.8(4.3 to 27.4)
OG00412.2(4.1 to 26.2)
OG00512.5(6.2 to 21.8)
ParticipantsOG00441
ParticipantsOG00580
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
Title
Measurements
OG0000.0(0.0 to 33.6)
OG00112.5(0.3 to 52.7)
OG0025.9(0.1 to 28.7)
OG0037.7(1.6 to 20.9)
OG0049.8(2.7 to 23.1)
OG0058.8(3.6 to 17.2)
ParticipantsOG00441
ParticipantsOG00580
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
Title
Measurements
OG0000.0(0.0 to 33.6)
OG0010.0(0.0 to 36.9)
OG0020.0(0.0 to 19.5)
OG0035.1(0.6 to 17.3)
OG0042.4(0.1 to 12.9)
OG0053.8(0.8 to 10.6)
ParticipantsOG00441
ParticipantsOG00580
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
Title
Measurements
OG0000.0(0.0 to 33.6)
OG0010.0(0.0 to 36.9)
OG0020.0(0.0 to 19.5)
OG0030.0(0.0 to 9.0)
OG0042.4(0.1 to 12.9)
OG0051.3(0.0 to 6.8)
ParticipantsOG00441
ParticipantsOG00580
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
Title
Measurements
OG0000.0(0.0 to 33.6)
OG0010.0(0.0 to 36.9)
OG0020.0(0.0 to 19.5)
OG0030.0(0.0 to 9.0)
OG0042.4(0.1 to 12.9)
OG0051.3(0.0 to 6.8)
8.5
(7.5 to 9.6)
OG0048.3(7.8 to 8.9)
OG0058.4(7.9 to 9.0)
OG0068.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
OG0078.2(7.8 to 8.6)
OG0088.1(7.9 to 8.3)
ParticipantsOG00449
ParticipantsOG00595
ParticipantsOG00624
ParticipantsOG00729
ParticipantsOG00853
Title
Measurements
OG0004.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
OG0014.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
OG0024.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
OG0034.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
OG0044.2(3.8 to 4.5)
OG0054.1(3.9 to 4.3)
OG0064.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
OG0074.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
OG0084.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
ParticipantsOG00451
ParticipantsOG00597
ParticipantsOG00631
ParticipantsOG00730
ParticipantsOG00861
Title
Measurements
OG0004.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
OG0014.8(3.2 to 7.4)
OG0024.4(3.6 to 5.4)
OG0034.1(3.9 to 4.4)
OG0044.1(3.9 to 4.3)
OG0054.1(4.0 to 4.3)
OG0064.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
OG0074.4(3.6 to 5.3)
OG0084.2(3.8 to 4.6)
ParticipantsOG00449
ParticipantsOG00595
ParticipantsOG00624
ParticipantsOG00730
ParticipantsOG00854
Title
Measurements
OG0004.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
OG0014.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
OG0024.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
OG0034.1(3.9 to 4.2)
OG0044.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
OG0054.0(4.0 to 4.1)
OG0064.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
OG0074.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
OG0084.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
ParticipantsOG00450
ParticipantsOG00595
ParticipantsOG00630
ParticipantsOG00729
ParticipantsOG00859
Title
Measurements
OG00042.2(22.6 to 79.1)
OG00123.5(10.1 to 54.9)
OG00232.0(19.7 to 52.0)
OG00324.6(17.8 to 34.2)
OG00436.8(26.9 to 50.3)
OG00530.4(24.3 to 38.1)
OG0068.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
OG0078.6(7.4 to 10.0)
OG0088.3(7.7 to 8.9)
ParticipantsOG00448
ParticipantsOG00595
ParticipantsOG00623
ParticipantsOG00729
ParticipantsOG00852
Title
Measurements
OG000101.6(64.0 to 161.2)
OG00168.6(28.2 to 166.8)
OG00282.6(51.4 to 129.9)
OG003117.2(89.7 to 153.0)
OG004104.6(80.4 to 136.0)
OG005110.6(92.0 to 133.0)
OG0064.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
OG0074.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
OG0084.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
ParticipantsOG00444
ParticipantsOG00586
ParticipantsOG00630
ParticipantsOG00729
ParticipantsOG00859
Title
Measurements
OG00010.6(6.2 to 18.0)
OG0016.9(4.1 to 11.5)
OG0028.6(6.1 to 12.2)
OG0036.0(4.7 to 7.8)
OG0048.5(6.4 to 11.3)
OG0057.2(5.9 to 8.7)
OG0064.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
OG0074.3(3.7 to 5.0)
OG0084.1(3.9 to 4.4)
ParticipantsOG00447
ParticipantsOG00594
ParticipantsOG00623
ParticipantsOG00729
ParticipantsOG00852
Title
Measurements
OG00023.5(9.3 to 59.4)
OG00121.1(6.5 to 68.3)
OG00222.2(11.2 to 43.9)
OG00322.1(15.5 to 31.6)
OG00417.0(11.8 to 24.4)
OG00519.4(15.1 to 24.9)
OG0064.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
OG0074.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
OG00840(NA to NA)CI was not estimable due to the lack of variability of geometric means.
ParticipantsOG00451
ParticipantsOG00596
ParticipantsOG00631
ParticipantsOG00729
ParticipantsOG00860
Title
Measurements
OG00080.6(30.9 to 210.7)
OG00182.3(36.5 to 185.8)
OG00281.6(46.6 to 142.8)
OG00363.0(44.5 to 89.3)
OG00471.4(52.7 to 96.6)
OG00567.3(53.7 to 84.3)
OG0068.6(7.5 to 9.8)
OG0078.6(7.7 to 9.6)
OG0088.6(7.9 to 9.3)
ParticipantsOG00448
ParticipantsOG00595
ParticipantsOG00624
ParticipantsOG00730
ParticipantsOG00854
Title
Measurements
OG000109.7(70.4 to 171.1)
OG001181.0(68.6 to 477.9)
OG002142.8(85.5 to 238.6)
OG003190.6(146.9 to 247.4)
OG004154.4(116.3 to 205.1)
OG005171.4(141.6 to 207.4)
OG0064.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
OG0074.3(3.7 to 4.9)
OG0084.2(3.8 to 4.5)
ParticipantsOG00450
ParticipantsOG00595
ParticipantsOG00631
ParticipantsOG00729
ParticipantsOG00860
Title
Measurements
OG00020.2(11.1 to 36.6)
OG00117.0(8.2 to 35.5)
OG00218.4(11.8 to 28.6)
OG00315.8(11.4 to 21.8)
OG00414.5(11.1 to 19.1)
OG00515.1(12.3 to 18.6)
OG0064.3(3.7 to 4.9)
OG0074.4(3.8 to 5.0)
OG0084.3(3.9 to 4.8)
ParticipantsOG00447
ParticipantsOG00594
ParticipantsOG00624
ParticipantsOG00730
ParticipantsOG00854
Title
Measurements
OG00029.6(11.6 to 75.8)
OG00134.3(15.0 to 78.2)
OG00232.0(18.3 to 55.8)
OG00346.3(31.6 to 67.8)
OG00444.9(31.3 to 64.5)
OG00545.6(35.2 to 59.0)
OG0064.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
OG0074.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
OG0084.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
ParticipantsOG00451
ParticipantsOG00597
ParticipantsOG00630
ParticipantsOG00728
ParticipantsOG00858
Title
Measurements
OG00010.6(6.5 to 17.0)
OG0018.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
OG0029.2(7.3 to 11.5)
OG00310.8(8.7 to 13.5)
OG0049.0(7.9 to 10.2)
OG0059.8(8.7 to 11.1)
OG0068.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
OG0078.8(7.5 to 10.4)
OG0088.4(7.8 to 9.0)
ParticipantsOG00447
ParticipantsOG00588
ParticipantsOG00624
ParticipantsOG00728
ParticipantsOG00852
Title
Measurements
OG0007.3(3.3 to 16.1)
OG00127.9(11.3 to 68.5)
OG00215.4(8.1 to 29.3)
OG00313.7(9.4 to 20.1)
OG00412.5(8.7 to 17.9)
OG00513.0(10.1 to 16.9)
OG0064.1(3.9 to 4.4)
OG0074.6(3.4 to 6.3)
OG0084.4(3.7 to 5.2)
ParticipantsOG00451
ParticipantsOG00597
ParticipantsOG00630
ParticipantsOG00728
ParticipantsOG00858
Title
Measurements
OG0004.9(3.5 to 6.9)
OG0014.6(3.4 to 6.3)
OG0024.8(3.9 to 5.9)
OG0034.4(4.0 to 4.9)
OG0044.9(4.2 to 5.8)
OG0054.7(4.2 to 5.2)
OG0064.1(3.9 to 4.3)
OG0074.3(3.7 to 5.0)
OG0084.2(3.9 to 4.5)
ParticipantsOG00446
ParticipantsOG00589
ParticipantsOG00624
ParticipantsOG00729
ParticipantsOG00853
Title
Measurements
OG0004.8(3.2 to 7.2)
OG0018.7(2.6 to 29.5)
OG0026.4(3.6 to 11.5)
OG0037.9(5.8 to 10.6)
OG0047.3(5.7 to 9.3)
OG0057.6(6.3 to 9.1)
OG0064.1(3.9 to 4.4)
OG0074.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
OG0084.1(3.9 to 4.2)
ParticipantsOG00450
ParticipantsOG00595
ParticipantsOG00627
ParticipantsOG00728
ParticipantsOG00855
Title
Measurements
OG0008.6(7.3 to 10.0)
OG0019.7(7.2 to 13.1)
OG0029.1(7.8 to 10.7)
OG0038.9(7.9 to 10.0)
OG0048.6(7.8 to 9.5)
OG0058.7(8.1 to 9.4)
OG0068.2(7.8 to 8.7)
OG0078.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
OG0088.1(7.9 to 8.3)
ParticipantsOG00448
ParticipantsOG00593
ParticipantsOG00623
ParticipantsOG00730
ParticipantsOG00853
Title
Measurements
OG0008.6(3.4 to 22.1)
OG00135.3(11.3 to 110.1)
OG00216.0(7.6 to 33.5)
OG0037.9(5.8 to 10.7)
OG0048.1(6.0 to 11.0)
OG0058.0(6.5 to 9.9)
OG0064.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
OG0075.3(3.8 to 7.3)
OG0084.7(3.9 to 5.6)
ParticipantsOG00449
ParticipantsOG00593
ParticipantsOG00627
ParticipantsOG00728
ParticipantsOG00855
Title
Measurements
OG0004.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
OG0015.1(3.5 to 7.5)
OG0024.6(3.8 to 5.5)
OG0034.1(3.9 to 4.2)
OG0044.4(3.8 to 5.0)
OG0054.2(3.9 to 4.5)
OG0064.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
OG0074.6(3.7 to 5.8)
OG0084.3(3.9 to 4.8)
ParticipantsOG00447
ParticipantsOG00590
ParticipantsOG00622
ParticipantsOG00729
ParticipantsOG00851
Title
Measurements
OG0004.3(3.6 to 5.2)
OG0014.9(3.0 to 7.9)
OG0024.6(3.7 to 5.6)
OG0035.3(4.4 to 6.6)
OG0045.0(4.2 to 5.9)
OG0055.2(4.5 to 5.9)
OG0064.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
OG0074.1(3.9 to 4.3)
OG0084.1(3.9 to 4.2)
ParticipantsOG00447
ParticipantsOG00581
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
Title
Measurements
OG0008.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
OG0018.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
OG0028.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
OG0038.9(7.6 to 10.3)
OG0048.4(7.6 to 9.1)
OG0058.6(7.9 to 9.3)
ParticipantsOG00440
ParticipantsOG00579
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
Title
Measurements
OG0006.9(2.0 to 23.8)
OG00116.0(7.5 to 34.2)
OG00210.2(5.1 to 20.6)
OG0035.1(4.0 to 6.6)
OG0047.3(5.1 to 10.5)
OG0056.1(4.9 to 7.6)
ParticipantsOG00448
ParticipantsOG00582
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
Title
Measurements
OG0004.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
OG0015.4(2.7 to 11.1)
OG0024.6(3.4 to 6.3)
OG0034.9(3.8 to 6.4)
OG0044.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.
OG0054.4(3.9 to 4.8)
ParticipantsOG00441
ParticipantsOG00580
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
Title
Measurements
OG0004.0(NA to NA)CI was not estimable due to the lack of variability of geometric means.